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Abstract
Cardiovascular diseases (CVD) are the leading cause of death worldwide and arterial stiffness,
in particular, is considered a major determinant of risk. This thesis meets its motivation in the
foreseeable impact that an accurate, non-invasive and easy-to-use instrument for hemodynamic
condition assessment could impart to the diagnosis and follow-up of CVD. Technically, the
approach to this question is based upon on the belief that the Arterial Pressure Waveform (APW)
conveys invaluable information about the arterial stiffness which can be accurately evaluated by
means of moderate-cost instrumentation. The lack of efficient APW analysis approaches, as
well as the growing interest in clinical decision support systems, brought extra motivation to this
work. The main goal along this work was the development of an electronic platform dedicated
to arterial stiffness assessment. Its full implementation included four main steps: (1) a multi-
modular platform designed to incorporate several clinical data modules, namely the APW module
designed to accurately retrieve pulse morphology; (2) an algorithmic tool capable of extracting
relevant information from the APW signal; (3) sets of validation tests used in the assessment of
probe repeatability and reproducibility and; (4) machine learning algorithms capable of dealing
with vectorized features. The first trials of the APW module consisted in the assessment of
its piezoelectric front end performance (interface between the patient and the probe itself) in a
special purpose test bench, where a root mean square error (RMSE) of 1.8± 0.22% was observed
using artificial cardiac-like pressure waves. The probe was incorporated in a collar and tested
using a specially developed database built from 217 subjects, organized in groups, with different
characteristics. It has been demonstrated that the identification of different time and amplitude
parameterizations for each group is possible, as well the identification of physiological changes
in a group of subjects, after a ”stent” implementation. The validation tests showed reproducible
and repeatable results whenever data were obtained by well-trained operators. The use of data
mining techniques demonstrated reliable results, in particular, classification algorithms (e.g., the
Random Forest algorithm achieved an accuracy of 96.95%) and clustering methodologies, for
which a good correlation between the high risk labels (retrieved from the implemented approach)
and the Augmentation Index (AIx) was observed. Globally, results give clear positive indications
concerning the use of the developed methodology (prototype and associated algorithmic tools) as
an alternative to costly techniques, such as ultrasound or applanation tonometry, in clinical and in
research environments.
Keywords: biomedical instrumentation, multichannel data acquisition system, learning algorithms,
cardiovascular diseases, arterial stiffness
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Resumo
As doenc¸as cardiovasculares (DCV) sa˜o a principal causa de morte mundial, e a rigidez arterial,
em particular, e´ considerada um importante factor de risco. Esta tese encontra a sua motivac¸a˜o
no impacto previsı´vel que um instrumento preciso, na˜o invasivo e fa´cil de usar para avaliac¸a˜o da
condica˜o hemodinaˆmica podera´ dar ao diagno´stico e acompanhamento das DCV. Tecnicamente, a
abordagem a esta questa˜o baseia-se na crenc¸a de que a onda de pressa˜o arterial (OPA) transmite
informac¸o˜es valiosas sobre a rigidez arterial, e que esta pode ser estudada com precisa˜o por
instrumentac¸a˜o de custo moderado. A inexisteˆncia de abordagens de ana´lise da OPA eficientes,
bem como o crescente interesse em sistemas de apoio a` decisa˜o clı´nica, deram motivac¸a˜o extra
a este trabalho. O principal objectivo deste trabalho foi o desenvolvimento de uma plataforma
electro´nica dedicada a` avaliac¸a˜o da rigidez arterial. A sua implementac¸a˜o incluiu quatro etapas
fundamentais: (1) uma plataforma multi-modular concebida para incorporar va´rios mo´dulos
clı´nicos, nomeadamente o mo´dulo OPA projectado para reproduc¸a˜o da morfologia de pulso; (2) uma
ferramenta algorı´tmica capaz de identificar informac¸a˜o importante na OPA; (3) testes de validac¸a˜o
usados na avaliac¸a˜o da repetibilidade e reprodutibilidade da sonda e; (4) algoritmos de aprendizagem
implementados para lidar com caracterı´sticas vectorizadas. Os primeiros ensaios do mo´dulo OPA
consistiram na avaliac¸a˜o do desempenho da sua sonda piezoele´ctrica (interface entre o paciente e o
pro´prio mo´dulo) em uma bancada de teste concebida para este propo´sito, onde um erro quadra´tico
me´dio (RMSE) de 1.8± 0.22% foi observado, usando ondas de pressa˜o sintetizadas. A sonda
foi incorporada em um colar, e testada usando um banco de dados especialmente desenvolvido,
construı´do a partir de 217 sujeitos, organizados em grupos, com diferentes caracterı´sticas. Foi
demonstrado que a identificac¸a˜o de diferentes parametrizac¸o˜es temporais e de amplitude para cada
um dos grupos e´ possı´vel, bem como a identificac¸a˜o de alterac¸o˜es fisiolo´gicas em um grupo
de sujeitos, apo´s a implantac¸a˜o de um ”stent”. Os testes de validac¸a˜o mostraram resultados
reprodutı´veis e repetı´veis, quando os dados foram obtidos por operadores bem treinados. O
uso de te´cnicas de minerac¸a˜o de dados demonstrou resultados confia´veis, em particular, para
os algoritmos de classificac¸a˜o (p.ex., o algoritmo Random Forest alcanc¸ou uma precisa˜o de
96.95%) e metodologias de agrupamento, para as quais foi obtida uma boa correlac¸a˜o entre as
indicac¸o˜es de alto risco (obtidas usando a abordagem desenvolvida) e o I´ndice de Aumentac¸a˜o
(AIx). Globalmente, os resultados da˜o bons indicadores, sobre o uso desta metodologia (proto´tipo e
ferramentas algorı´tmicas associadas), em alternativa a te´cnicas dispendiosas, tais como te´cnicas de
ultra-sons ou a tonometria de aplanac¸a˜o, em ambiente clı´nico e de investigac¸a˜o.
Keywords: instrumentac¸a˜o biome´dica, sistema de aquisic¸a˜o de dados multicanal, algoritmos de
aprendizagem, doenc¸as cardiovasculares, rigidez arterial
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1. INTRODUCTION
1.1 Motivation
Over the last few years, the medical community has been discussing the exact relevance of vascular
hemodynamics, with special focus on arterial stiffness [1–4]. It is well accepted by the scientific
community that arterial stiffness is an early predictor of Cardiovascular Diseases (CVD) and, there
are several studies that have stated its relation with diseases, such as: hypertension [5], coronary
atherosclerosis [6], End Stage Renal Disease (ESRD) [7] and diabetes mellitus [8].
In what concerns the instrumental means available to researchers and clinicians, the literature
shows that the real single issue behind the accurate assessment of arterial stiffness depends on the
faithfully reproduction of the Arterial Pressure Waveform (APW), preferably using a non-invasive
technique. Moreover, if this assessment could be performed with low cost devices, a significant
impact on public health could be, herein, derived. Historically, the cuff sphygmomanometer,
universally used by clinicians since the beginning of the 20th century, was the first device to quantify
a part of the information contained in the APW, the Systolic Blood Pressure (SBP) and the Diastolic
Blood Pressure (DBP), and conquered a (still) irreplaceable role in general clinical practice [9]. In
the last years the major interest is with the central aortic pressure measurement [10], and the 24-h
daily pressure monitoring [11]. On other hand, several physiologists and clinicians, started to pay
increasing attention to other aspects of the information carried by the APW that can only be unfolded
by its shape.
The history of arterial wave mechanic studies and applications is long. Being very early used by
Chinese, Indian, Greek and Roman physicians in the diagnosis of several diseases [12]. In the last
years, the separation of the incident from the reflected wave, and the analysis of parameters, such as,
the Pulse Wave Velocity (PWV) [13] and the Augmentation Index (AIx) [14], assumed a enhanced
relevance.
It is also accepted that the combination of several parameters (e.g., biochemical and APW
parameters) used in the clinical path of cardiovascular patients can provide a refined physiological
status assessment. The recent emergence of computer-aided diagnosis technologies provide new
insights for the development of innovative methods for professional health assistance in this area.
Data mining techniques can be used in the recognition of relationships and patterns in huge amounts
2
1.2. GOALS
of data, and so, being decisive in unveiling new biomedical and healthcare knowledge that can be
used in new clinical decision support systems [15–17].
1.2 Goals
This project is of a strongly interdisciplinar nature incorporating two balanced components:
engineering and medical sciences (as can be observed in the description, below). The hemodynamic
analysis is supported by the combination of available clinical information, with the developed non-
invasive instrumentation, which provides a detailed profile of the arterial pulse. To accomplish this,
the key tool, is a multi-parameter approach based on data mining and machine learning algorithms
capable to deal with a set of hemodynamic parameters.
1.2.1 Multichannel Biomedical Platform
This project finds its motivation in the foreseeable impact that an accurate, non-invasive and easy-to-
use instrument for hemodynamic condition assessment could impart on the diagnosis and follow-up
of the CVD. The APW conveys invaluable information about the condition of the cardiovascular
system, and it can be accurately evaluated by means of moderate-cost instrumentation. Worldwide,
the main specific devices, used in different experimental and clinical laboratories have been studied
by other authors, such as the ones presented by Bruno Pannier [18]. The applanation tonometry [19]
is a sophisticated and costly technique, that remains the preferred method for the APW analysis.
Being this problem crucial, because these waves carry in their pattern information about all the
mechanical factors that influence pressure and flow speed [20], it is important the development of
precise and easy-to-use instrumentation.
A new system, capable of delivering this information was developed, being the piezoelectric
(PZ) sensors studied and incorporated in a standalone module designed for APW monitoring.
Two prototype versions were developed following these methodologies. However, the clinical
trials evolved to a point, where it was considered the development of a multi-parametric
integrated instrument able to include other technologies, in addition to this module, useful for the
characterization of the patients.
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1.2.2 Data Collection and Validation Tests
Generally, the validation of medical data acquisition systems requires the exploration of large
databases. Therefore, the establishment of a database for this particular laboratory prototype is
critical, using subjects not only with cardiac pathologies but, also, healthy subjects, covering a
wide age range. A database for the APW module was established along this thesis by different
group of subjects. Some of the subjects were recruited via health visitors in the Coimbra Hospital
and University Centre (CHUC), Portugal, while others were obtained from the collaboration with
volunteers at screening mobilizations. This database was essential for the assessment of the system
repeatability (intra-operator variation) and reproducibility (inter-operator variation).
1.2.3 Hemodynamic Features
The selection of the most interesting hemodynamic indicators is an important task which has to
take into account the relative relevance of each one. The AIx and the arterial wave reflections
are classic themes of debate across the literature. However, this work also aims at providing
the design of new variables that could be used in a multi-parametric approach to retrieve more
information from the arterial blood pulse waveform, which have not yet been studied enough. So,
the combination of carefully selected APW features should significantly improve the arterial blood
pulse understanding, especially if compared with the traditional single parameter analysis, where
the failure in the determination of one component, such as the inflection point, can jeopardize the
whole assessment.
1.2.4 Clinical Assessment Support Systems
Most of the APW analysis frameworks result from the individually processing of each one of the
hemodynamic parameters and not from the evaluating of inter-dependencies in the overall pulse
morphology. One of the key contribution of this work is the application of machine learning
algorithms to deal with the vectorized features, extracted from APW. This methodology provide
a new insight into the analysis of a great number of parameters in such a way, that it is possible to
emphasize the relationships on the hidden patterns, for the different datasets. Several approaches
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have been used in many applications during the last few years, with interesting developments in
medical fields. In this work were implemented clustering and classification algorithms that allowed
the identification of different parameterizations for subjects of different groups.
1.3 Structure
This dissertation intends to provide a complete description of the developed multichannel electro-
mechanical platform and its algorithmic tools, as well as the methodologies adopted to perform the
system validation. The document can be systematized as follows:
Following this Introduction (Chapter 1), a short overview about CVD and the main risk factors
associated to their development are presented in Chapter 2. Firstly, the major risk factors are shortly
discussed, and then, a perspective analysis about the prevalence of CVD in Portugal is given. In this
chapter are also discussed the common used methods in the cardiovascular pulse measurement. In
addition, some of the most used CVD commercial devices are shortly discussed, as well as the most
relevant parameters.
The Chapter 3 describes the design and architecture of the three laboratory prototype developed
versions. It is also presented the multi-modular system architecture, where the final APW prototype
version was implemented. The remaining modules are shortly described.
Chapter 4 summarizes the main experimental measurements performed during pre-clinical
tests. Experimental measurements were conducted in subjects during a mobilized screening week
in the Department of Physics of the University of Coimbra, in collaboration with SCDSOS (Sudden
Cardiac Death Screening of Risk Factors) study and, in pre-clinical trials at the Coimbra Hospital
and University Centre (CHUC), among healthy, hypertensive and Coronary Artery Disease (CAD)
subjects. The risk factors distribution is also briefly discussed. General information about signal
processing techniques employed on the APW analysis are also presented.
The focus of the Chapter 5 are the data mining techniques employed it. Data pre-processing,
classification and clustering are the main detailed points. It also contains information about
the suitable risk assessment tools (Framingham Risk Score (FRS), PROspective CArdiovascular
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Mu¨nster (PROCAM), ASsessing cardiovascular risk using Scottish Intercollegiate Guidelines
Network (ASSIGN) and Systematic COronary Risk Evaluation project (SCORE)).
Chapter 6 introduces some approaches concerning the evaluation of the inherent precision of the
equipment, using general descriptive statistics, correlation techniques, and other relevant statistical
tests that were conducted to find out statistical significant differences among groups. The performed
tests included the characterization of the typical range of values for each group in the database, the
comparison of invasive and of the non-invasive waveform measurements, the study of the intra-and
inter-operator variances, as well as the analysis of the successive measurement differences.
The main conclusions and future potential improvements/developments of the proposed
approach are discussed in Chapter 7.
1.4 Scientific Contribution
Throughout the work development some scientific publications have been published. These papers
can be organized as: i) scientific international journals; ii) conference proceedings.
Papers in scientific international journals, with refereeing:
1. VG Almeida, M Pego, T Pereira, HC Pereira, C Correia JMR Cardoso, Cardiovascular risk
analysis by means of pulse morphology and clustering methodologies, submitted.
2. VG Almeida, J Vieira, P Santos, T Pereira, HC Pereira, C Correia, M Pego, JMR
Cardoso, Machine Learning Techniques for Arterial Pressure Waveform Analysis. Journal
of Personalized Medicine, v. 3, n. 2, p. 82-101, 2013.
3. VG Almeida, HC Pereira, T Pereira, E Figueiras, E Borges, JMR Cardoso, C Correia,
Piezoelectric probe for pressure waveform estimation in flexible tubes and its application
to the cardiovascular system. Sensors and Actuators A: Physical, v. 169, n. 1, p. 217-226,
2011.
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Papers in conference proceedings, with refereeing:
1. VG Almeida, J Borba, T Pereira, HC Pereira, J Cardoso, C Correia, Indices and repeatability
tests of cardiovascular function performed on the arterial distension waveform - Case Study:
Angiography intervention. In: INTERNATIONAL CONFERENCE ON BIO-INSPIRED
SYSTEMS AND SIGNAL PROCESSING, 2013. Barcelona, Spain. Proceedings of the
International Conference on Bio-inspired Systems and Signal Processing. SciTePress -
Science and and Technology Publications, 2013, p. 138-144.
2. VG Almeida, J Borba, T Pereira, HC Pereira, J Cardoso, C Correia, Data Mining based
methodologies for cardiac risk ptterns identification. In: INTERNATIONAL CONFERENCE
ON BIOINFORMATICS MODELS, METHODS AND ALGORITHMS, 2013. Barcelona,
Spain. Proceedings of the International Conference on Bioinformatics Models, Methods and
Algorithms. SciTePress - Science and and Technology Publications, 2013, p. 127-133.
3. VG Almeida, LFR Ferreira, C Correia, Hemodynamic parameters assessment. In: 2012 IEEE
2ND PORTUGUESE MEETING IN BIOENGINEERING (ENBENG), 2012. Coimbra,
Portugal. 2012 IEEE 2nd Portuguese Meeting in Bioengineering (ENBENG). IEEE, 2012, p.
1-6.
4. VG Almeida, J Borba, TM Pereira, HC Pereira, JMR Cardoso, C Correia, Validation of a
waveform delineator device for cardiac studies: Repeatability and data mining analysis. In:
2012 IEEE 2ND PORTUGUESE MEETING IN BIOENGINEERING (ENBENG), 2012.
Coimbra, Portugal. 2012 IEEE 2nd Portuguese Meeting in Bioengineering (ENBENG).
IEEE, 2012, p. 1-4.
5. VG Almeida, T Pereira, E Borges, JMR Cardoso, C Correia, HC Pereira, 2011. A real
time cardiac monitoring system - Arterial Pressure Waveform Capture and Analysis. In:
INTERNATIONAL CONFERENCE ON PERVASIVE AND EMBEDDED COMPUTING
AND COMMUNICATION SYSTEMS, 2011. Vilamoura, Algarve, Portugal. Proceedings of
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the 1st International Conference on Pervasive and Embedded Computing and Communication
Systems. SciTePress - Science and and Technology Publications, 2011, p. 83-90.
6. VG Almeida, TM Pereira, HC Pereira, JMR Cardoso, C Correia, C., A cardiac signal
monitoring and processing system. In: 2011 1ST PORTUGUESE MEETING IN
BIOENGINEERING - THE CHALLENGE OF THE XXI CENTURY (ENBENG), 2011.
Lisbon, Portugal. 1st Portuguese Biomedical Engineering Meeting. IEEE, 2011, p. 1-4.
7. V Almeida, P Santos, E Figueiras, E Borges, T Pereira, J Cardoso, C Correia C.,
2011. Hemodynamic features extraction from a new arterial pressure waveform probe.
In: INTERNATIONAL CONFERENCE ON BIO-INSPIRED SYSTEMS AND SIGNAL
PROCESSING, 2011. Rome, Italy. Proceedings of the International Conference on
Bio-inspired Systems and Signal Processing. SciTePress - Science and and Technology
Publications, 2011, p. 195-200.
8. V Almeida, T Pereira, E Borges, E Figueiras, J Cardoso, C Correia, HC Pereira, JL
Malaquias and J B Simes, 2010. Synthesized cardiac waveform in the evaluation of
augmentation index algorithms. In: 3RD INTERNATIONAL JOINT CONFERENCE
ON BIOMEDICAL ENGINEERING SYSTEMS AND TECHNOLOGIES (BIOSIGNALS
2010), 2010. Valencia. Proceedings of Conference on Biomedical Engineering Systems and
Technologies. 2010.
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Cardiovascular Diseases
This chapter presents some of the more important physiological aspects of CVD. Along the sections,
the most relevant risk factors are summarized and several diagnostic techniques are discussed. The
more used commercial devices are presented and, the most relevant parameters used in research and
clinical practise detailed. Nowadays, the concern to change the current healthcare paradigm, from
reactive towards preventive, justifies the growing interest in non-invasive techniques and new tools
for the management of the CVD risk assessment.
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2.1 Motivation
According to the World Health Organization (WHO), CVD represent 31 % of all global deaths [21],
and are the leading cause of death worldwide. As societies become more developed and the standard
of living improves, CVD increase in prevalence due to the life expectancy growing. However, the
improvements in living standards, are responsible by the decline of the mortality values, owing to
increasing knowledge and treatment of risk factors. This means that, although CVD mortality rates
are now decreasing in developed countries, the problem continues to escalate globally because rates
in developing regions are increasing.
Arterial stiffness and pressure wave reflection have gained increased attention of the clinical
community and, the prognostic value of these novel parameters and their association with
cardiovascular disease has been the subject of many clinical studies [22, 23]. The arteries can
be divided in four different groups: elastic arteries, medium muscular arteries, small arteries and
arterioles. The elastic properties of the arteries change along the arterial tree, being the proximal
arteries more elastic, and the distal arteries more stiff. Heterogeneity is caused by the molecular,
cellular and histological structure of the arterial wall, which differs between the various parts of
the arterial tree [19]. It is an important physiological and pathological factor that causes the pulse
amplification along the arterial tree. This amplification occurs from central to distal arteries due
to the occurrence of the wave reflections, that happens generally in peripheral arteries, since the
reflection sites are closer to the peripheral arteries, than to the central arteries.
Aortic stiffness has an independent predictive value for fatal and non-fatal coronary events and
fatal strokes in patients with various levels of cardiovascular risk [2, 24–26]. The aorta is the major
vessel of interest, but measurements of the local carotid stiffness may also provide an important
prognosis, since this artery is a frequent site of atheroma formation [2]. The carotid artery belongs
to the group of elastic arteries, being the muscular media layer relatively thin and, therefore the
thickening of the arterial wall is essentially caused by intimal thickening. The structure of a elastic
artery wall is organized in three different layers, as presented in Figure 2.1. The innermost layer is
the tunica interna (ou tunica intima), the middle layer is the tunica media and the outermost layer is
the tunica externa (or tunica adventitia).
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Figure 2.1: Structure of a medium-size elastic artery. Adapted from [27].
The increasing awareness of arterial stiffness [2, 28] started a new era of search for parameters
capable of, directly or indirectly, quantifying its development. There are several advantages of using
non-invasive methods, over invasive measurements. For instance, non-invasive methods can be used
in follow-up trials of populations free from symptomatic CVD, such as children or young adults.
Furthermore, these measurements might be a tool for risk stratification in addition to the established
risk factors, for high risk populations, aiming the disease prevention. It is possible to assess regional
and local arterial stiffness directly, and non-invasively, at various sites along the arterial tree. On the
other hand, the systemic arterial stiffness can only be estimated from models of the circulation [2].
Increased arterial stiffness, determined invasively, has been shown to predict a higher risk of
atherosclerosis, which it is involved in several pathological processes that can lead to heart attacks
(coronary heart disease) and strokes (cerebrovascular disease) [4,29]. Atherosclerosis is responsible
by the narrowing of the arterial wall, and it is a serious disease that affects many people [30].
The main situations that effect the normal blood flow are: the encroaching of the lumen, which
originates localized stenosis, the formation of thrombus that narrows the arterial lumen, the stiffening
of arteries that leads to the wave reflections occurrence in upstream vessels, and the encroaching
of the media that causes the destruction and atrophy of structural elements, which can lead to
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aneurysms formation. The major sites associated to its development are the carotid, the cerebral, the
epicardial coronary, the femoral and the iliac arteries, as well as the infrarenal part of the abdominal
aorta. The major risk factors associated to its development are: age, male gender, hypertension,
hypercholesterolemia, smoking habits (SMK) and adiposity [31] (see Section 2.2).
A heart attack can occur when the blood flow to the heart is cut off, due to a thrombus on
a ruptured atherosclerotic plaque. This causes a shortage in the supply of oxygen and nutrients,
that can damage the heart muscle. [21]. The pathology of ischaemic stroke includes, besides
thrombus formation in atherosclerotic cerebral blood vessel, small vessels in the brain [32]. A
possible bleeding caused by rupture of a blood vessel, caused by an aneurysm, can also be a cause.
Additionally, strokes can also be caused by a blood clot that may travel through the blood vessels to
the brain, as a consequence of irregular heartbeat [21].
There are evidence in studies of Dernellis and Panaretou [33] and of Liao et al. [34], together
with earlier studies, that arterial stiffness and hypertension interacting with each other in a
bidirectional manner. Liao et al. hypothesised that greater arterial stiffness in large and medium-
sized arteries represents a cumulative adverse impact of conventional risk factors on the arterial
wall, and that arterial stiffness, together with its adverse impact on other target organs, such as the
kidneys, contributes to the development of hypertension. There are also evidence that aortic stiffness
and arterial pulse wave reflections are key determinants of elevated central systolic pressure and that
they are associated with adverse cardiovascular outcomes [35].
2.2 Risk Factors
Risk factors can be divided in two general types, of non-modifiable and modifiable natures. In the
first group parameters are included parameters, such as hypertension, SMK and elevated cholesterol
levels, whereas the non-modifiable group includes parameters, such as age, socio-economic status
and heredity. Although, the non-modifiable factors cannot be modified, their presence helps to
identify subjects at greatest risk, enabling vigorous treatment of the risk factors that can be modified.
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2.2.1 Non-Modifiable
2.2.1.1 Ageing
Ageing is associated with changes in a number of structural and functional properties of large
arteries, including diameter, wall thickness, wall stiffness, and endothelial function [36]. Progressive
Intima-Media Thickness (IMT) caused by age has been reported [37]. Other studies showed that the
vascular ageing is accelerated by the coexistence of several cardiovascular risk factors [38,39], such
as hypertension or diabetes. Thus, it is expectable the reduction of the life expectancy for a young
person, if preventive measures are not adopted.
2.2.1.2 Genetics
The importance of the familial prevalence of early-onset CVD is not yet completely understood
in clinical practice [40]. However, there is evidence of a strong heritability relation of many
cardiovascular risk factors in premature CAD [41]. Therefore, it is important that the familial
prevalence of atherosclerosis disease, diabetes mellitus or hyperlipidaemia should be systematically
investigated in the first-degree relatives with early-onset CAD in men (before 55 years old), and, in
women (before 65 years old).
2.2.1.3 Socio-Economic Status
Familial history is also dependent of the surround environment. Multiple prospective studies have
shown that people with low socio-economic statues, i.e. low educational level, low income, low-
status job or living in a poor residential area, present an increase in the CVD mortality risk [42, 43].
2.2.2 Modifiable
2.2.2.1 Obesity
Obesity has not been considered an independent risk factor for CAD development. However, fat,
and in particular intra-abdominal visceral fat, is associated with the increase of the free fatty acids
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secretion, hyperinsulinaemia, insulin resistance, hypertension and dyslipidaemia [44]. Abdominal
obesity is also considered an independent risk factor for the development of atherosclerosis, namely
in obese children [45]. The relationship between the obesity and aortic stiffness was already
demonstrated [46], as well as the association of the abdominal fatty deposits with inflammatory
markers, namely the C-Reactive Protein (CRP) [47].
2.2.2.2 Blood Pressure
High Blood Pressure (BP) is a risk factor for Coronary Heart Disease (CHD), heart failure, peripheral
vascular disease, and renal failure in both men and women [48]. The amount of blood pumped by the
heart, and the size and condition of the arteries are determinant in the BP [40]. However, many other
factors can affect BP including the condition of kidneys and the levels of various hormones in the
body. Some people experience essential hypertension, that is a type that has no identifiable cause,
while others present secondary hypertension, that is caused by an external physiological condition,
such as kidney problems or certain medicines.
There are evidences that BP values are associated with the increase of the relative risk of
CVD [49, 50]. Recently, more emphasis has been assigned to the role of Pulse Pressure (PP) and
isolated SBP in the identification of individuals at high risk. As a matter of fact, it is important to
raise awareness regarding hypertension, the leading cause of mortality globally, and to renew efforts
to reduce sodium intake and hypertension control [51].
2.2.2.3 Diabetes
Prevention of CVD in diabetic patients follows the same general principles as in healthy subjects,
but with special concern with the glucose monitoring [40]. Several studies have demonstrated that
diabetic patients have an increased risk, when compared with healthy participants [52, 53].
Diabetes are classified in accordance with the different clinical stages of hyperglycaemia. Four
main categories have been identified in literature: type 1, type 2, other specific types, and gestational
diabetes. Subjects with diabetes type 1 are characterized by a deficiency in insulin levels due to
destructive lesions of pancreatic B-cells, which typically occurs for young subjects. Type 2 diabetes
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are caused by the combination of the decrease in insulin secretion and sensitivity. Its prevalence
comprises 90 % of adults with diabetes, and it is typically developed, after middle age, in obese
and physically inactive patients. Gestational diabetes arises from glucose perturbations that occur
during pregnancy, but it generally disappears after delivery. However, females with gestational
diabetes have higher probability to develop diabetes over time [54].
2.2.2.4 Smoking
Cigarette smoking is the most important modifiable risk factor. It is responsible for 50 % of all
avoidable deaths in smokers, half of these due to CVD [40]. Smoking is associated with increased
risk of all types of CVD diseases. Although the rate of smoking is declining in Europe, it is still
very common among individuals who have received little education; and widening education-related
inequalities in smoking-cessation rates have been observed in many European countries in recent
years [55]. Changing smoking behaviour is one of the most effective and cost effective things that
can allow to improve CVD health, since several of the advantages are almost immediate, in spite of
others take more time [51, 56].
2.2.2.5 Biomarkers
Established biomarkers associated to cardiovascular risk include dyslipidemia and glucose levels.
However, the number of potential novel markers is expanding yearly, each time the possible
candidates pass through the grading of clinical evidence. Novel biomarkers included: inflammatory
(CRP, fibrinogen) and thrombotic markers (homocysteine), lipoprotein-associated phospholipase
(LpPLA2) or the Renin-Angiotensin-Aldosterone System (RAAS). A short overview of these
parameters is presented bellow:
• Cholesterol
Several studies have established the crucial role of dyslipidaemia, namely the
hypercholesterolaemia in the development of CVD [51, 57]. The evidence that the reduction
of the plasma cholesterol contributes to decrease the CVD risk is strongly accepted. In
blood plasma, the cholesterol is bound to various proteins (apoproteins) to form lipoproteins.
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The most important types are the Low-Density Lipoproteins (LDLs) and the High-Density
Lipoproteins (HDLs). Most of the cholesterol in blood plasma is normally carried in
LDL and, over a wide range of cholesterol concentrations, it is strongly and positively
associated with CVD risk [58]. Epidemiological studies, as well as trials with angiographic
or clinical endpoints reinforce that the reduction of LDL cholesterol must be of prime
concern to adopt during CVD prevention [40]. Every 1.0 mmol/L reduction in LDL
cholesterol could correspond to 20−25 % of risk reduction in CVD mortality and non-fatal
myocardial infarction [59]. Lower HDL concentrations are strongly associated with higher
CVD risk levels. Several studies have demonstrated that the HDL cholesterol can contribute
substantially to the risk prediction [40, 60]. There is also evidence that the combination
of moderately elevated triglycerides (TGL) and low concentrations of HDL cholesterol is
a very common situation in high-risk patients with type 2 diabetes, abdominal obesity, insulin
resistance, or for those who are physically inactive [61].
• Tryglicerides
The role of the plasma TGL, as a risk factor for CVD, for both men and women, in the general
population, is being discussed for many years [62]. However, its effect is attenuated by the
adjustment of other factors, namely the HDL cholesterol [40, 63].
• High sensitive C-reactive protein
High-sensitivity CRP has shown high consistency across a large prospective study underlying
the development of unstable atherosclerotic plaques [64]. Other authors also included CRP
in the evaluation of incremental usefulness of multiple biomarkers for predicting the risk of
cardiovascular events [40, 65].
• Homocysteine
Several studies reported the association between homocysteine levels and different measures
of arterial stiffness [64]. However, it was observed that the magnitude of its effect on risk is
modest, and the consistency is often lacking, mainly due to nutritional, metabolic (e.g., renal
disease) and lifestyle markers [65].
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• Lipoprotein-associated phospholipase 2
LpPLA2 has recently emerged as a marker with high associated consistency and precision,
and as an independent risk factor in the plaque rupture and atherothrombotic events. Recent
studies showed its continuous association with the risk of CHD, with similar magnitudes as
the ones verified with non-HDL cholesterol or SBP prevalence [66].
• Renin-angiotensin-aldosterone system
Serum aldosterone and plasma renin are markers of the neuro-hormonal activity and, it
is recognised that patients with hyper-aldosteronism present higher arterial stiffness [67].
Despite the role of the RAAS in modulating the arterial compliance, in essential hypertension
and in normotensive subjects, is not clear, it has been related to the measurements of the
arterial stiffness, such as PWV. It was verified that carotid-femoral PWV is higher in patients
with primary aldosteronism, when compared with patients with essential hypertension and
with healthy subjects [64].
2.2.3 Prevalence in Portugal
In Portugal, during 2011, 31670 people died (≈ 31 %), from CVD, being 5.9 % reported
hypertensive disease, 22 % ischaemic heart disease and, 20 % cerebrovascular disease. These values
represent a decreased of 1.6 %, since 2008. The knowledge about the differences in prevalence of the
major risk factors by gender and region can influence cardiovascular prevention strategies. Health
surveys based on interviews and questionnaires have been the common methodology employed by
the Portuguese National Health Survey. Statistical studies have been carried out periodically, since
1987, based on interviews, providing information about risk factors [68].
The AMALIA study [69] was an important epidemiological study carried out in Portugal with
the purpose to assess the prevalence and distribution of the main risk factors. The prevalence of the
risk factors considered, were identified in the following descending order: sedentarism (76 %),
overweight/obesity (51.6 %), hypertension (23.5 %), hypercholesterolemia (19.7 %), smoking
(16.3 %), and diabetes (8.9 %). The self-reported prevalence of hypertension was higher in women
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(24.9 %) than in men (21.8 %) and, the higher prevalence was verified for obese or sedentary
participants, or in individuals with family, or had a family historic of CVD. It is also interesting
to note that the smoking prevalence in these three high risk groups was low. However, the same was
not true for those with a family history of CVD, probably because of the lower awareness of the risk.
2.3 Diagnostic Tools
There are several methods that can be used for the CVD diagnosis, but only some of them are widely
applicable in the clinical settings. A brief review of those methods is presented in this section.
2.3.1 Blood Pressure Monitoring
BP measurement is the basis of the cardiovascular diagnosis, management, treatment, epidemiology
and research of hypertension. An accurate BP reading is a pre-requisite, regardless the used
technique [70]. The oscillometric method is used for BP measurement, involving the analysis of
the oscillations in the cuff pressure. SBP is generally easily identified as the cuff pressure where the
oscillations begin. The DBP has not always correspondence with the vanishing of the oscillations
and generally the devices employ proprietary algorithms to identify its value [9]. Pereira, H.C. [71]
developed an apparatus for pressure values measurement based on accelerometers that is now under
provisional patent.
Ambulatory blood pressure monitoring (ABPM) has gradually established its utility, not only
in the research field but also in clinical practice, as it allows the study of the BP, Heart Rate (HR)
and circadian 24-h BP profile of the patients [72, 73]. The 24-h BP parameters are reproducible
and correlate better with target organs damage than the office BP [11]. There is also evidence
that ambulatory values predict better cardiovascular morbidity and mortality, rather than office
values [74, 75]. Investigations using a photoplethysmographic system have been carried out by
several authors, in Massachusetts Institute of Technology (MIT) [76], but also by other research
groups [77, 78].
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2.3.2 Applanation Tonometry
The applanation tonometry is a non-invasive method that can be applied in superficial arteries that
are flattened against a bone structure [79]. This technique is only reliable in peripheral arteries to
avoid the effect of the subcutaneous tissues between the tonometer and the artery. The disadvantages
of the tonometer include the required operator sensitivity to the sensor placement, because it should
be properly immobilized upon the artery of interest, as well as the movement artefacts that may lead
to signal distortions, during the data acquisition [79, 80].
2.3.3 Photoplethysmography
Photoplethysmography (PPG) is the more common method used for pulse wave recording, and it is
based on the finger blood volume monitoring [9,81]. It uses a light emitter and a detector to measure
the pulsatile blood flow. Recent studies have highlighted the use of the PPG signal in blood volume
changes monitoring [82], and in pulse waveform analysis. Other studies extended the use of the PPG
waveform for the detection of ventricular ejection and for the identification of other relevant pulse
transit parameters [83].
2.3.4 Optical Sensors
A simple photoelectric method for measuring vessel diameter changes was developed by Pereira, T.
et al. [84] by employing distinct types of silicon optical sensors, such as a planar type from Silonex
and an avalanche photodiode from Advanced Photonics. Additionally, appropriated light emitting
diodes (LEDs) were used as the light source. It was observed that the probes are able to detect and
reproduce the waveform distension .
2.3.5 Angiography
Imaging methods can be relevant in CVD risk assessment in individuals with moderate risk. The
”gold standard” imaging method is intracoronary angiography, that allows to localize and to quantify
vessels occlusions. This is traditionally done by injecting a radio-opaque contrast agent into the
19
2. CARDIOVASCULAR DISEASES
blood vessel and imaging using X-ray based techniques such as fluoroscopy. However, this method
is invasive, carrying risk for the patients [85].
2.3.6 Magnetic Resonance Imaging
Methods based on flow pulse detection using magnetic resonance imaging have been proposed as a
non-invasive option for the arterial PWV computation or even local distensibility [18,86]. However,
MRI time resolution is below the one required for flow detection, limiting its clinical application.
2.3.7 Ultrasounds
Risk assessment using carotid ultrasound is based on the measurement of the IMT, and in the
presence of plaques and their characteristics [87]. Individuals without known CVD with high
increased IMT have high risk of cardiac events and stroke [40].
Arterial diameter can be determined very accurately by ultrasound [88]. Several diameter
calibration schemes have previously been reported [89–91]. The ultrasound system measures the
intensity of the echo, providing information about the type of structures in the scanned region. The
technology is especially accurate in the detection of the interface between solid and fluid filled
spaces, which is a key requirement in the vascular analysis. Superficial structures such as vessels,
muscles, tendons, breast and the neonatal brain are imaged at higher frequencies (7 to 18 MHz),
which provides better axial and lateral resolution. On the other hand, deeper structures such as liver
and kidney are imaged at a lower frequencies (1 to 6 MHz), which provides lower axial and lateral
resolution, but higher penetration depth [92].
2.4 Parameters used in Arterial Stiffness Assessment
The non-invasive measurement of arterial stiffness implies the measure of surrogate parameters that
are intrinsically associated with its development [6, 93]. Three main methodologies are involved:
pulse transit time or PWV, analysis of the arterial pressure pulse and its wave contour, and direct
stiffness estimation by measuring the diameter and vessel distending.
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2.4.1 Pulse Wave Velocity
The PWV measurement is generally accepted as a simple, non-invasive, robust, and reproducible
method that can be applied to the arterial stiffness estimation [13]. Measurements along the
aortic and the aorto-iliac pathway are the most clinically relevant values. A systematic review,
concerning the predictive value of the aortic PWV in cardiovascular events and all-cause mortality,
was presented by Vlachopoulos et al. [94], where 15877 subjects were included, from the meta-
analysis of 17 longitudinal studies. Carotid-femoral PWV was also studied by Laurent et al. [95]
and by Boutouyrie et al. [1]. They proved that the aortic stiffness is an independent predictor of
primary CHD in patients with essential hypertension.
There are several algorithms that can be employed on the PWV measurements, being the time
delay measured between the foot of two waveforms the most usual [96, 97]. It is also important to
consider the heterogeneity of the available algorithms. For example, there is no universal consensus
concerning the distance that should be introduced in the PWV equation for its computation [94].
2.4.2 Waveform Parameters
There are several characteristics in the arterial waveform that are indicative of arterial disease [9].
The wave reflections are probably the most studied, often addressed in several studies. The AIx
is one of the most relevant parameters in this field, which expresses the ratio of the augmented
pressure, assigned to the reflected wave into the overall pulse. Increased AIx and arterial stiffness
are highly associated with several cardiovascular risk factors, such as age, smoking, hypertension,
diabetes mellitus, and hypercholesterolemia. There is also a strong correlation between them and
the high risk of developing CAD.
Another common hemodynamic measurement is the Sub-Endocardial Viability Ratio (SEVR),
also known as the Buckberg ratio, that represents the ratio between the myocardial perfusion supply
and its demand. It can be calculated measuring the ejection length, determined from the peripheral
pulse, the area under the systolic and diastolic portions of the pressure waveform. A lower SEVR
may indicate a decrease in the myocardial perfusion.
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Further, other parameters can be identified based on the most relevant feature points. Parameters,
such as the Reflected Wave Transit Time (RWTT), which is calculated as the elapsed time from
the wave foot to the systolic inflection point can be referred as an indirect measurement of the
arterial compliance. The Systolic Wave Transit Time (SWTT) can also be computed. Additionally,
the systolic ejection time is related with the elapsed time between the beginning of the pulse and
the closure of the aortic valve, as indicated by the dicrotic notch, or incisura. This parameters is
commonly referred as the Left Ventricular Ejection Time (LVET). Lower ejection duration may be
indicative of systolic dysfunction in heart failure patients. A detailed description of these parameters
is presented in Section 4.4.6. A review of some studies regarding the association between wave
reflections and clinical endpoints is presented in Table 2.1
2.4.3 Diameter Based Parameters
The measurement of the diameter elastic properties of arteries is essential in the study of the dynamic
arterial properties. Different techniques have been employed in the distension measurements.
Mostly, these techniques are based on electrical, optical and ultrasonic technologies [98, 99]. The
arterial distension waveform is almost identical to the pressure waveform [30], but the diameter
based waveforms must be converted to pressure, by applying empirical exponential relationships.
Most of these techniques have been used in clinical applications. The simultaneous assessment
to the diameter and pressure waveforms have been employed in some studies, allowing the
computation of the incremental compliance, distensibility, PWV and elastic modulus [89, 98]. The
current commercial devices are essentially used to infer local PWV [100, 101]. However, other
authors [90, 102] have developed techniques, based on ultrasound image analysis to assess the
systolic local arterial BP, from the analysis of the B-mode diameter waveforms. The evaluation
methods require some technical skills and have not been yet generalized to the clinical practice.
Other works, related to the management of neurosurgical disorders, have also considered the
waveform morphology of other physiological signals, such as the intra-cranial pressure through the
analysis of peak locations [103,104], and the temporal dependency between successive pulses [105].
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2.5 Clinically Approved Devices
The available commercial devices generally estimate the arterial stiffness by the analysis of PWV or
AIx values [117].
• Complior
The Complior System (Alam Medical, Les Lilas, France) [118] employs dedicated pressure
sensors, directly applied on the skin. It has been widely applied in the carotid-femoral
segment [119], and it uses two probes that allow PWV measurement based on the transit
time measured between probes. The measurement requires two operators: the first one begins
positioning the probe on the common carotid artery, in the central detection site; while the
other operator places a second probe at the femoral artery site. The transit time is determined
by employing a correlation algorithm between each simultaneous recorded wave.
Its newer version, the Complior Analysis, offers, in addition to the distension waveform
information, the recording of the pressure wave, allowing the assessment of the central
pressure and pulse wave analysis [120]. The central BP is not estimated using a transfer
function, but using another method based on the second systolic peak (SBP2) of the peripheral
waveform. Another relevant difference between both Complior versions is related with the
algorithms used for the wave foot determination. In the first version, it was employed a
foot-to-foot algorithm based on the wave second derivative, whereas in the last version, an
algorithm based on the intersecting tangent is used. The first results from the newer version
were presented by Sztrymf et al. [120], in a limited population of 12 subjects, and the SBP2
and AIx were only detected in 4 out of the 12 subjects. In spite of the limited number of
samples, the results demonstrated that the pressure waveforms are acquired with accurately
by this device. The mean difference between the invasive measurements and Complior form
factor was 4.2±2.8 % and, differences of 0.4±1.7 % and −0.09±2.8 % were detected for
the SBP2 and AIx, respectively.
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• SphygmoCor
The SphygmoCor system (ArtCor, Sydney, Australia) [121] is a non-invasive diagnostic
device that enables the analysis of the central and ascending aortic pressure wave, using a
single high-fidelity applanation tonometer (Millar). The pressure wave is calibrated through
a brachial cuff and, it is then converted to the ascending aortic waveform using a generalised
mathematical transfer function. The Millar tonometer used by SphygmoCor was introduced
in 1989 by Kelly et al. [122]. Its performance was assessed by comparing, directly and
indirectly, recordings of the radial pressure waves in 62 subjects, of the femoral pressure
waves in 3 dogs and of the carotid pressure waves in 17 subjects. It was shown that is possible
to monitor the arterial pressure wave contour under a wide variety of clinical conditions
and pulse pressures. However, small differences were observed in the frequency analysis,
namely, the trend to overestimate the 1st harmonic and to underestimate moduli above 4th
harmonic [120]. SphygmoCor is also capable to perform measurements of a wide number of
parameters, such as AIx, PWV, Ejection Duration (ED), HR, dp/dt, SBP, DBP, SEVR.
Several authors have validated SphygmoCor system measurements, by comparing the
peripheral to central aortic transfer function data, against transducer-tipped catheter
measurements [123, 124], while others have been dedicated to the study of the calibration
algorithm [125]. The accuracy of the aortic AIx determination showed a consistence,
presenting a moderated underestimation of the aortic AIx [126]. In what concerns the pressure
values, Cloud et al. [125], obtained on average, an underestimation of the SBP in 13.3 mmHg
and an overestimation of the DBP in 11.5 mmHg.
• Finapress
Finapress (Finapres Medical Systems, Amsterdam, The Netherlands) uses the volume-clamp
method, in which the finger artery is gauged with an infrared transmission plethysmograph
mounted inside an inflatable cuff. When the size of the artery increases due to the higher blood
volume (and pressure), the air pressure in the cuff also increases, in order to keep the arterial
size constant. The arterial size and the transmural pressure are kept constant, by modulating
the cuff pressure in parallel with the BP in the finger, through a pneumatic servo system.
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• Arteriograph
The Arteriograph (TensioMed Kft., Budapest, Hungary) is an oscillometric based device used
for BP, AIx and PWV computation [117]. The oscillometric pressure curves are registered in
the upper arm (brachial artery). Initially, the BP is measured in the upper arm, followed by
the increase of the cuff pressure, 35 mmHg above the SBP measured. For the analysis of the
pulse wave, the time difference between the beginning of the first wave and the beginning of
the second (reflected wave), required for the PWV measurement, is identified. Then, the AIx
is computed by the amplitude difference between the first and second wave in relation to the
pulse pressure.
The PWV and AIx values, measured using the Arteriograph, were compared with the
corresponding Complior and SphygmoCor measurements, in 254 untreated hypertensive
patients. It was verified that the Arteriograph PWV and AIx values are closely related, when
compared with Complior (r = 0.60, p < 0.001) and SphygmoCor (r = 0.89, p < 0.001).
• PulsePen
The PulsePen (Diatecne, Milan, Italy) is an instrument used in several population studies
and clinical trials, for the assessment and analysis of the pressure waveforms, and for the
measurement of arterial distensibility [127, 128]. It is composed by one tonometer and
an integrated electrocardiogram (ECG) unit, and it provides the PP values. The system is
calibrated to the mean arterial pressure value and the DBP is obtained using a conventional
method. Salvi, et al. [129] performed a clinical validation, by monitoring the pulse waves in
the carotid artery, using the PulsePen versus the intra-arterial simultaneous measurements, in
10 patient undergoing cardiac catheterization. The invasive signals were recorded at the origin
of the ascending aorta, and at the initial tract of the carotid artery, using fluid-filled catheters;
while non-invasive waveforms were recorded at the common carotid artery and at the base of
the neck (bottom carotid). The comparison between both methods showed no differences
in spectral moduli from harmonics 1 to 6. Additionally, a good PWV performance was
verified from the data collected with the PulsePen, in comparison with the Millar tonometer
measurements in 68 subjects
26
2.5. CLINICALLY APPROVED DEVICES
2.5.1 Standardization of Measurements
The standards for evaluation medical measurement devices are set by three main professional
societies: the Association for the Advancement of Medical Instrumentation (AAMI), the British
Hypertension Society (BHS) and the European Society of Hypertension (ESH) [9]. The oldest
standards for devices validation are related to the sphygmomanometers and were published by
AAMI in 1986.
In what concerns the waveform analysis, the existence of devices using different technologies,
renders the use of waveform based parameters difficult in clinical practice, namely in the elaboration
of proper reference values. Comparative studies have been made by several authors that evaluated
the correlation of data obtained with different devices. Salvi et al. [130] compared the Complior and
the PulsePen devices and, verified that the PWV is significantly lower when measured by Complior.
These differences occur due to the use of different algorithms in the computation of the foot-to-foot
time delay. This study also shows that is not possible the definition an absolute reference for PWV,
without consider reference values for each one of the available devices. In another study from Jatoi
et al. [117], it was also verified a poor agreement between the PWV and AIx measurements for
devices (Arteriograph, Complior and SphygmoCor).
2.5.2 Accuracy Validation Studies
Beside the biological variability of a human being, the reproducibility depends on two technical
factors. On the one hand the variation of the measurement method and, on the other the effect of the
operator. Several investigations can be found regarding this topic for several devices in literature.
In order to apply reproducible data in clinical practice, three levels of acceptance of the
measurements have been used in literature. Good variability is defined below 10 %, variability
values between 10 % and 30 % are considered satisfactory, but dependent of the use in practice, the
cost, and the availability of alternative methods, and finally, variabilities over 30 % are considered
unsatisfactory [131, 132].
Unfortunately, the comparison between measurements from different devices is hard, since
different statistical measures are used by each one of the studies, such as the Coefficient of
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Variation (CV), Standard Deviation (SD), Repeatability Coefficient (RC) or 95 % Confidence
Interval (CI). The intra-observer variability can be assessed by the same observer on different
but close occasions and the inter-observer variability correspond to the measurements performed
by independent observers. The day-to day variability is another typical measurement that can be
assessed by the same observer at different occasions (after few days or weeks). A comparison of
obtained values from relevant published literature is presented in Table 2.2.
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Table 2.2: Comparison of variability values obtained from different commercial devices.
Device Parameter Variability Test Values n Ref
Complior
PWV
Intra-observer
CI
3.30 %
20 [131]Inter-observer 2.60 %
Day-to day 5.60 %
PWV
Intra-observer
RC
0.935
56 [119]
Inter-observer 0.89
PulsePen
PWV Inter-observer CV 7.94 %
68 [129]
Intra-observer 7.20 %
AIx Inter-observer CV 15.80 %
Intra-observer 15.15 %
SphygmoCor
PWV aor
Inter-observer
Bland-Altman
(mean±SD)
0.3±3.2 m/s
19 [133]
Day-to-day −0.7±1.9 m/s
Intra-observer1 −1.0±3.9 m/s
Intra-observer2 −0.1±3.6 m/s
Intra-observer3 −0.3±2.4 m/s
AIx
Inter-observer 0.9±15.8 %
Day-to-day 2.6±11.2 %
Intra-observer1 2.7±18.8 %
Intra-observer2 1.9±10.6 %
Intra-observer3 0.9±9.3 %
RWTT
Inter-observer −1.9±30.8 ms
Day-to-day −2.4±12.3 ms
Intra-observer1 −6.9±52.7 ms
Intra-observer2 −2.7±32.8 ms
Intra-observer3 −3.2±33.9 ms
AIx
Inter-observer
Bland-Altman
(mean±SD) 0.4±6.4 %
25 [134]
Intra-observer1
(mean±SD)
14.8±12.7 %
Intra-observer2 12.6±14.3 %
Intra-observer3 12.7±14.0 %
Intra-observer4 12.8±14.1 %
Intra-observer5 9.4±14.0 %
Intra-observer6 12.2±12.0 %
AIx@75HR Inter-observer Bland-Altman
(mean±SD)
1.0±3.9 %
20 [135]Intra-observer −1.5±7.0 %
Intra-observer 0.1±8.0 %
AIx Intra-observer Bland-Altman (SD) 7.50 % 302 [136]
Ultrasound
(Aloka
Pround)
AIx
Intra-observer
CI
17.80 %
20 [131]Inter-observer 8.40 %
Day-to day 23.80 %
CV−Coefficient of Variation, SD−Standard Deviation, RC−Repeatability Coefficient, CI−95 %
confidence interval
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2.6 Reference Values
The purpose of this section is to provide reference values from a survey of the literature about
normal and reference values for the set of parameters used in this document, namely information
about the BP values, the biochemical markers levels, as well as, indications about the PWV and
APW parameters.
2.6.1 Blood Pressure
Elevated BP is a major risk factor for several diseases, such as heart failure, cerebrovascular disease,
renal failure and atrial fibrillation. The standard definition and classification of the hypertension
levels is shown in Table 2.3.
Table 2.3: Definition and classification of hypertension. Values based on [40].
Category SBP (mmHg) Condition DBP (mmHg)
Optimal < 120 and < 80
Normal 120−129 and/or 80−84
High Normal 130−139 and/or 85−89
Grade I hypertension 140−159 and/or 90−99
Grade II hypertension 160−179 and/or 100−109
Grade III hypertension ≥ 180 and/or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
2.6.2 Body Mass Index in Adults
The Body Mass Index (BMI) has been extensively used in the body weight analysis. In adults,
overweight is defined by a BMI ranging from 25 to 29.9 kg/m2, and obesity by a BMI ≥ 30 kg/m2.
It is proved that high BMI is associated with risk of CVD [137].
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2.6.3 Dyslipidemia
Dyslipidemia is connected with the abnormal amount of lipids in the blood. The most common
alterations are related to the increase of the plasma cholesterol and LDL cholesterol levels.
Hypertriglyceridemia and low HDL cholesterol levels are also independent CVD risk factors. The
threshold risk values are presented below:
• Plasma cholesterol - In general plasma cholesterol should be < 190 mg/dL [40].
• LDL cholesterol - LDL cholesterol should be < 115 mg/dL [40].
• HDL cholesterol - HDL cholesterol < 40 mg/dL in men and < 45 mg/dL in women may be
regarded as a marker of high risk [40].
• Tryglicerides - TGL value > 1.7 mmol/L is the threshold to be considered a marker of high
risk [40].
2.6.4 Augmentation Index
The peripheral and central AIx values increase with age and with the mean arterial pressure, and
are inversely related to the HR and body height. Janner et al. [138] studied 4561 subjects in
The Copenhagen City Heart Study, and calculated reference values for the AIx, measured with
the SphygmoCor. AIx reference equations considering age, HR and height were defined, for both
men (Equation 2.1) and women (Equation 2.2):
AIxmen = 79.20+0.63(age)−0.002(age2)−0.28(HR)−0.39(height) (2.1)
AIxwomen = 56.28+0.90(age)−0.005(age2)−0.24(HR)−0.34(height) (2.2)
Recently, many studies have AIx values in different races. Table 2.4 present some results
obtained from the analysis of different populations. Proposed values in South African [143], Chinese
[141] and Korean [142] populations are higher, comparatively to those estimated in Europeans. This
discrepancy might be due to the differences in the mean age of the populations (the European group
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Table 2.4: AIx reference values for different populations
Population Gender Mean Age (y) AIx (%) n Ref
European
Women 35.1±13.6 15.1±16.3 306
[139]
Men 34.6±13.4 7.2±14.6 228
American
Women 57±8 17±10 333
[140]
Men 56±9 9±12 188
Chinese
Women 38.7±11.6 21.0±14.4 456
[141]
Men 42.7±13.2 16.6±15.6 468
Korean Women/Men 36.3±9.6 28.2±43.0 522 [142]
African Women/Men 33.5±13.1 22.2±14.3 185 [143]
was younger), as well as due to the ethnic differences (e.g., the shorter stature evident of Korean
subjects). Wojciechowska et al. [139] (2006) observed central AIx values, for the European subjects,
very similar to the values obtained by Mitchell et al. (2004) [140], in the Framingham Heart Study
Offspring Cohort, despite the predominance of older subjects in the first study.
The detailed threshold values for different ages, presented in the European study [139], can be
seen in Table 2.5. The central AIx values were on average lower among men subjects. The authors
also observed that the values were curvilinearly related to age, but similar in men and women.
Table 2.5: AIx reference values for healthy white European subjects, measured using SphygmoCor.
Gender Age Group n AIx (%)
Men
< 30 106 −1.5±12.1
30-39 51 9.4±10.7
40-49 33 13.7±11.4
≥ 50 38 23.1±10.6
Women
≤ 30 134 3.7±14.3
30-39 64 16.6±10.2
40-49 56 25.6±10.6
≥ 50 52 31.1±8.7
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Comparisons between AIx and PWV measurements (considered the ”gold standard” parameters
for arterial stiffness estimation), have also been reported. Data from a large cohort of healthy
individuals, in the Anglo-Cardiff Collaborative Trial (ACCT), showed that the central AIx might
be a more sensitive marker of arterial ageing in young and middle-age individuals (< 50 years), and
that the aortic PWV is more sensitive in older individuals (>50 years) [144].
2.6.5 Pulse Wave Velocity
Commonly, the norms and reference group data, used for the statistical analysis are established
according to the health status, age and by combined hypertensive-diabetic status, but more rarely to
the hypertensive and normotensive degree. In Table 2.6 the results achieved by Elias, M. et al. [145]
are presented, from a sample (n = 502) ranged from 40 to 93 years old, after exclusion of individuals
with acute stroke, probable dementia, and diabetes history. The rise of the PWV values with age and
hypertension was observed, as expected.
Table 2.6: PWV reference values obtained using SphygmoCor system [145].
Type Age group n Value (m/s)
Normotensive
40-49 34 8.1±1.3
50-59 69 8.0±1.3
60-69 48 8.9±1.9
70-79 40 10.1±2.1
80-83 15 11.4±2.6
Hypertensive
40-49 17 8.6±1.5
50-59 63 9.3±1.5
60-69 85 10.3±2.3
70-79 84 12.3±3.1
80-83 47 13.1±3.1
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2.6.6 Waveform Analysis
Few studies regarding the waveform reference values can be found in the literature, due to the
novelty of its concept in the scientific community and the inherent difficulty in gather a population
size statistically significant. The studies in this area are mainly dedicated to RWTT, SWTT
and LVET analysis. A brief review of the observed values, organized by population groups, is
summarized in Table 2.7.
Table 2.7: Timing reference values for the RWTT, SWTT and LVET parameters.
Parameter Reference Gender n Value Ref
RWTT (ms)
Frimodt-Moller M. et al. Men/Women 19 137.1±32.1 [133]
Mitchell G. et al.
Men 188 138±28
[140]
Women 333 124±28
SWTT (ms) Mitchell G. et al.
Men 188 201±53
[140]
Women 333 210±29
LVET (ms) Mitchell G. et al.
Men 188 312±23
[140]
Women 333 320±22
2.7 Risk Assessment
The international guidelines [40, 146] consider that individuals with established CVD should be the
first priority for preventive measures application. The concern in changing the current healthcare
paradigm, from reactive towards preventive care, aims at identify individuals for risk in early stages,
and then, direct more efforts and attention to the risk factors modification [147, 148]. Fortunately,
this is an emergent tendency that can be addressed using the traditional risk scores or machine
learning techniques.
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2.7.1 Risk Scores
During the last years many risk estimation systems have been developed in order to assist clinicians
in the risk factor assessment, and in the individual chances prediction, for CVD development. The
major challenges of these tools are: (1) identify high risk individuals, (2) weight the individual
effects of all risk factors, (3) stratify or organize who needs lifestyle advice or medical therapy, and
finally (4) avoid overmedicalization of individuals at low risk [149]. Taking this challenges into
account, several risk factors were identified, by their association with an increased risk of CVD
development, such as atherosclerosis.
CVD risk assessment tools differ from each other on the selected risk factors, disease for what
they were designed (coronary heart disease, heart failure, etc.), selected event type, considered
period of time (long or short term) for the prediction and cohort location. The most popular are:
FRS, PROCAM, ASSIGN and SCORE.
2.7.2 Machine Learning Techniques
Computer-aided diagnosis methodologies, based on data mining and machine learning techniques,
have been used in many biomedical applications during the last years [150–153]. Amongst the many
different definitions that are found in the literature, data mining can be described as the automatic
or semi-automatic process for discovering patterns in huge amounts of data. These techniques
could contribute to the development of clinical decision-making approaches, using information taken
from different measurement setups, overcoming the limitations in the management of complex and
unstructured data [17, 150, 154, 155].
2.7.2.1 Classification Techniques
An interesting approach is the exploration of different classifiers, as it was proposed by Jovic et
al. [151]. The ECG classification problem was addressed using a combination of several features
in the analysis of the HR variability. Other approach presented by Tsipouras et al. [150] was based
on the development of a fuzzy rule-based decision support system for CAD diagnosis. On the
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other hand, multi-classifiers should perform better in some situations, overcoming errors from single
classifier analysis [156]. The incorporating of the prediction outcome of each one of the individual
classifier was suggested [157], as a way to reduce the classification errors.
2.7.2.2 Clustering techniques
Clustering analysis is another important branch of unsupervised learning that allows the arrangement
of objects into groups (i.e., the clusters), wherein the objects in the same cluster are more similar
(in one or more characteristics), than those in different clusters [158]. There is a wide variety of
clustering methodologies available in literature, essentially organized in three general classes [159].
The three types include parametric model-based, hierarchical and partitioning algorithms.
Shah, et al. [160] has proved the usefulness and feasibility of using clustering risk factors in
the detection of CVD in youth, by the comparison with the Patholobiological Determinants of
Atherosclerosis in Youth (PDAY) risk score. Other studies have also referred the role of clustering
methodologies in CVD assessment, such as the work developed by Haseena et al. [161], where a
fuzzy C-mean clustered probabilistic neural network for ECG beats discrimination was described.
Clustering methodologies were also applied in other medical fields, such as in the identification of
patterns in blood glucose measurements and regular insulin doses taken before meal time [162].
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Multichannel Biomedical Platform
In this chapter the multichannel biomedical platform is presented. The platform is based on
several modules interfaced to a standard PC for data processing, storage and display. A brief
discussion about the power management circuitry used to ensure the required autonomy of the
portable instrument, as well as the database connectivity and synchronisation mechanism between
all of the modules is presented. The APW module is described in detail, focusing on the hardware
blocks, the implemented firmware and the mechanical design. The system performance was assessed
in a test bench.
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3.1 Motivation
The underlying idea for the development of a multi-modular integrated instrument is the possibility
to sum up several technologies and methodologies used in the traditional clinical path of
cardiovascular patients in order to provide a refined assessment of their physiological status. Such
accomplishment is granted by the combination of traditionally available clinical information (ECG,
PPG), usually not fully correlated, with the one obtained with newly developed non-invasive
instrumentation modules. Together, these modules can provide a detailed profile of the arterial
pulse structure.
Several modules were developed in Electronics and Instrumentation Group - GEI
(Instrumentation Centre of the University of the Coimbra - Portugal), and in Institute of
Nanostructures, Nanomodelling and Nanofabrication - I3N (University of Aveiro). These modules
are dedicated to PWV assessment (double piezo and sound probes) [96,163], ECG monitoring, PPG
measurements [164], and pulse waveform measurements, using optical [84,165], piezoelectric [166]
and fiber-Bragg sensors [167]. Some of these modules have been implemented in the multichannel
platform, shown in Figure 3.1.
Figure 3.1: Multichannel biomedical platform.
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3.2 System Architecture
This multichannel platform was implemented using mainstream technologies and protocols,
mechanically based on a Schroff crate (24572-003 - 3U, 315MM, 42HP). A schematic view of
the system is illustrated in Figure 3.2, where it is possible to identify the main components. The
electronics rack provides the core of the real-time hemodynamic system, using a custom made
backplane bus for communication between the individual modules, and grants the interface with the
computer, and with the autonomous power supply (PS unit), a rechargeable 12 V lead acid battery.
A detailed description of each one of the developed modules is presented in the following sections.
Figure 3.2: System architecture of the multichannel platform, where M1, M2, M2, Mn are the
individual models, and PS is the power supply unit.
3.2.1 Power Supply Module
The entire electronics box is designed to run from a single 12 V DC power source, using an
embedded lead acid battery. From this power source several other DC power supplies lines are
derived using DC-DC converters. These supply lines are +5 V , +15 V , −5 V , −15 V and +3.3 V .
Each of these supplies is routed along the backplane to feed all of the modules. It is also ensured
common ground potential lines.
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Figure 3.3: Battery power test module.
Two power module versions were implemented. The first one with visual alarms that are
activated when specific voltage thresholds are reached (see Figure 3.1 - module 1). And another,
only available for laboratory trials, which allows the battery status monitoring during the discharge
process (Figure 3.3).
3.2.1.1 Autonomy
Tests on the battery autonomy were performed for two different discharge loads. It was considered
the discharge time, expressed as hours elapsed until a fully charged cell reaches the cut voltage and
has to be recharged. Figure 3.4 shows the constant current discharge behaviour of the battery with
Vbegin = 12.5 V and Vcut = 11 V . The blue and black curves in the plot correspond to the discharge
currents for loads of 24 Ω and 12 Ω, respectively. When the battery was subjected to a continuous
discharge current of ≈ 1 A, it reached an autonomy of about 3 hours, while when subjected to a
discharge current of ≈ 500 mA, it reached an autonomy of nearly eight hours.
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Figure 3.4: Discharge behaviour of the load acid battery with Vbegin = 12.5 V and Vcut = 11 V .
3.2.2 Bus
The backplane (100x100 mm2) printed circuit board (PCB) is the only physical communication
channel between the various cards inserted in the rack. Connections to each card are provided via six
64-pin DIN bus connectors. Five of these connectors are spaced at 4HP (1HP= 5.08 mm) from each
other, while another is at a distance of 6HP. It is an entirely passive device with three main groups
of signals. Fourteen lines are used for DC power delivering to each one of the cards, as outlined
in Section 3.2.1. The remain 52 pins of each connector are connected to the parallel bus, used in
the communication between the cards: 16 lines to analogue communication, and the remaining are
dedicated to digital channels. Its configuration is schematically represented in Figure 3.5.
3.2.3 Individual Models
The APW module was initially considered to operate as a standalone module. However, the clinical
trials evolved to a point, where it was considered the development of a multi-parametric integrated
instrument able to include other technologies useful for the characterization of the patients.
The implemented modules include: the APW module (presented in detail along this document),
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Figure 3.5: Backplane bus configuration.
the PPG module (developed by Pedro Santos [164]), the PWV module (developed by Catarina
Pereira [96]) and the ECG module (developed by Prof. Dr. Requicha Ferreira). Table 3.1 presents
the main characteristics associated to each of the modules. The PPG, PWV, ECG and NI 6210 (used
as the data acquisition board) modules are shown in Figure 3.6. The APW module is described in
detail in Section 3.3.
Table 3.1: Modules used in the multichannel platform.
Module Description Sample rate(min)
NI 6210
Multifunctional DAQ module that offers 16 analogue inputs, a
250 kS/s single-channel sampling rate, 4 digital input lines and
4 digital output lines
-
PWV Double-PZ probe devoted to PWV measurements 20 kHz
ECG 3-Lead ECG module with a 1st-order notch filter (50 Hz) 1 kHz
PPG
Photoplethysmographic module based on red and infrared (IR)
LEDs
1 Hz
APW
Dedicated system to APW (single PZ probe), and respiration
monitoring. It also offers an extra channel for a double PZ probe
1 kHz
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Figure 3.6: Detailed front panels of some of the modules: 1-PPG module, 2-ECG module, 3-PWV
module, 4-NI 6210 module.
3.2.4 Synchronization
Synchronization is a key factor in the performance of the multichannel platform, since there are
signals acquired by different DAQ components (the NI6210 from National Instruments R© and the
PIC33FJ256GP710 from Microcip R©). This means that signals might not be properly synchronized,
in time, due to offsets or differences in the different acquisition rates, unless a proper sync procedure
is performed.
A synchronization algorithm was developed by Vaz, P. [168], based on the cross-correlation
between signals of the different modules. This method is based on the random nature of white noise
and, its large frequency band, allowing the determination of the delay between modules and, the
establishment of a common temporal reference.
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3.2.5 Database
All the retrieved clinical parameters obtained, from each patient with one or more modules, are
concentrated on a secure 1 dedicated relational database, developed by Santos, P. [169], along with
their corresponding historical, physiological and biochemical data. The database was implemented
using MySQL.
Cardiocheck main menu has a set of shortcuts that can be used to select common general tasks
such as acquisition, search, creation of instances, data processing and settings (Figure 3.7). Other
relevant informations are presented in Appendix A.
Figure 3.7: Cardiocheck main menu.
1These data are strictly confidential.
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3.3 Arterial Pressure Waveform Module
Three architectural designs have been experimentally characterized through prototype versions
with timely incrementing features (each re-designed taking advantage of the previously achieved
experience). The final prototype (DAQFP) was implemented in the multichannel platform. The
main characteristics of each one of the prototype versions are summarized in Table 3.2, and the
corresponding pictures of the first two versions are shown in Figure 3.8.
• First Prototype Version
The First Prototype Version (DAQP1) system was a first design attempt, in order to assess
the performance of PZ sensors in APW monitoring. The NI 6210 DAQ board was used.
This first prototype configuration contributed for the selection of the best hardware topology,
namely: electronic signal conditioning test circuits, front-end electronics, PZ signal recovery
amplification circuit, and baseline restorer (BLR) circuit (see 3.3.1.5). Several limitations
were found during the test of this version in subjects, mainly the difficulty to deal with the
physiological variability between subjects.
• Second Prototype Version
The Second Prototype Version (DAQP2) was the first proof of concept prototype capable to
perform the pulse-by-pulse APW data acquisition. This prototype contributed to debug and
customize DAQ firmware, as well as, to settle the basis for the acquisition software. It is
based on a custom designed acquisition and processing board from the Microchip R©.
Figure 3.8: First and second prototype versions developed along this thesis.
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• Final Prototype
The DAQFP is the final version of the laboratory prototype in which all of the two previous
versions converged. This module was also designed to be integrated in the multichannel
platform. The board assembly was performed in a 100x60 mm2 standard Eurocard board,
with 64 pins DIN plug and, with an appropriate front panel plate. Additionally, this version is
powered by an external autonomous power supply. A detailed view of the designed PCB of
this module is presented in Figure 3.9
3.3.1 Hardware Architecture
The PZ sensors were the first block to be explored, due to their fundamental role of being the signal
source interface between the patient and the acquisition module. In the next sub-section, a brief
description about PZ sensors is presented and, then, the full discussion of each building block of the
Table 3.2: Main characteristics of DAQ prototypes.
Prototype version Date PCB Area Characteristics
1st prototype (DAQP1) April 2010 100 cm2
– Manual reset
– Baseline restoration based on an
analogue circuit
– NI6210 board
– USB supply
2nd prototype (DAQP2) Nov 2010 152 cm2
– Automatic reset
– Baseline restoration based on a
digital process
– PIC board
– USB supply
Final prototype (DAQFP) July 2012 160 cm2
– Modular platform
– Connectivity with other modules
– Synchronization
– Battery supply
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Figure 3.9: The final version of the APW module prototype based on the dsPIC-based core, housed
in a eurocard (100x160 mm2) format.
complete electronic circuit enclosed in the shaded boxes of Figure 3.10 is presented: the PZ sensors,
the first amplifying stage that connects to the sensor; the peak detector and timer; the integrator with
reset; and the BLR (responsible for eliminating very low frequency fluctuations of the foot of each
pulse). Additionally, the breathing circuit and the dsPIC circuit implementation, that are also part
of the APW module, such as represented in Figure 3.9, are presented.
3.3.1.1 Piezoelectric Sensors
PZ sensors exhibit the capability of delivering very high Signal-to-Noise Ratio (SNR) voltage signals
when small forces are applied. Figure 3.11 shows the T heve´nin equivalent lumped-parameters of
the PZ converter (a) and its simulated frequency response (b). Due to its construction process, the
electric equivalent of a PZ sensor is, essentially, a capacitive impedance (CS) in series with additional
elements that account to the wiring inductance and resistances (Lm, Rm1 and Rm2) and an eventually
associated electrical load (Rk and Ck). In this circuit: V S is the voltage replica to the external
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Figure 3.10: Complete circuit with its main functional blocks enclosed in the shaded boxes. VTest
and VOut are the voltages from which performance of the circuit is evaluated. Vd is a monitoring
point for the circuits studied in 3.3.1.2. These voltages are outlined by circles.
mechanical excitation, x(t); RS is the insulation (or leakage resistance) generally in the 10 to 50 MΩ
range, and CS is the series capacitance which, among others, depends on the characteristics of the
PZ element and geometry of the sensor. For the device used in this work this value stays around
8 nF [171]. This value is consistent with the capacitance of a disc capacitor of 1 cm of radius and
with the distance between plates of 0.5 mm, and a 2000 relative dielectric constant.
If the frequencies of interest are confined to the flat plateau of the frequency response (area
limited to the dashed box in Figure 3.11(b)) the circuit can be satisfactory modelled as the simple
series capacitor, CS. This is the case in hemodynamic studies, where the bandwidth of signals is well
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Figure 3.11: PZ sensor characteristics: (a) T heve´nin equivalent based on [170] and (b) its frequency
response, obtained by simulation.
below the frequency of the resonance peak (4.6±0.5 kHz for the Murata R© 7BB-27-4 in use [171]).
This model also explains the fact that PZ sensors act as AC coupled voltage generators (note that RS
is the modelled insulation resistance, similar to the one specified in most capacitor datasheets) and,
consequently, do not respond to static excitation. It also gives a lead for two possible amplifying
topologies for the electronic circuit that immediately follows the sensor: the Charge Mode Amplifier
(CMA) and the Voltage Mode Amplifier (VMA) [170].
3.3.1.2 Amplifying Stage
This block accepts inputs from two different sources: one originated from the sensor, VSens, and
another one, usually derived from a signal generator, VTest , used for test purposes (see Figure 3.10).
As the aim is the precise rendering of the pressure waveform, P(t), this section is devoted to the
identification of three topologies to achieve this goal. Firstly, due to the inherently capacitive nature
of the sensor, depicted in the equivalent circuit of Figure 3.11(a), its voltage signal, VAB, inevitably
occurs with the shape of a time derivative of P(t) and, consequently, at output stage the integration
of the signal must be performed in order to recover the original P(t) waveform. Figure 3.12 shows
the three topologies that can be used in the amplifying stage, immediately after the sensor. The
VMA and CMA topologies have been studied by others, [170, 172], but little or no attention, has
been regarded to the Active Differentiator Mode amplification (ADM) type. Their performances
were evaluated by determining the Root Mean Square Error (RMSE) between VTest and the final
circuit output voltage (Vout), represented in Figure 3.10.
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Figure 3.12: The three main topologies for amplifying the sensor signal: (a) voltage or
passive differentiation mode amplifier (VMA), (b) charge mode amplifier (CMA) and (c) active
differentiator mode amplifier (ADM).
3.3.1.3 Peak Detector and Timer
Cardiac waveforms show a pulsatile profile, characterized by a prominent peak and the purpose of
this sub-circuit is to extract the reference time signal associated to this peak. To achieve this goal, Vd
is fed to a peak detector formed by two peak stretchers (U2, D1, C2, R4 and U4, D3, R5, C3) a level
shifter (U3, Vre f ) and a comparator (U5) (see Fiqure 3.10). To avoid false triggers the peak stretchers
have different time constants, R4C2 and R5C3, chosen according to the values of typical signals, and
one of them is level shifted before being fed to the comparator. The signal at R4 is slightly negatively
shifted by the instrumentation amplifier U3 at a gain of 1 (R3 = ∞) using an adjustable reference
voltage, Vre f , derived from the supply voltages (not shown). The negative shifting, although it
introduces a small delay, is essential to avoid erroneous triggering of comparator U5 (LM311). In
fact, without the shifting action of U3, the two signals at the comparator input would remain close
enough to cause repeated triggering of the comparator during the rising edge of the signal, even for
low noise levels. Physiologically, this instant occurs when the rate of change of the systolic pressure
upstroke is maximum, a few milliseconds prior to its peak and, it is unambiguously determined for
a large number of differently shaped real and synthesized waveforms. In practice, the output signal
exhibits a SNR higher than 40 dB and peak amplitudes of around 1.5 V , allowing a very clear peak
detection operation exhibiting very low levels of jitter.
The comparator output, in the DAQP1, triggers a tandem of two timers. The first one is set to
produce an up to 1.2 s wide pulse that acts as a delayed trigger to the second 1.5 ms wide reset
pulse used by the integrator block. The timing sequence, based on two LM555 timers is represented
(details omitted) by the box labelled Timerx2 in Figure 3.10. In Figure 3.13 this process is detailed
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Figure 3.13: Amplitude and phase of the transferisk function of the circuits. Vertical axes are in
decibels (dB) for amplitude and degrees for phase.
using simulated data: the Vd signal that is fed to the peak detector circuit, the identified peak at the
LM311 output, and the Timer1 signal that precedes the Timer2 signal, also called, the RST signal,
that actuates before each one of the pulses.
3.3.1.4 Integrator with Reset
A precision integrator (U7, C4 and R6) was implemented in the DAQP1 to ensure the re-establishing
of the original input signal. The integrating current was set by R6 (10 kΩ) to a maximum value below
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0.1 mA for a typical 1 V peak in Vd , a value well within the current capability of the OPA2704 output.
It should be noticed that the timing of the reset signal, delivered to the DG419 analogue switch,
described in the previous sub-section, leaves the physiologically interesting parts of the cardiac
signal (mostly the systolic upstroke, systolic peak and diastole) untouched and is compatible with a
wide range of HR values.
Charge injection, 10 pC maximum for the DG419, shows up only as a few microVolt voltage
step due to the large value of C4 and, more importantly, it affects the cardiac pulse waveform at its
very end, a region of little physiological interest. This electronic block was replaced in DAQP2 and
DAQFP (Section 3.3.2.2) by the inclusion of a microcontroller.
3.3.1.5 Baseline Restorer
This concept of BLR, introduced by Robinson [173] is used in nuclear detector electronics, where
the baseline of detector pulses generally is randomly shifted due to the combined effect of the
unpredictable time of arrival of particles and the capacitive coupling of the detector signal, necessary
to block its high voltage bias. All AC-coupled amplifier systems in pulsed signal applications suffer
from baseline variations, which originate errors in measurements that depend on the accuracy of the
pulse amplitude measurement. The capacitive nature inherent to the PZ sensor front-end, inevitably
turns the system into an AC coupled circuit, subject to strong baseline deviations that, in addition to
other errors, impairs real time visualization of the signals. The elimination of the baseline drift by
the BLR circuit consists in forcing the foot of systolic pulses to start close to zero without affecting
the shape of the signal. This requirement is met if the BLR is activated only at the end of the cardiac
pulse, just before the upstroke of a new pulse.
Like many other biosignals, APW pulse drift essentially correlates to three sources: respiratory
activity, variations in signal shape and signal jitter (defined as a random variation of the pulse period).
If an operator holds the probe during data collection, an extra source of baseline drifting shows up
due to the variations of its interaction with the tube of the phantoms or, in the case of biomedical
applications, with the patient. The use of a fixed support, a collar in biomedical applications, rules
out the influence of the operator. In biomedical applications, the low frequency respiration effect,
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Figure 3.14: Equivalent electronic circuit for the CCII+.
although attenuated by the AC coupling itself, and even if it is minimized by the use of a collar,
shows up, at the output, as a major contributor to baseline drift. However, the last two sources
(signal shape and signal jitter) are intrinsic and can only be eliminated by the BLR circuit.
A BLR circuit was developed based on the properties of the Second Generation Current
Conveyor (CCII) OPA860, referred, by the manufacturer (Texas Instruments R©), as an Operational
Transconductance Amplifier (OTA) [174]. The defining equations are described in Equations 3.1
and 3.2 and, the CCII symbols are depicted in Figure 3.14. The signal following the acronym CCII
(CCII+ or CCII−) refers to the relationship between the direction of IX and IZ. In the OPA860 case,
CCII+ means that the two currents are mirrored. Unlike operational amplifiers, the CCII does not
require the establishment of negative feedback to operate.
Vx =Vy (Vx f ollows Vy) (3.1)
Iz = Ix (Iz mirrors Ix) (3.2)
The OPA860 still offers an extra unity gain voltage buffer that can be useful in applications
where its high input bias current (up to 8.5 µA) can be tolerated. It is not the case in this circuit,
which mandatory demands the use of U6 (Figure 3.10).
Figure 3.15 explains the working principle of the CCII+ based BLR: when voltage at A tends
to be negative, at the falling edge of each pulse, current IR = VA/R flows through R and is mirrored
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Figure 3.15: BLR circuit (a) and its Orcad simulation for a trapezoidal signal (b), with (S ON, black
line) and without (S OFF, grey line) restoration.
at the B output. This linear unidirectional feedback mechanism, due to the action of diode D, tends
to restore the baseline of the pulses in such a way that the foot of the systolic pulse always starts
at zero, as depicted in timing diagrams of Figure 3.15(b), obtained by simulation. In the circuit of
Figure 3.10, an adaptation of this principle is used. In this case, the BLR effect is obtained by the
controlled injection of current from the CCII+ output in the summing point of the integrator, forcing
the integrating capacitor to discharge, before a new pulse occurs.
3.3.1.6 Breathing Circuit
Respiratory rate is important for many clinical uses, including: detecting sleep apnea, sudden infant
death syndrome, and chronic obstructive pulmonary diseases. The respiratory rate is also measured
by many intensive care equipment [175]. To monitor respiration several methods can be used:
thermistors, thoracic abdominal bands, nasal prongs and pneumotachographs. Thermistors are the
most common sensors used for this purpose, in spite of showing a long time-constant response.
During several trials, it was verified that the breathing rate modulates both, amplitude and
frequency of the APW signals, and that this information would be useful for further data processing.
So, a circuit for breath rate monitoring was implemented, such as depicted in the APW module in
Figure 3.14 (Resp dashed box). The circuit uses a Wheatstone bridge (see Figure 3.16), where R4 is
a Negative Temperature Coefficient (NTC) thermistor.
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Figure 3.16: Breathing circuit implementation, where Resp is the respiratory signal.
3.3.1.7 Microcontroller Circuit
The advantages in developing a microcontroller based system show up in increasing the functionality
of the system, as well as in decreasing the associated cost. There are different types of controllers
technologies in the market. However, Digital Signal Processors (DSPs) assumed, over the last years,
an increasing importance due to the enhanced functionalities that they are capable to grant. The
development of this technology has enabled significant improvements in the speed analysis, in the
accuracy, in the noise immunity, in the programmability, in the circuiting size reduction and, in
addition, in the decrease of equipment cost. In particularly, the dsPIC33 family from Microchip R©
employs a powerful 16-bit architecture that integrates the control features of a microcontroller with
the computational capabilities of a DSP.
The adopted solution was dsPIC33FJ256GP710, that is a 16-bit, general purpose controller
in a 100-pin DIL package, with a 40 MIPS processor speed, 256 kbyte programme memory and
a 30 kbyte of RAM data memory. Figure 3.17 illustrates the complete circuit diagram. The
blocks diagram, where the grey boxes outline the main hardware blocks, elsewhere described
that communicate with dsPIC through the indicated ports. The blue blocks indicate hardware
accessories required for the dsPIC operation. The microcontroller is clocked with a 8 MHz
crystal and communicates with the host PC though the USB at a baud rate of 460800 bits/s. The
microcontroller was programmed using a C-compiler from Microchip R© (MPLAB ICD2), that is
described in Section 3.3.2.2. Additionally, a push-button was added to allow microprocessor reset,
as well as, a set of LEDs for testing and debugging purposes.
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Figure 3.17: Generic block diagram of the hardware connections in the APW DAQ board. The grey
boxes indicate the main hardware signal blocks that communicate with dsPIC, and the blue blocks
the hardware accessories required for the dsPIC operation.
3.3.2 Firmware Development
Several cardiovascular applications have been previously reported in the literature, using
microcontrollers: Klig et al. [176] used these systems for BP monitoring and ECG signals;
Bing-Nan et al. [177] proposed an embedded medical advisory system for mobile cardiovascular
monitoring devices, that provides microcirculation information; while Germano et al. [178]
introduced a generic architecture for biomedical embedded systems, dedicated to clinical analysis
and patient monitoring.
There are two important parts of design procedure: the modelling and simulation of the system
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dynamics and the implementation of the control algorithm within the microcontroller. The modelling
task was implemented in the Matlab/Simulink platform. This option allowed to speed up the
prototype development cycle, since programming the microchip-embedded digital controller directly
from a Simulink model, significantly speeds up the process.
3.3.2.1 Pulse-by-pulse Control
The pulse-by-pulse control strategy, which is presented here, grants continuous and stable real-time
monitoring. It is important to ensure the capability to deal with a heterogeneous set of patients,
despite any disturbances suffered by the body, such as patient movements or respiration rate. The
main control scheme includes the baseline detection and pulse-by-pulse reset based on the peak-
detector signal described in the Section 3.3.1.3. The implemented control algorithm allowed the
advantageous replacement of the implemented hardware in DAQP1, which comprised a set of two
timers that were not able to deal with the physiological variability between subjects.
As previously mentioned, the signal from the peak-detector circuit corresponds to the highest
peak rise slope in the PZ signal, that occurs a few milliseconds after the systolic upstroke,
denominated tmin. To deal with this constraint a delay-time needs to be introduced to force the
correspondence of the beginning of the integration process, marked by the peak-detected signal,
with the beginning of each pulse. The determination of the exact time delay required is not possible,
so, alternatively, the estimation of this value (td) is used from previous physiological statements.
Firstly, it is known that the typical values associated to the upstroke time (tu) vary between 110 ms
and 230 ms, as determined by Buteler [179]. It is also known that tu values are typically twice of
the tmin value that is required for the algorithm. Therefore, tmin is, approximately, in the range of
55−115 ms (Equations 3.3 and 3.4). During the delay computation, it is preferred to set this value
near to the upper limit to avoid errors in low upstroke time values, that are commonly associated to
more complicated physiological situations. So, a td value of 110 ms was adopted.
tu = 2× tmin (3.3)
55 < tu < 115 (3.4)
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Figure 3.18: PZ waveform is represented in grey line and delayed PZ waveform in black line. The
integrated waveform PZ int (integrated) represented in blue line was obtained from the delayed PZ
waveform. The tmin represents the ideal delay value, tu is the systolic upstroke time and td is the
delay time used in the PZ waveform integration.
Figure 3.18 shows the original PZ signal (grey line) and the delayed PZ signal (black line).
Integration (blue line) is performed for the delayed PZ signal. As the pulse-by-pulse analysis
requires a reset pulse, a special concern with baseline is also required in this process. Reset signal
(RST) sets the signal to 0, and as the signal for the dsPIC is monopolar, the mean value is of the
order of 1.5 V . This situation leads to the occurrence of drastic level decrease at begin of each pulse.
To overcome this limitation, the mean value is removed internally.
This mechanism is essential for the real time pulse-by-pulse analysis. However, an alternative
post-processing algorithm (see Section 4.4.2) was also developed to further processing raw data,
avoiding some inaccuracies that can occur during real time pulse segmentation.
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3.3.2.2 Simulink Implementation
The Simulink model presented in Figure 3.19 intends to be an alternative to the hardware described
in Section 3.3.1.5. Its implementation is based on the available blockset Embedded Target for
PIC/dsPIC [180]. The ADC Input block converts the analogue signals from the PIC input channel,
configured to work as 10 bit ADC converter, according to the specifications. Then, in the Simulink,
this value is converted in a signed 16 bit variable (Data Type Conversion), where just the 10 lower
bits are used. The Tx Output Multiplexed for Matlab-Labview Output block can write 16 variables
to Matlab R© using the serial protocol. In case the host computer has no serial interface, an USB to
serial converter hardware is used. Configuration options are detailed in Appendix B.
In a typical measuring session, the first few pulses are used just for system adjustment, mainly
HR measurements. Then, real data collection lasts for as long as possible, without causing
discomfort to the patient, who is asked not to swallow during data acquisition. Typically, less than
two minutes allow for the acquisition of a number of cardiac pulses with enough statistical relevance.
The state-of-the-art acquisition systems, with similar purposes, hardly exceed acquisition rates
of 300 Hz. In this work, a bandwidth of 500 Hz was considered as adequate, since the relevant
Figure 3.19: Simulink model used for C-code generation for dsPIC using Kerhuel blockset [180].
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information remains below this value, such as presented in Section 3.4.1, and consequently a 1 kSPS
acquisition rate was used throughout
3.3.2.3 dsPIC Programming
Microchip R© MPLAB v8.30 was used in the models programming, through the C30 compiler, and
using the C-code generated by the Simulink model. This approach provides an interactive graphical
environment where the algorithms are developed in the form of block diagrams. Simulink platform
also allows the interface required to real time data transmission through Universal Asynchronous
Receiver/Transmitter (UART). In Figure 3.20 is shown a flowchart with the main stages of
programming.
Figure 3.20: Schematic of the stages of programming. (1) The model is generated in the Simulink
platform and, then, is compiled in C code; (2) programming of the dsPIC using the MPLAB ICD2;
(3) microcontroller real time data transmission through UART.
60
3.3. ARTERIAL PRESSURE WAVEFORM MODULE
3.3.3 Probe Mechanical Design
The distension wave associated to the propagating of the pressure wave, generates forces that,
given the adequate mechanical interface transmission mechanism, actuate upon the sensor. This
mechanical interface plays an important role in the overall performance of the probe, as it determines
the forces that are exerted over the sensitive part of the sensor body. Apart from the PZ sensor itself
(brass coated disc), the main mechanical skin contact element of the probe is the mushroom-shaped
part shown in Figure 3.21(a) and (b), responsible for transmitting the distension associated to the
pressure wave. The transversal and shear effects are suppressed and only the longitudinally external
applied forces are allowed to originate an electrical response. The probe dimensions are depicted in
Figure 3.21(c) and the final probe is depicted in Figure 3.21(d).
Figure 3.21: Mounting details of the probe elements shown in a transversal cut (a) and 3D exploded
(b), views. The arrow in (a) indicates the externally applied forces and, (1) is the mushroom-shaped
interface, (2) is the PZ disc sensor and (3) is the PCB frame. In (c) it is shown the upper view and
probe dimensions, where (1) is the support PCB layer, (2) is the PZ disc and (3) the mushroom-
shaped PVC (PolyVinyl Chloride) interface, and in (d) is shown a photo of the probe with collar.
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3.4 Performance Tests
The evaluation of the performance of the APW electronic board was accomplished taking into
account functional tests.
3.4.1 Spectral Bandwidth
The spectral limit of the physiological information contained in the APW pulse is an important issue.
This information is essential for the processing routines that can include filtering procedures. The
frequency components of cardiac waveforms were analysed by using the FFT routine, as it is shown
in Figure 3.22 and, it is possible to conclude that the critical information spans up to a 20− 25 Hz
higher limit.
Figure 3.22: Harmonic contents of the amplitude response of an APW segment, where is pointed
the interest zone. Frequencies higher than 25 Hz are within in the noise plateau.
3.4.2 Analogue Circuit Transfer Function
Figure 3.23 shows the amplitude and phase of the transfer functions of the full circuit, for each of
the amplifying circuits of Figure 3.12, obtained using Pspice simulation. The grey and black lines
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refer to the ADM circuit and, clearly, lead us to expect a very good performance in terms of RMSE
due to its uniformity along frequency, for gain and phase.
Figure 3.23: (a) Amplitude and (b) phase variation of the transfer functions of the ADM(4K),
ADM(8K), VMA and CMA circuits.
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At the high frequency end of the ADM curve (without resistor RL), the effect of Common-Mode
Rejection Ratio (CMRR) degradation becomes visible and shows up as a sudden as a sudden increase
in gain (grey line). The CMRR versus frequency response curve generally holds constant for low
frequency values and starts to decay at a certain frequency value. If unattended, this CMRR spike
would allow the amplification of high frequency noise which would greatly impair the signal. The
resistor RL (see Figure 3.12(c)) counterbalances this effect, by cutting the high frequency response of
the circuit. The frequency band response of this circuit is limited, according Equation 3.5, yielding
the behaviour shown by the black line. This effect imparts the important feature of preventing the
high frequency noise to contaminate the signal, as it is very common in differentiating circuits, and,
consequently, impairing the extracting processing feature, that depends on it. The value of RL is
determined by the value of the selected cut frequency combined with the equivalent sensor capacity
CS, 2 kHz and 8 nF , respectively, according to:
f =
1
2piRLCS
(3.5)
In Figure 3.23(a), in the amplitude response, the effect of RL is stressed by showing the two
responses obtained from a well balanced (black line) and an under balanced circuit (grey line)
corresponding to RL values of 8 kΩ and 4 kΩ, respectively. The VMA curves reveal very low
gain, as well as a great deal of phase shift (Figure 3.23(a) and (b)) respectively.
As the frequency range of cardiac signals spans up to around 25 Hz (Figure 3.22), it is not
surprising that both, ADM and CMA, show very good amplitude response and phase uniformity,
because their operation is based on an operational amplifier circuit that behaves very close to ideal,
for this frequency range. In principle, the CMA circuit could be used with no further integration
to delivering the final cardiac waveform. However the availability of a differentiated signal is
essential for extracting the time reference signals used by the BLR and by the integrator. Therefore,
a configuration where the ADM circuit is followed by the integrator was adopted, which, in any
case, is the best performing configuration, as it is presented in the next section.
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3.4.3 Input/Output Error
A set of cardiac-like synthesized pulses [181] shaped to reproduce the different classes typified by
Murgo [182], were used during the RMSE calculation for simulated and real data. In the real data
tests, the test input (VTest , represented in Figure 3.10) is driven by the arbitrary waveform generator
(excited with the same signal type used in the simulations). RMSE is calculated taking VTest as the
reference, thus
RMSE = RMS(Vout −VTest) (3.6)
If any of the circuits performs ideally (no distortion introduced) its RMSE would be zero, in the
absence of noise. However, if noise is present, the ideal circuit yields a non-zero, minimum value,
for RMSE:
RMSEmin =
√
n2V S +n
2
Vout (3.7)
where nV S and nVout are the RMS of noises at the input and output, respectively. The RMSEmin
has been calculated to all waveforms, that were previously normalized to discard interference of gain
and offset, that are not important for evaluating the accuracy in reproducing the input waveform.
Finally, the so called RMSEc is computed, subtracting the noise contribution from RMSE according
to,
RMSEc = RMSE−RMSEmin (3.8)
In Figure 3.24 a Type B (see Section 4.4) waveform collected at Vin and at Vout is shown for
each one of the electronic topologies at study. The simulated and measured data are represented
in (a) and (b), respectively. The RMSE values between input and output for each of the three
topologies, computed from simulated as well as measured data, using the very same synthesized
pulse waveforms as inputs in the simulator and in the physical circuits, are shown in Table 3.3,
for all four types of cardiac waveforms. The circuit data is split in three columns to show the
contribution of noise. The results clearly demonstrate the superiority of the ADM topology in the
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Figure 3.24: Normalized input and output for a Type B cardiac pulse in the three circuit topologies,
as given by the simulator (a) and measured in the circuit (b). Noise is only visible in the real data,
plotted in (b).
precise rendering of the input signal waveform. Therefore, the ADM topology was used to perform
the mechanical tests, as well for the test bench characterization and the in vivo tests.
Table 3.3: RMSE measurements for each of the three amplifying circuits, using cardiac - like
synthesized pulses to reproduce the different classes described in the literature. Data are taken
from simulator (PSpice) and measured in the circuit (real data).
Circuit Wave Type
Simulation a Real Data
RMSE (%) RMSE (%) RMSEmin (%) RMSEc (%)
VMA
A 5.53 4.39 0.05 4.34
B 5.36 4.65 0.04 4.61
C 5.68 3.66 0.05 3.61
D 5.32 3.47 0.05 3.42
CMA
A 2.52 2.27 0.05 2.22
B 2.47 2.11 0.06 2.05
C 2.61 2.13 0.05 2.08
D 2.34 2.04 0.06 1.98
ADM
A 0.14 0.31 0.31 ≈ 0
B 0.19 0.33 0.33 ≈ 0
C 0.07 0.33 0.33 ≈ 0
D 0.14 0.30 0.30 ≈ 0
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3.4.4 Pulse Delay
Due to the specificity of the described module (the one that makes use of the PIC in the
multichannel platform), signals coming from the PZ transducer are delayed, and as consequence
some computations are made. On the contrary, the synchronization signal described in Section 3.2.4
is acquired and sent to the PC with no firmware transformations. Therefore, it is extremely useful
to measure the delay between signals from the APW module and synchronization module to assure
that signals are correctly time aligned.
The time delay was measured using the same signal fed to two different ADC channels of the
PIC. One used as the synchronization channel, fed directly to the ADC, and another following the
normal PZ path, since the VTest input (Figure 3.10) to a ADC channel. For each channel, a pulse
train with a frequency of 1 Hz and a duty cycle of 20 % was used as the input signal. Signals were
generated using two Agilent 33220A, acting, one as a master, and the other one as a slave, so that
external trigger could be used in the slave to synchronize both signals. Both were synchronized with
a mismatch of 1 µs, which was assessed with the oscilloscope. This error is negligible, given the
time scale that is used in signal processing routines.
Figure 3.25 shows both signals, being visible the delay between both signals. The delay was
computed from differentiated signals, where the beginning of each pulse (and also its ending) are
clearly identified by peaks, as it is visible in Figure 3.25(b).
A total of 19 acquisitions, comprising 1712 variable length valid pulses were performed.
Between each acquisition, power was turned off, so that the PIC could be reset. A delay value (tdelay)
of 112 ms was measured, which is close to the expected value, since firmware routine introduces a
delay of about 110 ms (see Section 3.3.2.1).
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Figure 3.25: In (a) the pulses acquired from both ADC channels are shown, where the delay between
channels is clear and in (b) the pulse differentiation of both ADC channels is depicted.
3.4.5 Optimal Mechanical Design
A number of tests were conducted to determine the optimal shape of the mushroom mechanical front-
end interface in order to repeatedly obtain the best (undistorted) pressure waveform transmitted to
the sensor. In these tests three, differently shaped, mushrooms were fitted to the probe and submitted
to the direct action of the actuator. The difference is in the geometry of the mushroom base, which
directly contacts the sensor, that can be shaped pointy, flat and intermediate. The stroke of the
actuator was adjusted to about 10 µm, and the response was collected by the probe and stored in the
memory of the Data Acquisition System (DAS). Again, the overall error is quantified as the RMSE
between normalized input and output, VTest and Vout (see Figure 3.10), respectively. Results, shown
in Figure 3.26 and Table 3.4, are obtained for an Type A (see Section 4.4) cardiac waveform [181],
because it is the most demanding in terms of circuit performance. The pointy probe exhibits the best
performance in reproducing the input waveform with the lowest RMSE variance.
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Figure 3.26: RMSE for differently shaped sensor interfaces measured for a Type A waveform. In
the first row, the three probe geometries are diagrammatically shown. The second row depicts the
input and output acquired signals. The last row shows the RMSE distribution, demonstrating the
superior consistency of the pointy probe.
Table 3.4: Statistics of measurements depicted in Figure 3.26.
Probe type Pointy Intermediate Flat
Number of pulses 50 50 50
Mean 1.80 1.76 1.93
SD 0.22 0.67 0.88
Minimum 1.34 0.66 0.77
Maximum 2.30 3.28 3.62
3.5 Test Bench Characterization
For testing the probe, as well as the several parameter extraction algorithms, a special purpose
test bench was developed [96], represented in the diagram of Figure 3.27. The pressure wave was
generated by a piston mechanism coupled to a 0.7 mm stroke actuator (ACT) driven by a high voltage
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Figure 3.27: Schematic representation of the test bench. The signal conditioning block encloses the
circuit of Figure 3.10 and the device under test (DUT) is the probe presented in Figure 3.21.
linear amplifier (HV Amp) (Physik Instrumente GmbH, ref. P-287 and ref. E-508, respectively)
and launched into an 8 mm internal diameter, 0.5 mm wall thickness silicone rubber tube (from
J. Lindemann GmbH). The waveforms were programmed into an arbitrary waveform generator
(AWG) Agilent 33220A. According to the HV Amp specification, for the 290 nF load represented
by the ACT, a 200 Hz bandwidth can be obtained if the output of the E-508 does not exceed 200 V .
Such bandwidth allows the synthesis of the more sophisticated cardiac-like waveforms, as well as
low frequency triangular, sinusoidal and Gaussian test signals used to characterize the test bench.
To comply with these constraints, as the gain of the E-508 HV amplifier is factory fixed at around
100, the amplitude of the waveforms at the AWG output does not exceed 2 V . In addition to the
propagating pressure wave, a static pressure level (PDC) of around 60 mmHg is forced by a piston-
mass (m) combination at the other extremity of the tube.
This test bench allows the full study of the propagating wave dynamics, including reflections
at the extremities of the elastic tube, as is visible in Figure 3.28. The forward and the repeatedly
reflected waves, originated by a Gaussian shaped stroke of 100 ms duration along the tube, can be
clearly seen. The map of Figure 3.28(a) is obtained for successive sensor positions, 2 cm apart,
covering the full 80 cm of tube length. Figure 3.28(b) shows one single pressure curve collected by
the probe positioned at 48 cm from the ACT.
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Figure 3.28: Test bench characterization using a Gaussian shaped excitation. (a) Shows the mesh
map of the probe signal along the tube, (b) depicts the excitation (black line) and probe signal at the
identified tube position (48 cm from the ACT) (grey line).
3.6 Conclusion
A multi-modular platform for non-invasive cardiovascular assessment has been designed and
implemented. The APW module was the core of this thesis and it was described in detail. This
module is based on a piezo disc sensor, analogue and digital signal electronic blocks able to recover
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from the piezo signal the pressure waveform which can be displayed, and stored, sequentially.
Numerical simulations and test bench measurements, aimed at demonstrating the effectiveness
of the proposed system, were carried out. The probe performed very well in a good number of
fundamental accuracy tests using elastic tubes at the test bench. The maximum RMSE introduced by
the electronic circuit itself is 0.33 % and the total average error (including the mechanical interface
contribution) amounts to 1.80 %. The results lead to believe that the probe has the potential to be
used as an alternative to costly devices in clinical trials.
3.6.1 Manufacturing Costs
The cost of a multichannel platform unit (considering the basic modules, APW and PWV) can reach
2160 e, at 2013 prices, as is presented in Table 3.5. There is a significant part in the cost of the
system that can be saved by the development of a global control unit, replacing the NI 6210 (600 e).
If considered the human resources costs for building and testing the prototype, as well as the required
PC, the global system cost can reach 7000 e.
It is also important to note that the presented prices are unitary, meaning that buying in large
quantities will significantly decrease the total price. Regarding commercial prices, equipment such
as the SphygmoCor CPV or the Complior can reach 23500 e and 12500 e, respectively.
Table 3.5: Table of costs.
Module Manufacturing Costs (e)
Box 520
Power supply 300
APW module 190
PWV module 60
NI 6210 600
ECG 140
Oximetry 200
Other components 150
All prices include VAT at 23%
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Data Collection and Processing
This chapter presents information about collected data, acquisition protocols and processing tasks
performed along this work. Firstly, the input variable groups are described, and then, the main risk
subsets are identified (smoking history, lipid disorders, hypertension, diabetes mellitus and obesity).
Processing techniques used along this work concerning pulse wave analysis are also introduced.
The preliminary analysis includes baseline fluctuation elimination, pulse-by-pulse segmentation and
pulse normalization. The delineator algorithm developed for the prominent points identification is
introduced and, the selected morphological parameters are also detailed.
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4.1 Recruitment of Participants
The data analysed throughout this thesis were collected in different groups of subjects. Some of
the subjects were recruited through follow-up appointments of patients at the Coimbra Hospital
and University Centre (CHUC), Portugal, while the others were obtained from the collaboration
with volunteers at screening mobilizations. All of the subjects received detailed information about
the study and agreed with criteria for participation. Figure 4.1 details the database cohorts fully
described along this chapter. The grey rows report the experimental data used in the hardware and
software tests. A review of demographic, clinical and non-invasive parameters included in the data
analysis is presented in Table 4.1.
Figure 4.1: Database constitution by cohorts.
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Table 4.1: The group variables.
Variable Variable type Description
Demographic
Patient related Age, gender
Procedure related Date, time length, location, operator description
Clinical
Risk factor Smoking habits, obesity
Target value Cardiovascular disease diagnosis
Pressure values SBP, DBP, HR
Biochemical TGL, CH, CH-LDL, CH-HDL, Aldosterone, Renin
Other Medication
Non-Invasive
Time and amplitude SWTT, RWTT, LVET, SWA, RWA, DWA
Ratios and Indexes AIx, R1, R2, R3, R4, R5, R6
Variance values
RMSSDSPt , RMSSDSPa, RMSSDPit , RMSSDPia,
RMSSDDWt , RMSSDDWa, FWHM, RMSE
4.1.1 First Trials (GroupF)
This group was essential during the DAQP1 development. The data were used during the first tests
to assess the system capability to deal with different waveform morphologies [166] and during the
development of the algorithm dedicated to the APW prominent points identification [183].
4.1.2 Repeatability Cohort (GroupR)
This group was used in the validation tests, during two distinct trials, for the assessment of the
differences between sessions (intra-subject variability), the left and right carotid differences, the
monthly variability, and the operator dependency. The main characteristics of each dataset (Trial 1
and Trial 2) within this group are described in Table 4.2.
4.1.2.1 Trial 1
Dataset I consists of 12 healthy subjects (8 female, 4 male), under < 30 years. All of the subjects
were non-smokers, and had no documented history of diabetes or cardiovascular disorders. All
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measurements were made at the same time of day and at the same controlled room temperature
(22− 23 ◦Celsius) to minimize climatic variations. The subjects remained seated and quiet in a
comfortable chair. Two successive monthly sessions, containing both left and right carotid data,
were performed. At least 3 acquisitions of roughly 30− 40 s were made, per carotid, for each
subject, per month. This dataset has a total of 2983 pulses, with ≈ 200− 250 pulses for each
subject.
4.1.2.2 Trial 2
Dataset II consists of 20 healthy subjects (12 female, 8 male), also under < 30 and with no
documented history of cardiovascular disorders. The acquisitions were made by three operators with
different levels of experience and training. Two operators (operator 1 and operator 2) have received
one week of intensive instruction and training before recording measurements for the study. While
the other (operator 3) had, at the time, more than 2 years of experience. Each operator performed
several measurements, which consisted of three sessions for each one of carotid arteries (left and
right), comprising a set of 18 acquisitions of about 60−90 s for each subject. This dataset includes
11664 pulses, ≈ 500−550 pulses per subject.
Table 4.2: GroupR characteristics for each one of the trials.
Characteristics Trial 1 Trial 2
Subjects 12 20
Age range (years) 21-29 21-55
Total measurements per subject 12 18
Total number of pulses 2983 11664
Time acquisition per each measure (sec) 30-40 60-80
Repeatability-daily
√ √
Repeatability-monthly
√
X
Inter operator variability X
√
Bilateral variability
√ √
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4.1.3 Control Cohort (GroupC)
The acquisitions for this group started in 2010, denominated the Phase 1, with 20 subjects. However,
the majority of data were obtained in 2012 (114 subjects), during the Phase 2 [184], in the
collaboration with Sudden Cardiac Death Screening of Risk Factors study (SCDSOS) and during a
mobilized screening at the Department of Physics of the University of Coimbra. This group consists
of 134 healthy subjects, comprising 4471 pulses.
4.1.4 Hypertensive Cohort (GroupH)
This cohort includes 50 hypertensive subjects. Hypertension is diagnosed when SBP ≥ 140 mmHg
and/or DBP≥ 90 mmHg, or if the patient was taking anti-hypertensive medication. The data were
acquired during hospitalization, but prior to taking any medication. For each patient three sessions
were performed during 30−40 s.
4.1.5 Angioplasty Cohort (GroupA)
All the subjects at this group were monitored before and after a carotid intervention (due to a stenosis
that partly blocked the artery blood flow). The intervention consisted in the angioplasty with stent
placement, the ”gold-standard” invasive procedures to treat a narrow or blocked carotid artery. The
angiography procedure was used by injecting a contrast fluid to highlight the blood vessels, and
making images of the highlighted vessels, such as described in Section 2.3.5
After local anaesthesia, a surgical cut is executed near to the groin and, a filter device is opened
above the lesion for the stent implementation. The balloon is inflated at the stenosis plaque level.
Finally, the filter device is kept open, as prevention, for an eventual embolic trapping. With this
surgical technique, the blood flow is restored to the normal values, since the diameter of the
vessel enlarges to the same one imposed by the stent. The APW was sequentially collected by
the developed APW module and by the invasive equipment, Axiom Sensis XP (Siemens, Erlangen,
Germany) [185]. A small segment of 3−4 s for each subject was analysed.
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4.1.6 Data Prediction Cohort (GroupD)
This group consists of 10 subjects that were used during the validation tests performed on the
machine learning algorithms. The subjects were selected for both criteria: young subjects, and
with waveform characteristics of individuals that are developing arterial disorders (such as, positive
AIx values). To accomplish this selection, a preliminary waveform analysis was performed. This
dataset comprises of 627 pulses.
4.2 Patient Characteristics
The clinical characteristics of this study population are shown in Table 4.3. The Kruskal-Wallis test
was used to assess the differences amongst groups (see test description in Section 6.2.5). This test
demonstrated significant differences in the analysis of the groups for all of the parameters, excluding
height.
In GroupH, mean age is 58.89± 12.47 years, significantly higher than the observed for the
other groups (excluding groupA). The same situation was verified for the BP values, that are higher
comparing to the normal range (see Section 2.6.1) in the GroupA and in the GroupH. The values
of 144.33± 40.08 mmHg (SBP) and 81.00± 18.34 mmHg (DBP) were verified in the GroupH
and, the values of 147.37± 30.89 mmHg (SBP) and 89.63± 16.29 mmHg (DBP) were observed
in the GroupA. It was also verified that the Body Mass Index (BMI) is superior to the ideal
recommendations (< 25 kg/m2) for the GroupH. In the GroupC, GroupR and GroupD, the BP
ranges are within optimal values: SBP< 120 mmHg , and DBP< 80 mmHg. The mean age for
the GroupD is 24.10± 2.81 years, similar to the value observed for the control group (GroupC)
(21.90±3.32) years, as expected, and the BP values are also within normal range.
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4.3 Risk Factor Characteristics
The factors used to describe the cases at risk were: the current or past history of smoking,
the diagnosis of hypercholesterolaemia or hypertriglyceridaemis (hyperlipidemia), the presence
of hypertension, the diagnosis of diabetes mellitus and the overweight. Figure 4.2 shows the
distribution of the risk factors for all of the subjects in the database. The age distribution is depicted
in Figure 4.3, where the predominance of subjects aged between 20 and 35 years is clearly evident.
Figure 4.2: Risk factors distribution.
Figure 4.3: Distribution of subjects in study by age subsets.
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4.4 Arterial Pressure Waveform Analysis
Pulse wave analysis relies on a clean waveform, in which the morphological features are reliably
identified. The APW is the result of the the interaction of the amount of blood that is pumped
out of the heart along the arterial tree. The APW contains important physiological information
concealed on its morphology: the Systolic Peak (SP), the Point of Inflection (Pi) and the Dicrotic
Wave (DW) [9]. SP results from the action of the left ventricle blood pumping, while Pi results
from the both action, of the forward wave travelling along the arterial tree and of the backward
wave returning towards the heart, from the reflection sites [2]. These waves superimpose originating
a visible inflection change in APW profile. DW occurs when the aortic valve closes moving a
small portion of the ejected blood back to the left ventricle. The prominent point locations are
schematically represented in Figure 4.4, for a Type A (a) and a Type C (b)waveform. Depending of
the AIx value the pulse wave type is defined as follows: when a negative value occurs the pulse is
Figure 4.4: Schematic representation of the pulse wave analysis process, for a Type A (a) and a Type
C (b) waveform, where the APW features are identified.
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considered type C (characteristic of healthy subjects) and, when a positive value occurs the pulse is
considered type A (characteristic of subjects suffering from arterial stiffness). Type B occurs for the
intermediate cases, where the Pi occurs shortly before SP, and Type D when the Pi is not identified.
4.4.1 Pulse Waveform Modelling
Cardiac-like pressure waveforms were synthesized and used during the hardware and the software
tests [181]. The set of pulses was synthesized using a weighted combination of exponentially shaped
sub-pulses, each one representing a physiological component of the real cardiac pulses (the systolic
stroke, the reflected wave, and the aortic reservoir). Each sub-pulse is built up by two consecutive
exponential curves, describing the rising edge and another the falling edge. The general expression
used is presented in Equation 4.1,
c(t) =
3
∑
k=1
Ae
− t−DRkτRk −e−
t−DFk
τFk
k (4.1)
Prior to summing, the sub-pulses are submitted to a moving average filtering process in order to
smooth the corners that, otherwise, would show up in c(t). Table 4.4 describes the parameters used
in Equation 4.1. The set of synthesized waveforms contains the interesting situations, namely the
ones that occur during the AIx positive to negative transitions.
Table 4.4: Parameters used in Equation 4.1, where k = 1 corresponds to the systole component,
k = 2 corresponds to the reflection wave and k = 3 corresponds to the dicrotic wave, and w was used
to sweep the range of interesting Pi situations.
Parameter Description Systole wave Reflected wave Dicrotic wave
(k = 1) (k = 2) (k = 3)
A(k) Amplitude 1 0.2 0.3
DRk(s) Delay of rising exponential 0.1 0.1201+(w×0.003) 0.35
τRk(s) Rising exponential constant 0.001 0.01 0.001
DFk(s) Delay of falling exponential 0.192 0.17+(w×0.003) 0.45
τFk(s) Falling exponential constant 0.0007 0.0006 0.0001
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4.4.2 Baseline Flutuations
The baseline flutuations can occur due to electrical signal fluctuations, small motion of the probe
attached to the patient’s neck or patient breathing. The baseline modulation can lead to a misleading
and inaccurate determination of the characteristic points. A methodology to remove the baseline
fluctuation from the raw signal by applying a baseline adjustment was employed, ensuring that the
APW is precise and valid. Firstly, the baseline index points are accurately determined y(n), such
as depicted in Figure 4.5. These points match the onset and offset of APW pulses, as shown in
Figure 4.5. Then, the baseline fit is linearly interpolated from the baseline index points, correcting
the signal by vertically adjusting each sample.
Figure 4.5: Method adopted for baseline correction, where y(n) and y(n + 1) are adjacent APW
onset pulses.
4.4.3 Criteria for Pulse Flagging
The morphological APW pulse quality is an important issue that must be taken into account. The
artefacts, that can occur during data acquisition, are responsible for volume changes that compromise
the quality of the signal. So, after the baseline removal, each pulse must be analysed and several
morphological indexes computed by a series of constraints in order to check abnormal beats. The
criteria were defined based on the normal range values for systolic and diastolic amplitudes, and
pulse width. If any abnormality criterion is matched, the pulse is removed (see Table 4.5).
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Table 4.5: APW features and abnormality criteria for pulse flagging.
Feature Description Abnormality Criteria
As Systolic amplitude As > 3×Am
Am Mean systolic amplitude Am < As2
AD Diastolic amplitude AD < 0
T Pulse Width T > 1.5×T m
Tm −Mean width of all pulses
4.4.4 Pulse Segmentation and Normalization
The APW signal segmentation into individual pulses and the amplitude normalization is an
important process during data pre-processing. Figure 4.6 depicts the effect of baseline removal
and pulse segmentation procedures. A raw time signal segment of 25 seconds, corrupted by baseline
fluctuation, is exhibited in Figure 4.6(a) and the baseline removal result is shown in Figure 4.6(b).
Pulse-by-pulse analysis is shown in Figure 4.6(c), where the variability among pulses is visible. In
Figure 4.6(d) the prominent points (SP, Pi and DN) are pointed out.
Figure 4.6: Pulse wave analysis, (a) raw data; (b) baseline removal; (c) pulse segmentation and (d)
the prominent points marked in a pulse during the segmentation process.
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4.4.5 Pulse Contour Algorithm Implementation
Several waveform delineators have been reported in literature concerning the APW characterization,
such as the ones presented by Donelli et al. [186] and Oppenheim et al. [187]. De Melis et al. [188]
also presented an interesting approach by the use of a discrete waveform transform (DWT), namely
the ”mother” wavelet Daubechies 4 (Db4), in the determination of the temporal dynamic properties.
The use of the second derivative of photopletysmographic (PPG) signals is also commonly referred
as a reliable technique by other authors [189].
The first results were achieved during MSc thesis (2009) [190], by the implementation of
algorithms based on the DWT and Probability Density Function (PDF) [181, 190]. Wavelet
transform is a time-scale representation, based on the multi-resolution signal decomposition, which
allows to follow the spectrum of the frequencies into the signal. The wavelet transform is an
appropriate tool to rapidly locate changes in physiologic signals, such as in APW and ECG signals.
PDF relies on the creation of a local maximum for the amplitudes close to a inflection [191].
Unfortunately, several maxima are also created whenever the signal amplitude is slow varying, as
happens close to its peaks. To make things worse, these peaks can occur for amplitudes of the
same order of magnitude of the Pi point, making the identification of this point a task very hard to
accomplish. The preliminary results, using synthesized waves, have demonstrated the superiority of
the wavelet approach.
The purpose along the current work was the development of a robust set of algorithms capable
of dealing with a wider variability of physiological conditions. The minimal requirements remain
on the capability to perform the identification in the waveform (in time and relative amplitude) of
the most relevant points of the cardiac cycle and make them available for further analysis in an
understandable and clear way. An algorithm based on the first order derivative was implemented,
as described in Figure 4.7. The use of the first derivative curve justifies that, immediately following
the data acquisition, a low pass filter needs to be implemented to suppress high frequency noise, that
would otherwise make the first derivative signal unusable. The 30 Hz cutoff frequency of the filter
ensures that the interesting range of frequencies is preserved. A short overview about each of the
identified points is presented as follows:
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• Systolic Peak
The SP identification is carried out using a local extreme identification routine. A maximum
is detected, only in case the value of the previous minimum differs by a configurable value
(referred to as delta). As, the cardiac cycle shows a variable number of local maxima (2 to 4
depending of the wave type and of the presented artefacts), this routine must run repeatedly
(for different values of delta) to ensure the correct SP identification.
Figure 4.7: Flowchart representing the algorithm implementation.
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• Dicrotic Notch
The SP identification combined with zero crossing values of the first order derivative is used
in the DW features identification, notch (DN) and peak (DP). The major problem are the
oscillations that inevitably may occur, and mask the true DN and DP.
• Inflection Point
The Pi identification is carried out in three steps (validation procedure): the localization of
candidates, the elimination of oscillations and the comparison with APW maximum.
4.4.5.1 Performance Evaluation
Some acquisitions were carried out in a small universe of eight volunteers. In a first step, the
prominent points (SP, DN, DP and Pi) were identified using the algorithm under test, and then, a
Human Expert Engineer (HEE) carefully inspected each APW pulse and manually annotated the
same points. Both annotations were compared and classified in three classic types: the true positives
(TPs) and the true negative (TNs), and for the discrepant ones, the false negatives (FNs) and the
false positives (FPs). The HEE results were taken as reference, and a 8 ms threshold value was
adopted, such as indicated by others authors [192, 193]. An identical procedure was carried out
for the amplitude parameters, using a 1 % of the maximum pulse amplitude as the threshold value.
Sensitivity (S), positive predictive value (P+) and error associated to the algorithm were computed,
according to the following equations:
S =
T P
T P+FN
(4.2)
P+ =
T N
T N +FP
(4.3)
Error =
T P+T N
T P+T N +FP+FN
(4.4)
Tables 4.6 and 4.7 show the sensitivity, the positive predictive value and the error verified
during the time and amplitude analysis, respectively. As expected, Pi shows the worst performance,
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Table 4.6: Validation of algorithm performance (time) in comparison to HEE annotations.
Feature Pulses TP FP FN Error (%) S (%) P+(%)
SP 173 171 2 0 1.15 100 98.84
DN 173 165 8 0 4.62 100 95.37
DP 173 169 4 0 2.31 100 97.69
Pi 173 159 8 6 8.38 96.36 95.20
Table 4.7: Validation of algorithm performance (amplitude) in comparison to HEE annotations.
Feature Pulses TP FP FN Error (%) S (%) P+(%)
SP 173 173 0 0 0 100 100
DN 173 171 2 0 1.15 100 98.84
DP 173 172 1 0 0.58 100 99.42
Pi 173 158 9 6 8.98 96.34 94.61
due to the superior difficulty associated to its identification, observed by the HEE well as by the
implemented algorithm. Relatively to time measurements, average values of 4.20 %, 99.09 % and
96.77 % for error, S and P+ were observed, respectively. And, for the amplitude analysis were
observed values of 2.68 %, 99.08 % and 98.22 % for the same parameters.
Figure 4.8(a) shows the correlation plots between the HEE and the algorithmic values (SP and
Pi analysis), as well as the the corresponding Bland-Altman plots. The straight line fittings for
the SP and Pi time analysis show an excellent correlation, where R2 is the square of the sample
correlation coefficient, between both estimates (R2 = 0.996 and R2 = 0.907, respectively). The
developed algorithm, in average, overestimates the SP by 0.009 ms and underestimates the Pi by
0.99 ms. To understand the 100 fold factor between the estimation errors between SP and Pi, one
should bear in mind that, in the APW curve, SP is a peak and Pi is an inflection. This makes the SP
estimation much easier for the HEE, as well as for the algorithm.
It was also observed that the amplitude errors summarized in Table 4.7 are much lower than the
corresponding time errors (Table 4.6). In fact, as all points are associated to a peak or an inflection,
the first derivative of the APW curve shows close-to-zero values in their vicinity, hence the small
amplitude estimation error. This fact is visible in Figure 4.8(b) that shows the correlation observed
for Pi amplitude values, as well the corresponding Bland-Altman plot.
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Figure 4.8: Agreement between the SP and Pi obtained via PPIA and HEE, measured using
regression plots (top) and Bland-Altman plots (bottom), (a) time information of SP and Pi, (b)
relative amplitude of Pi.
4.4.6 Pulse Waveform Features
Most of APW analysis frameworks individually process each hemodynamic parameter and do not
evaluate the dependencies among features. The proposed approach allows for the design of new
hemodynamic morphology vectors and techniques for multiple APW analysis. This approach
improves the arterial pulse understanding, especially when compared to the traditional single-
parameter analysis, where the failure in one parameter measurement component, such as Pi, can
jeopardize the whole evaluation. Several hemodynamic features were explored and are described as
follows:
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• Time/amplitude Intervals
The most important APW intervals are considered for each pulse. These parameters include
time intervals, the time to the systolic peak (SWTT), the time to the point of inflection
(RWTT) the time to the dicrotic wave (LVET) and the downstroke time (DSt ; and amplitude
considerations, the height at the systolic peak (SWA), the height at the inflection point (RWA)
and the height at the dicrotic wave (DWA).
• Ratios and Indices
Although time and amplitude parameters are effective, they lack a complex analysis. Other
parameters and indices were studied based on time and amplitude intervals, as presented in
Table 4.8.
Table 4.8: Ratios and indices used in the multi-parametric approach.
Attribute Description Units
R1 =
SWT T
T Upstroke time ratio [-]
R2 =
SWT T −LV ET
T
Downstroke time ratio calculated between the systolic
and the diastolic waves
[-]
R3 =
DSt
SWT T Time ratio calculated between the global downstroke
time (DSt) and the upstroke time (SWT T )
[-]
R4 =
DWA
SWA Amplitude ratio between the dicrotic and the systolic
heights (SWA)
[-]
R5 = |SWA−RWA| Amplitude difference module between the systolic and
the inflection points
[V]
R6 =
RWA
SWA The systolic and the inflection points amplitude ratio [-]
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The well-established AIx, which measures the augmented pressure is computed according to
Equation 4.5, that was defined by Murgo et al. [182], where A is the normalized amplitude.
AIx(%) =±SWA−RWA
A
×100 (4.5)
The key issue concerning the AIx computation is the Pi identification, that can occur after, or
before, systolic wave front. Negative values are used to distinguish pulses where Pi arrives
after the systole (RWA−SWA), from the positive values that occur when the Pi occurs before
the systolic peak (SWA−RWA).
• Pulse Variance
Some statistical measurements were performed to assess the variance associated to the
prominent points locations, such as presented in Table 4.9. The Root Mean Square Successive
Difference (RMSSD) was computed for all of the variables, and the overall list includes:
RMSSDSPt , RMSSDSPa, RMSSDPit , RMSSDPia, RMSSDDWt and RMSSDDWa. Additionally,
the pulse morphology variability was assessed using the RMSE measure, taking as reference
the average pulse. Finally, the Full Width at Half Maximum (FWHM) was also evaluated.
Table 4.9: Pulse variance attributes.
Pulse Variance Description Units
RMSSDx√
∑n−1i=1 (xi+1− xi)2
n−1
RMSSD, where x is:
– SPt (represents SWTT)
– SPa (represents SWA)
– DWt (represents LVET)
– DWa (represents DWA)
– Pit (represents RWTT)
– Pia (represents RWA)
[%]
RMSE√
∑n−1i=1 (x1,i− x2,1)2
n
RMSE (measured in reference to the average
pulse)
[%]
FWHM Full Width at Half Maximum [s]
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5
Clinical Assessment Support Systems
The aim of this chapter is the exploration of data mining techniques to deal with the vectorized
features extracted from the APW. Different machine learning algorithms were used: Random Forest
and J48 (decision trees), BayesNet (probabilistic), RIPPER (rule-based induction) and Artificial
Neural Networks (ANNs) topologies. Additionally, clustering techniques were also implemented.
The performance evaluation included the comparison with traditional parameters: AIx, lipidic
measurements (e.g., cholesterol, cholesterol-LDL, cholesterol-HDL and tryglicerides), as well as
risk scores commonly used in clinical practice.
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5.1 Motivation
The major motivation of this chapter was the development of an efficient waveform analysis
methodology able to deal with multiple APW parameters. There is growing interest in data mining
methodologies that can ease the understanding of large biomedical datasets. The application of
machine learning algorithms can ease the data analysis, ensuring the learning of the system from
the data at which it is exposed to. Once trained, the system is able to predict a result, for a set
of new inputs based on the internal rules previously established. This methodology could bring an
interesting impact comparatively to the traditional cardiovascular tools used for risk prediction.
The Weka (Waikato Environment for Knowledge Analysis), a free machine learning platform,
is a very powerful tool that can be used for the analysis of the predictive value of each attribute, and
for the implementation of classification and clustering techniques. Additionally, it is a very efficient,
versatile and affordable tool, A detailed description is presented in Appendix C.
There are several terms that need to be understood, before delving into the question of how
machine learning schemes operate. In this work three main learning schemes were explored:
classification, clustering and prediction. Classification is the process of finding a model to describe
and to distinguish data classes. Typically, the derived model can be represented, e.g., in the form
of classification rules, decision trees or neural networks.The purpose is to build a model able to be
used in the prediction of the class of objects whose class label is unknown. Prediction can be viewed
as the construction and use of a model to assess the class of an unlabelled object, or to assess the
value or value ranges of an attribute that a given object is more likely to have. Finally, clustering
methodology can be used to analyse data objects without class label. The objects are clustered or
grouped based on the principle of maximizing the intraclass similarity and minimizing the interclass
similarity [158].
The input to a machine learning scheme is a set of instances. These instances are the things that
are to be classified, associated or clustered. Each instance is characterized by the values of attributes
that measure different aspects of the instance. There are many different types of attributes, although
typical data mining schemes deal only with numeric and nominal. There is a broad distinction
between quantities that are numeric and ones that are nominal. Numeric attributes, sometimes called
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continuous attributes, measure numbers, while nominal attributes take on values in a pre-specified,
finite set of possibilities and are sometimes called categorical [194].
5.2 Feature Subset Selection
Attribute selection is an important task that allows the improvement of dataset analysis, in a process
where the unneeded information is identified due to its low predictive value. An attribute may not be
selected, when presents too many missing values, and, there is (almost) no difference between the
values. The identification of redundant and/or irrelevant attributes before the training process allows
the optimization of the memory space and ensures time machine computing speed requirements.
There are several algorithms that can be used for this purpose, such as the InfoGainAttributeEval
(available on WEKA) that is a single-attribute evaluator algorithm very suitable for the analysis. It
uses a Ranker search method that evaluates the selected attributes, by measuring their information
gain, according to the defined classes using a discretization method [194]. So, the attributes are
ranked according to their average merit (expressed as a number between 0 and 1).
5.3 Classification
Several experiments were made in order to select the most suitable algorithms both from the
standpoint of discrimination ability, and the time spent to make a decision. The evaluation was
focused on different types of machine learning algorithms, namely: decision trees, association rules,
Bayesian networks, and Artificial Neural Networks (ANNs).
5.3.1 Single Classifiers
5.3.1.1 J48
The J48 is the Weka implementation of C4.5 algorithm, the most popular tree classifier, which was
developed by Quinlan (1993) [195]. Its implementation is based on a non-backtracking approach.
J48 uses two heuristic criteria to rank possible tests: the information gain and, the default gain
95
5. CLINICAL ASSESSMENT SUPPORT SYSTEMS
ratio. After the building process, each attribute test, along the path (from the root to the leaf)
becomes a rule antecedence (precondition), and the classification at the leaf node becomes the
rule consequence [158]. Decision trees are easy to interpret, capable to work with missing values,
categorical and continuous data, characteristics that appeal for its application in medical field.
5.3.1.2 Random Forest
Random Forest is a meta-learner algorithm comprising many individual trees, which has been
developed to operate quickly over large datasets [196]. Each tree depends on the values of a random
vector independently sampled and with the same distribution for all trees in the forest. For forests,
the generalization error converges to a limit as the number of trees in the forest becomes larger
[197]. The main advantages are related to the robustness to noise, and the fast computation ability.
However, the output can be difficult to interpret which is a disadvantage in medical environment.
5.3.1.3 RIPPER
RIPPER is a rule-based induction algorithm. After producing a rule set for the class, each rule is
reconsidered using reduced-error pruning, before proceeding to generate rules for the next class.
RIPPER was evaluated through JRIP which is the implementation of RIPPER in Weka [194]. The
main advantages of using this algorithm are: a clear set of classification rules used, and a high speed
computation.
5.3.1.4 BayesNet
BayesNet is a Bayesian network based on probabilistic graphical models. It was developed to deal
with nominal values (in case of numeric values, they are pre-discretized) and absence of missing
attributes [198]. Bayesian networks have a significant impact on the modelling and in the analysis
of the patient data. The major advantages are: the easy interpretation of the results and the robustness
in dealing with missing data.
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5.3.1.5 Artificial Neural Networks
ANNs are sophisticated analytical techniques, inspired by the biological nervous system. A network
is a set of connected input and output units, in which each connection has a specific weight associated
to it. The network learns by adjusting the weights. Even though ANNs need high computational
resources and rigorous parameter tuning (e.g., the number of hidden neurons), being sometimes
difficult to interpret, they present advantages that make their effectiveness undeniable. Amongst the
several set of architectures, it should be stressed out, the outstanding accuracy, the ability to work
with continuous attributes and the high tolerance to redundant attributes.
The most popular ANN architecture is the Multi-Layer Perceptron (MLP), which consists of an
input unit, an output layer and one or more hidden layers that can be determined by the user. It uses
a backpropagation learning algorithm. The network inputs pass through the input layer, and then,
they are weighted and fed to a second layer (the hidden layer). The outputs of the hidden layer can
be inputs to another hidden layer or, inputs to the output layer, which emits the network’s prediction
for the given tuples.
The Radial Basis Function (RBF) network is another popular approach. They are typically
configured with a single hidden layer of units whose output function is selected from a class of
functions called basis functions [199]. Being similar to the backpropagation in many aspects,
radial basis function networks have several advantages. They are usually trained much faster than
backpropagation networks. They are also less susceptible to problems with non-stationary inputs.
5.3.2 Classifier Ensemble - Bagging and Voting
The combination of multiple classification algorithms is based on the idea that each learning
technique has its limitations and that no single technique can significantly outperform the
others [200]. Essentially, there are two general groups of classifier fusion techniques, homogeneous
ensemble and heterogeneous ensemble.
Homogeneous ensemble uses the same learning technique on different distribution of training
datasets. Bagging is a well-known homogeneous ensemble technique that generates multiple sample
97
5. CLINICAL ASSESSMENT SUPPORT SYSTEMS
datasets by repeatedly sampling with replacements from training datasets. Each of them can be used
to build a prediction model using the same learning technique. The output is estimated by averaging
all the predictions [201].
Heterogeneous ensemble operates mainly on the classifier outputs combining different
supervised learning techniques. Each classifier is first build on training data and then associated
with a weight and measured by its prediction accuracy [201]. Then, a specific combination rule is
selected for the final estimation of the output value. The voting system is one of the strategies that
can be used in the combination of the results from the different classifiers.
5.4 Clustering
Clustering is defined as an unsupervised learning technique that can be used in the analysis of
the independent variables (all variables except class). In fact, the capability to deal only with
independent variables is the main feature that distinguishes clustering from classification techniques.
For this reason, clustering techniques may be best used for exploratory studies, especially those that
encompass large amount of data. During the cluster assignments, the pulses are independently
grouped according to their cluster similarities. The maximum level of similarity for each subject
occurs when all pulses fit in only one cluster. Expected Maximization (EM) and k-means clustering
algorithms are the most studied.
5.4.1 k-Means
The k-means algorithm is a type of partitional clustering that continuously iterates until a specific
criterion function (usually the square error) converges. It acknowledges the number of desired
cluster inputs (k) and divides the set of objects (n) into k clusters. The result is a higher intra-
cluster and lower inter-cluster similarity. The cluster similarity is measured considering the mean
value of the objects contained in the cluster, which is, in fact, the cluster centroid. k-Means
clustering is relatively scalable and efficient in processing large datasets. However, it cannot handle
categorical attributes and it is not suitable for dealing with non-convex shapes. Also, it is quite
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sensitive to the presence of noise and outliers. It requires an efficient data pre-processing before its
application [158].
5.4.2 Expectation-Maximization
The Expectation-Maximization (EM) clustering algorithm is a complex probabilistic extension of
the k-means method that primarily differs by the way how the initial groups are obtained. Instead
of assigning each object to a cluster, with which it is most similar, EM assigns each object to
a cluster according to a weight that represents the probability of membership. In this manner,
there are no strict boundaries between clusters, and new means are determined based on weighted
measures [158].
5.5 Risk Scores - Reference Method
Such as described in Section 2.7.1 there are several risk scores that have been developed to assist
clinicians in the CVD risk assessment. Four risk scores were considered along this work namely,
FRS, PROCAM, ASSIGN and SCORE. The FRS was developed from a general population in
Framingham, Massachusetts, USA, while the remaining scores derive from European studies. The
largest is the SCORE, since it consists of ≈ 205 000 subjects from 12 cohort studies from European
countries. The other two, ASSIGN and PROCAM, were developed in Scotland and Germany,
respectively. In general, the tools have distinct characteristics, different risk factors, specific disease,
event type, period of time and cohort locations. Table 5.1 summarizes the main characteristics of
them. The evaluation platforms are shown in Appendix D.
These tools are important to help physicians in their daily practice. However, its application in
different population remains a topic concerning attention. Estimation of cardiovascular risk can be
constrained by some inaccuracies due to the heterogeneity of populations in study. There are several
issues raised considering its application in different geographical regions according to the original
areas of the study. The clinical practice demonstrated that missing values may be problematic and
the majority of the current used risk scores are not prepared to deal with them.
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Table 5.1: Risk assessment tools (10 years term).
Model Patients Country of Origin Risk factors
FRS 8491 USA Age, Gender, Total-CH, CH-
HDL, SBP, BPT, SMK
SCORE 205178 Finland, Russia, Norway,
Denmark, UK (England), UK
(Scotland), Sweden, Belgium,
Germany, Italy, France and
Spain
Age, Gender, Total-CH, CH-
HDL, SBP, and SMK
ASSIGN 13297 Scotland Age, Gender, FH, DB, SMK,
SBP, Total-CH and CH-HDL
PROCAM 5389 Germany Age, CH-LDL, SMK, CH-HDL,
SBP, PE, DB, and TGL
Total-CH − Total Cholesterol, BPT − Blood Pressure Treatment, FH − Family History,
TGL − Triglycerides, SMK − Smoking habits, DB − Diabetes, PE − Previous Event, SBP
− Systolic Blood Pressure, CH-HDL−High-Density Lipoprotein, CH-LDL− Low Density
Lipoprotein.
The trend for overestimation the risk factor in low-risk populations and underestimation in
high-risk groups has been successfully demonstrated by Cooney, et al. [149]. It is known that
an examination of 5 % SCORE can equate to a 10− 25 % FRS risk, depending on which of the
several FRS functions is selected [40]. Haq, et al. [202] studied several methods for risk estimation
(FRS, PROCAM, Dundee, and British regional heart-BRHS) and the results demonstrated a close
agreement between all these, regarding average risk and showed moderate agreement for estimation
among individuals. Finally, it was also concluded that FRS function is acceptably accurate in
northern European populations.
5.6 Methods
5.6.1 Training
Commonly, there are three types of datasets: the training data, the validation data and the test
data. The training data are used by the learning schemes to come up with classifiers, while the
validation data could be used in the parameters optimization, or in the selection of a particular
100
5.6. METHODS
one. The test dataset is commonly used in the computation of the error rate. All these datasets
must be independently chosen. For a larger database this process is easier, since a larger and more
representative sample can be selected for training while another independent large sample can be
used for training purposes. For these cases, the error rate of the test set is a more reliable measure.
However, whenever a larger database is unavailable and, the amount of data is limited, the best
solution is reserve some data for testing, and use the remaining data for training, thus assuring the
representatively of samples. Cross-validation is a simple form to ensure this. In this process, a
fixed number of folds (or partitions) is defined and then, each of the folds is used once for testing,
while the remaining folds are used for training. The procedure is repeated, so that, at the end,
every instance has been used once in the testing procedure. Extensive tests on numerous different
datasets and learning techniques, have shown that 10 is a good number of folds to be used in the
error estimation [194]. In this case, the original dataset is partitioned into 10 subsets (folds) of equal
size, P1, (...), P10. The global accuracy is the average of the accuracy of the 10 trials.
5.6.2 Classifiers Performance
Data from GroupC and GroupH were used, during the training procedure of the classifiers. Several
experiments were made in order to select the most suitable methods both from the standpoint of
discrimination ability, as well as, from the time spent to make a decision [158].
Such as depicted in Table 5.2, the measurements are generally presented in a confusion matrix.
The True Positive (TP) and True Negative (TN) values represent the correct classifications; the
False Positive (FP) values occur when the outcome is incorrectly predicted as positive and; the False
Negative (FN) values occur when the outcome is incorrectly predicted as negative. Each column of
the matrix represents the predicted classes, while each row represents the actual classes.
These values can be used in the computation of several indices (error rate, sensitivity, specificity
Table 5.2: Confusion matrix of observed class vs. predicted class.
Positive (predicted) Negative (predicted)
Positive (actual) TP FP
Negative (actual) FN TN
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Table 5.3: Parameters used in the assessment of the classifiers’ performance.
Parameter Description
Sensitivity
T P
T P+FN
Percentage of positive labelled instances
(actual condition) that were predicted as
positive
Specificity
T N
T N +FP
Percentage of negative labelled instances
(actual condition) that were predicted as
negative
Positive Predictive Value
(Precision)
T P
T P+FP Percentage of correct positive predictions
Negative Predictive Value
T N
FN +T N Percentage of correct negative predictions
Error Rate
T P+T N
T P+T N +FP+FN
Percentage of correct predictions
and precision) such as is shown in Table 5.3. It is also important to consider the training time
along experiments. The following rank was adopted: * [0− 2 s], ** [2− 10 s], *** [10− 20 s],
**** [20−60 s], ***** [>60 s].
On the other hand, the Receiver Operating Characteristic (ROC) curve is a graphical plot of the
sensitivity, given by the true and the false positive rate, being a good tool for the assessment of the
classifiers’ performance. The Area Under Curve (AUC) of the ROC is often used for the models
comparison. A larger AUC value corresponds to a more accurate classifier (ideally AUC = 1).
5.6.2.1 Learning Curves
The study of the ”learning curves” is an interesting point to consider during the classifiers evaluation,
giving information about the effect of gradually increasing the amount of training data [203]. This
process allows to gain insight into the generalization of the capabilities of each classifier. The
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classifiers can be trained with a varying number of subjects, randomly selected from the whole
dataset along repeated trials. As the number of subjects increases, it is expectable that the training
performance should approach an asymptotic value, for each classifier.
5.6.2.2 Artificial Neural Network Performance
The definition of the best ANN configurations, especially for small datasets, is a complex and
challenging task. An extensive search, even though it could lead to an optimal set of features,
is impractical in terms of effort and computational time. Along this work different parameter
configurations were tested and, the accuracy, the sensitivity, the specificity and the precision values
comparatively analysed.
5.6.3 Predictive Models
The validation of the models was carried out using GroupD (see Section 4.1). The models obtained
from the training of J48, Random Forest, BayesNet and JRIP were loaded to the class prediction
of each pulse, individually. The majority-voting system (see Section 5.3.2) was used to merge the
labels from each of the considered models.
The following nomenclature for predicted class labels was adopted: the labels correlated to the
APW patterns from GroupH were coded as A, while the ”normal” APW patterns similar to those of
GroupC (negative AIx values) were coded as B. Each subject can have pulse instances observed in
both classes. In this case, the final value is presented as a percentage of the class A and the class B,
within the set of analysed pulses.
5.6.4 Clustering
Clustering methods are very useful when little or no information is known about the dataset, and
a primary visual data inspection is essential. GroupC and GroupH were selected and analysed for
the set of characteristics available for each one. Different nomenclatures were adopted to help
understanding the data at hand, numeric labels (1, 2, ...) for the GroupC and alphabetic labels
(A, B, ...) for the GroupH.
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During the cluster assignments for each subject, the pulses were independently grouped
according to their cluster similarities. The maximum level of similarity within a cluster occurs
when all pulses for each subject fit in only one cluster group. Therefore, the cluster risk is assessed
as a percentage of the pulses in the fit of the predefined cluster at risk.
5.6.4.1 Number of Clusters
The choice for the number of clusters is often a difficult task. The clusters are evaluated according
to the total squared distance criterion. The goal is to minimize the square-error that is the sum of the
Euclidean distances between each pattern and its cluster centre.
The adopted strategy for the determination of the ideal number of clusters consisted, firstly, in
the selection of two clusters (k = 2) followed by a tentative to split each of these clusters. During
the process, clusters can also be merged if they are sufficiently close or, if there is too many patterns
and an unusually large variance. As, the presence of outliers influences the number of clusters, these
points should be eliminated from the data [15].
5.6.5 Risk Evaluation
The CHD risk was computed for each patient of GroupH based on the FRS, SCORE, ASSIGN
and PROCAM functions. Firstly, the significance of correlation between the risk values and the
other parameters at test was studied. The comparison included parameters from pulse wave analysis
(APW parameters), BP values, and lipidic measurements.
The analysis was performed using statistic methodologies, to evaluate the normality of the
distribution (Kolmogorov-Smirov test) and the correlations among variables (Spearman’s rank
correlation or Pearson product moment correlation). A full description of these methods is presented
in Sections 6.2.2 and 6.2.5, respectively.
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5.7 Results
5.7.1 Ranked Feature List
The InfoGainAttributeEval ranker method was used in the analysis of the set of features at test.
Results are presented in Figure 5.1. The parameters are ranked according to the degree of correlation
within the class, and the redundancy among them. Values near to 1 are obtained for those that
are highly correlated with the class analysed and that show low correlation inter-parameters. The
RWTT and SWTT time positions revealed to be the best predictors, as well as some of the computed
ratios (R6, R1, R3 and R2) and index (R5). This task was essential for the discrimination of the
most interesting features for further analysis. The parameters with low merit (a threshold of 0.1
was considered) were discarded. The overall list of parameters selected includes: RWTT, R6, R5,
SWTT, R1, R2, R3, DWA, R4, LVET, AIx and RMSSDPit .
Figure 5.1: Ranking of analysis features based on the average merit.
5.7.2 Classifiers Configuration
5.7.2.1 Learning Curves
In Figure 5.2 are displayed the learning curves obtained varying the number of subjects in the dataset.
The performance was assessed considering 5 trials for each configuration. The performance of all
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the classifiers converged for a stable value, as presented in Figure 5.3. The Bayesian algorithms
evidence the worst accuracy values comparatively to the other classifiers.
Figure 5.2: Classifier performance curves obtained by the variation of the number of subjects in the
dataset.
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Figure 5.3: Accuracy measured with increased subjects number.
5.7.2.2 Artificial Neural Networks
Different parameter configurations were tested for each neural network (MPL-1 hidden layer,
MPL- 2 hidden layers and RBF). The first trials showed that the manipulation of the neurons number
is preponderant in the analysis. During the procedure, accuracy, sensitivity, specificity and precision
were computed. The results are detailed below:
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• MPL-1 Hidden Layer
The analysis of Table 5.4 suggests that the optimal number of hidden neurons may be
approximately between 19 and 20. The first condition (run 5) presents higher sensitivity and
precision but, on the other hand, run 6 presents higher specificity. The second configuration
is preferred for further analysis due to the higher specificity, which is quite important. One
should consider models with higher specificity, because it is preferable having a classifier with
few FPs as possible, to avoid the misdiagnosing of unhealthy patients as healthy. However,
methods with high sensitivity should not be discarded, since high FNs rates can lead to the
identification of other problems (such as, bad data acquisitions, for instance).
Table 5.4: MLP performance study for 1 hidden layer.
Run Hidden neurons Accuracy (%) Sensitivity (%) Specificity (%) Precision (%)
1 15 96.06 95.43 96.64 96.38
2 16 96.57 95.56 96.58 96.35
3 17 96.67 96.56 96.78 96.56
4 18 96.84 96.63 97.04 96.85
5 19 96.98 96.84 97.10 96.91
6 20 96.98 96.77 97.17 96.83
7 21 96.70 96.07 97.10 96.40
8 22 96.77 96.98 96.58 96.37
9 23 96.34 95.93 96.71 96.47
10 24 96.60 95.35 96.85 96.62
11 25 96.34 95.35 96.32 96.08
• MPL-2 Hidden Layers
A similar approach was performed for the 2-hidden layer case, following the methodology
used for MPL-1 hidden layers. The number of hidden neurons was manipulated in the 20−22
range. The overall performance is listed on Table 5.5, where run 3 excels for the case of 22
considered neurons on the 2-layers.
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Table 5.5: MLP performance study for 2 hidden layer.
Run
Hidden neurons
(layer1,layer2)
Accuracy (%) Sensitivity (%) Specificity (%) Precision (%)
1 20,20 96.51 96.56 96.45 96.22
2 21,21 96.44 96.42 96.45 96.22
3 22,22 96.74 96.52 96.91 96.70
• RBF
The analysis of the RBF performance focused on two parameters: the clustering seed (a
random estimate of the initial weight) and the number of clusters. Results are expressed in
Table 5.6. It was verified that the number of clusters was preponderant. Run 6 presents the
best global results for accuracy, specificity and precision. Therefore, in the runs 8 and 9,
the same number of clusters was used and the clustering seed was manipulated. The seed
value is used for generating a random number which is used for making the initial assignment
of instances to clusters. Run 8 presents the best results, namely higher accuracy (96.23 %),
sensitivity (96.23 %) and precision (96.65 %).
Table 5.6: RBF performance study, while manipulating clustering seed and the number of clusters.
Run
Clustering
seed
Number of
Clusters
Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
Precision
(%)
1 1 2 91.92 92.56 91.33 91.92
2 1 5 92.26 90.46 93.96 92.26
3 1 10 94.49 94.25 94.71 94.49
4 1 20 95.32 95.02 95.60 95.32
5 1 50 95.79 94.46 97.04 95.79
6 1 100 96.03 94.74 97.24 96.03
7 1 250 95.32 94.53 96.06 95.32
8 5 100 96.23 96.23 95.79 96.65
9 10 100 95.76 95.12 96.36 96.13
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5.7.3 Classifiers Selection
The classification results are presented in Table 5.7. These results demonstrate the superior
performance of Random Forest. Classifiers with 90−95 % accuracy are regarded as solid rules [15],
which in this case represent six of the eight evaluated classifiers, and the others remain very close to
90 % (Table 5.7). On the other hand, ANN methods require high computational resources, as they
can take several minutes to be trained. ANNs showed excellent results in the specificity analysis,
which means that FP error rate is low.
The ROC curves corresponding to four of all the classifiers are plotted in Figure 5.4. The area
values obtained for each of the classifiers were: 0.994 for Random Forest, 0.961 for J48, 0.965 for
JRIP and 0.939 for BayesNet. Examining the ROC curves it is possible to conclude that the better
results were achieved with Random Forest, J48 and JRIP.
Table 5.7: Comparative classifier selection performance results.
Classifier Accuracy Sensitivity Specificity Precision Training Time
(%) (%) (%) (%)
C4.5 95.72 95.58 95.86 95.58 **
Random Forest 97.15 97.47 96.85 96.66 **
RIPPER 95.72 95.72 95.34 95.07 ***
Naı¨ve Bayes 88.05 88.05 86.60 89.42 *
Bayesian Network 89.01 84.60 92.90 91.80 *
MLP (1 HL) 96.98 96.84 97.11 96.91 ****
MLP (2 HL) 96.74 96.56 96.91 96.70 *****
RBF 96.23 96.23 95.23 96.93 ***
* [0−2 s], ** [2−10 s], *** [10−20 s], **** [20−60 s], ***** [>60 s]
5.7.4 Predictive Model Evaluation
The data prediction results (for GroupD) are presented in Table 5.8. For each subject, the class was
predicted using the J48, Random Forest, BayesNet and JRIP classifier models previously tested. All
the pulses were considered, and the final prediction is presented as a percentage of the number of
class A and class B pulses, within the dataset.
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Figure 5.4: Semi-log ROC curves for J48, Random Forest, JRIP amd BayesNet classifiers.
The AIx values were compared with these labels. The correlation between the higher class A
percentage and the higher positive AIx values is clearly visible (Figure 5.5). For the pulses in class
A, an average AIx value of 14.80± 8.60 % was obtained and, for the class B group, a value of
4.10±8.70 % was observed.
Table 5.8: Data obtained from class prediction analysis and the AIx values (for each subject).
Subjects
Predicted class (%)
AIx (%)
A B
1 87.13 12.87 19.05±3.57
2 86.09 13.91 12.28±10.11
3 76.00 24.00 16.15±3.76
4 65.53 34.47 7.13±9.41
5 62.98 37.02 10.70±11.58
6 61.85 38.15 12.46±7.14
7 61.04 38.96 11.50±8.40
8 60.66 39.34 9.89±4.37
9 54.87 45.13 6.63±9.92
10 13.95 86.05 −3.33±8.29
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Figure 5.5: Boxplot of AIx distribution for classes A and B. The horizontal bold lines represent
the medians, the box represent the interquartile ranges (50 % of the distribution) and the whiskers
represent the range of values obtained for all subjects from GroupD in an overall set of 627 pulses.
5.7.5 Comparison of Risk Scores Estimates
The comparison of the risk values obtained for the GroupH by each of the scores was performed
through on Bland-Altman plots (Figure 5.6) and Pearson’s correlation matrix (Table 5.9).
• SCORE vs. FRS
The mean risk of CHD events calculated by the SCORE function was 2.5 % per year and
by the FRS function was 12 % per year. A significant correlation between these methods
(r = 0.641, p < 0.01) was verified. The Bland-Altman plot (Figure 5.6(a)) showed a
systematic mean difference of −9.50 % that resulted from the overestimation of risk levels
by the FRS.
• SCORE vs. PROCAM
Estimates of CHD event risk by the SCORE function (2.5 % per year) were much lower than
those obtained by PROCAM (17.31 % per year). It was observed a moderate correlation
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between these methods (r = 0.639, p < 0.01). The Bland-Altman plot also shows a large,
but systematic difference (mean value of −14.81 %), such as it is visible in Figure 5.6(b).
Figure 5.6: Bland-Altman plots for the individual risk estimative by the FRS, PROCAM, ASSIGN
and SCORE functions.
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• SCORE vs. ASSIGN
Estimates of CHD event risk by the SCORE function were also much lower than those by
ASSIGN (17.50 % per year). In this case a weak but significant correlation between estimates
was achieved (r = 0.529, p < 0.05). The Bland-Altman plot (Figure 5.6(c)) confirmed the
large and systematic difference, among methods on average (−15.00 %).
• ASSIGN vs. PROCAM
The mean risk of CHD events calculated by the ASSIGN function was 17.50 % per year,
and by the PROCAM function was 17.31 % per year, presenting only a mean difference of
0.19 %, the lowest difference verified within all the considered scores. A moderate correlation
for the CHD risk estimates from both methods was verified (r = 0.588, p< 0.01). The Bland-
Altman plot (Figure 5.6(d)) showed agreement on average, and does not evidence a systematic
bias, but presents large variability at higher values.
• ASSIGN vs. FRS
The mean risk of CHD events calculated by the ASSIGN function was 17.50 % per year,
and by the FRS function was 12 % per year, with a mean difference of 5.50 %. A moderate
correlation between CHD risk estimates among methods (r = 0.670, p < 0.01) was verified.
The Bland-Altman plot (Figure 5.6(e)) does not show any systematic error.
• PROCAM vs. FRS
The mean risk of CHD events calculated by the PROCAM function was 17.31 % per year,
and by the FRS function was 12 % per year. The higher significant value was verified for
these methods (r = 0.782, p < 0.01). However, from the analysis of Figure 5.6(f) it was also
verified that the PROCAM function comparatively to the FRS tends to overestimate the CHD
risk in general (mean difference of 5.31 %), in spite of underestimation at lower risk levels.
Similar results were achieved, by Haq et al. [202].
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5.7.6 PWA Parameters Evaluation
The analysis of Table 5.9 allows to conclude that significant correlations occur between
the AIx and the remaining parameters, namely strong correlations with RWA (r =
−0.965, p < 0.001) and RWTT (r = −0.758, p < 0.001). The negative values in
the correlation are associated to early reflections that tend to occur at lower amplitudes.
The AIx values present a significant correlation with SWTT (r = 0.642, p < 0.001) and
LVET (r = 0.493, p < 0.001). On the other hand, no significant correlations were verified
between RWTT and SWTT (r = −0.283, p = 0.227) and between RWTT and LVET
(r = −0.158, p = 0.506). For an early reflection wave, the SWTT and LVET values increase,
leading to the negative values observed. Finally, a strong significant correlation was also achieved
between SWTT and LVET (r = 0.928, p < 0.001).
Figure 5.7 shows the correlation plots for SWTT, RWTT and LVET parameters, with each risk
scores (FRS, SCORE, ASSIGN and PROCAM). A clearly positive trend occurs for the SWTT and
LVET. This result supports the assumption that the forward wave duration is associated to the CHD
risk increase, as was also demonstrated by Mitchell el. al. [140]. RWTT values assume a low
relevance in the risk prediction. This conclusion is also supported by the low significant values
observed in Table 5.9.
It was also observed an interesting correlation value between the AIx values and the score results,
namely for the ASSIGN (r = 0.491, p < 0.05), and FRS (r = 0.384, p = 0.095). Similar results
were achieved by Song et al. [204].
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Figure 5.7: Correlation plots between transit time based parameters and all the considered risk scores
(ASSIGN, PROCAM, SCORE and FSR).
5.7.7 Clustering Analysis
The cluster analysis was performed for GroupC and GroupH. As referred previously, different
nomenclatures were adopted to help understanding the data at hand, numeric labels (1, 2, ...) for the
GroupC and alphabetic labels (A, B, ...) for the GroupH.
117
5. CLINICAL ASSESSMENT SUPPORT SYSTEMS
5.7.7.1 GroupC
The first approach consisted in the selection of the best clustering algorithm to deal with the set of
features at test, as well as the ideal number of clusters to the group characterization. Figure 5.8
displays RWTT and SWTT plot for 2-clusters analysis using EM (a) and k-means (b) algorithms.
Red and blue coloured points represent the pulse labels (blue = Cluster 1, red = Cluster 2).
Figure 5.8: Clusters performance obtained for EM (top) and k-means (bottom) algorithms using two
clusters, Cluster 1=blue, Cluster 2=red.
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Categorical features (gender, smoker) were not considered during the analysis, since k-means
analysis is not able to deal with this kind attributes.
The figure shows that the EM plot has an unsatisfactory division between the clusters, with
some points from Cluster 2 (red) identified as being in the Cluster 1 area (blue), as well. Visually,
the results from the k-means clustering have a more efficient separation, as the dataset is partitioned
in two homogeneous risk groups. For both EM and k-means, the blue group (Cluster 1) represent
the pool of healthier subjects when compared to the red group (Cluster 2), since it represents the
cases where the reflection wave arrives after to the systolic peak. The analysis of Cluster 2 also
indicates the presence of another sub-cluster. Taking this into account, the k-means method was
used to explore the distribution of a third cluster, since it performed well, comparatively to the EM,
in the two cluster distribution. The obtained results for a 3 cluster distribution are presented in
Figure 5.9. The detailed information about this cluster disribution is presented in Table 5.10. The
Cluster 3 (green homogeneous zone) is mostly representative of Type C APW pulses (see waveform
types definition in Section 4.4), where RWT T > SWT T . The mean AIx value of the cluster
centroid is negative (−11.2 %), thus being considered the lower risk cluster. Cluster 2 (red points)
predominantly consists of Type B pulses, with SWT T > RWT T and AIx > 0, being thus considered
the intermediate risk group. Cluster 1 pulses (blue points) represent the less homogeneous group,
Figure 5.9: RWTT and SWTT plot after k-means clustering for using three clusters. Blue=Cluster 1,
red=Cluster 2 and Green=Cluster 3.
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Table 5.10: Average values for the 3-clusters features.
Attributes
Cluster
1 2 3
Pulses 458 1550 2463
Age (y) 21.6 21.0 21.7
Weight (kg) 63.0 55.4 63.2
Height (m) 1.7 1.6 1.7
BMI (kg/m2) 21.3 20.8 21.8
SBP (mmHg) 109.9 106.1 108.6
DBP (mmHg) 69.6 70.3 68.9
HR (bpm) 72.8 67.5 72.9
SWTT (ms) 172.7 234.4 117.1
RWTT (ms) 103.0 143.2 179.9
LVET (ms) 240.3 306.4 274.4
SWA (a.u. a) 1.0 1.0 1.0
RWA (a.u. a) 0.8 0.9 0.9
DWA (a.u. a) 0.8 0.8 0.7
R1 (-) 67.6 72.0 157.3
R2 (-) 0.8 0.8 0.7
R3 (-) 0.2 0.1 -0.1
R4 (-) 0.8 0.9 -0.9
AIx (%) 21.0 12.6 -11.2
RMSSDSPt (ms) 34.9 25.5 21.7
RMSSDSPA (a.u. a) 0.0 0.0 0.0
RMSSDPia (a.u. a) 0.5 0.0 0.2
RMSSDDWT (ms) 54.2 18.5 42.8
RMSSDDWA (a.u. a) 0.1 0.1 0.1
FWHM (ms) 459.0 450.6 466.3
RMSE (%) 0.1 0.0 0.1
a Arbitrary Amplitude Units
with some points also scattered across the Cluster 2 area. These pulses are mainly APW Type
A pulses, with some punctual Type B pulses. This group evidences a higher cardiovascular risk
comparatively to the Cluster 2 and Cluster 3.
During the clustering procedures, RMSSDPit negatively interfered with cluster measurements.
For this reason, this parameter was removed from the analysis alongside the categorical features.
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5.7.7.2 GroupH
The k-means was also used in the GroupH analysis. Figure 5.10 depicts the 2-cluster distribution,
where Cluster A and Cluster B were the labels adopted.
Figure 5.10: Scatter plots for: (a) RWTT and RWA, (b) LVET and SWTT, where the grey and black
markers denote Cluster A and Cluster B, respectively.
The characteristics of each of the clusters are presented in Table 5.11. It can be verified that
the clusters do not differ significantly according to the SBP and DBP values. The most significant
Table 5.11: Cluster distributions for subjects in GroupH.
Attributes Cluster A Cluster B
SBP (mmHg) 169.68±10.38 172.56±13.59
DBP (mmHg) 101.22±7.03 102.00±7.14
Total-CH (mg/dL) 206.50±26.16 204.01±13.69
CH-HDL (mg/dL) 59.35±25.07 66.33±23.31
TGL(mg/dL) 160.41±44.95 142.94±40.96
RWTT (ms) 99.90±23.62 140.32±42.76
RWA (a.u. a) 0.60±0.11 0.90±0.06
SWTT (ms) 257.34±35.76 185.34±40.70
LVET (ms) 326.24±39.43 272.16±44.17
AIx (%) 40.01±11.15 6.2±9.67
Clustered instances 723 (52 %) 664 (48 %)
a Arbitrary Amplitude Units
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parameters (except APW parameters) were the CH-HDL and the TGL values. Cluster A presents
higher TGL values, but also lower CH-HDL levels, that are characteristics of subjects at risk. From
the waveform analysis, lower RWTT, higher SWTT and, consequently, higher positive AIx values
were obtained. The suitable number of clusters was considered to be two as may be confirmed by
visual inspection.
During the evaluation, the pulse instances were independently grouped according to their cluster
similarities, being the maximum level of similarity achieved, for each subject, when all the pulses
fit in a single cluster. So, for each subject a value representing the cluster risk (as percentage) was
computed and used in the correlation with other available parameters (including the studied scores).
Since only two clusters are studied, at this point, the values of Cluster A (%) are symmetric to the
values of Cluster B (%). The Cluster A (%) correlations are presented in Table 5.12.
The lipidic and the BP values present low significance with the Cluster A (%), similarly to the
values observed from the correlation with scores (see Table 5.9). On the other hand, significant
correlation values were obtained between Cluster A (%) and PWA parameters. Additionally, it
Table 5.12: Spearman’s correlation coefficients
obtained for Cluster A (%).
Attributes Cluster A (%)
SBP -0.131
DBP -0.080
Total-CH 0.011
CH-HDL -0.177
TGL 0.017
AIx 0.921 **
SWTT 0.649 **
RWTT -0.632 **
RWA -0.933 **
LVET 0.574 **
FRS 0.458 *
SCORE 0.275
ASSIGN 0.582 **
PROCAM 0.391
Significant levels: ** p < 0.01, *p < 0.05
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was obtained a significant correlation between Cluster A (%) and the risk scores. In this case was
observed a very significant correlation with ASSIGN (r = 0.582, p < 0.01), a significant correlation
with FRS (r = 0.458, p < 0.05) and, weaker correlations with SCORE (r = 0.275, p = 0.241) and
PROCAM (r = 0.391, p = 0.088). These results are good indicators for the use of this methodology
as a tool for the cardiovascular risk assessment.
5.7.7.3 Comparison of Groups
The evaluation was performed by the comparison of the clusters in GroupH (Cluster A and Cluster B)
and clusters in GroupC (Cluster 1, Cluster 2 and Cluster 3). The cardiovascular risk, assessed by the
scores is available for the GroupH, for that it was demonstrated that a higher risk is association to
the Cluster A. Since, there is no information about the risk associated to GroupC, each of the three
clusters was compared to the GroupH parametrizations. The comparison was performed using the
chi-squared (χ2) value, obtained from the Kruskal-Wallis test, as shown in Table 5.13.
There are significant differences for the majority of clusters in GroupH and GroupC, as expected
due to the distinct population characteristics of each group. However, some similarities were found
between the Cluster B (the score at lower risk in groupH) and the Cluster 1 (belonging to the
GroupC), namely: for LVET (χ2 = 4.79, p < 0.01) and SWTT (χ2 = 0.02, p < 0.01) measures.
Additionally, from the analysis of Table 5.10 that Cluster 1 has a higher AIx value associated, and
Table 5.13: Comparison of clusters from GroupH (Cluster A and Cluster B) and GroupC (Cluster 1,
Cluster 2 and Cluster 3) using Kruskal-Wallis test, measured through χ2 value.
GroupH GroupC
Parameters
RWTT RWA SWTT RWTT LVET AIx
ClusterA
Cluster1 38.66 ** 402.42** 526.65** 38.66** 369.23** 402.40 **
Cluster2 1149.82** 1399.96 ** 248.87 ** 1149.82** 154.81** 1399.97**
Cluster3 1454.05** 1545.50** 1619.16** 1454.05** 706.65** 1638.37**
ClusterB
Cluster1 536.38 ** 458.25** 0.02 536.38** 4.79 538.34 **
Cluster2 265.77** 3.16 ** 892.34 ** 265.77** 598.03** 49.97 **
Cluster3 593.88** 4.06** 998.62** 593.88** 60.22** 1158.33**
Significant levels: ** p < 0.01
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that it is the cluster at higher risk in GroupC. So, it can be concluded, that this cluster presents
closest parametrizations with the ClusterB from hypertensive group, a cluster at risk, but in lower
levels. It would not be trustable, if the similarities occur for the group of subjects in advanced
stages of disease. This conclusion is very important, since allowed the screening of a healthy
population (using only waveform parameters) concerning the cardiovascular risk using clustering
methodologies.
5.8 Discussion
This section includes the discussion of the results obtained with the data mining implemented
methodology for the feature selection, classification, clustering and predictive model algorithms,
as well as risk scores implementation.
5.8.1 Features Selection
Concerning the predictive value of the APW attributes (Figure 5.1), arrival time (RWTT) revealed to
be the most significant in the ”subjects” discrimination. This relevance of Pi-related parameters
can be explained by the known fact that arterial stiffness strongly correlates to its components
(both in time and amplitude). Clinically, this effect is usually quantified on the well-known AIx.
Compared to the single AIx analysis, the proposed framework has the main advantage of being
more flexible when dealing with poor quality pulses, where pulse wave analysis can be difficult, or
even impossible, to perform. The difficulty in obtaining AIx values invariably occurs in cases where
the inflection point is very close to (or buried in) the SP. In these cases, this approach is an efficient
way to sort out this ambiguity by the combination of the information coming out from several other
morphological parameters. Naturally, for the developed model, some degree of dependence on the
accuracy of the inflection determination remains. However, the interaction with other parameters,
implied by the method, decreases this dependence to a point where prediction becomes reliably
possible. Naturally, systolic time (SWTT) also appears as one of the key attributes in this dataset.
The other indexes, R1, R2 and R3, still have considerable merit, but not as high as those of Pi and
SP. However, they are quite important, because being Pi-independent parameters, they account for
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a more robust class prediction, whenever Pi is hidden in the APW and its parametrization is not
achieved. Dicrotic wave values changed less than expected, due to the absence of registered cardiac
valves complications in this database. Also related to this fact is observed the low predictive value
of the R4 ratio.
5.8.2 Classification Model
The results from the classification performance are expressed in Table 5.7. All classification methods
except Bayesian based classification exhibited accuracy values >95 %. Random Forest was the best
classifier, in overall, since it produced the highest accuracy and sensitivity values. In comparison
with the other classifiers, ANN methods require higher computational resources, as they can take
more than 30 seconds to be trained. However, ANN algorithms have shown superior results in terms
of specificity, which means that the FP error rate is low. The three classifiers with highest accuracy
scores were: Random Forest, MLP-1 hidden layer and MLP-2 hidden layers.
Results from the ROC curves confirm the good accuracy verified previously. A very high
true positive rate was achieved for Random Forest, J48 and JRIP contrasting with the BayesNet
performance. These differences are clear in the zoom window view, in Figure 5.4, where the x axis
is plotted on a logarithmic scale.
The analysis of the learning curves revealed that it is possible achieve the classifiers maximum
performance with 25− 30 subjects in the dataset. It was also concluded that the combination of
several classifiers should be used in APW studies in order to avoid the limitations of single-parameter
analysis.
5.8.3 Predictive Model
In the validation group, the subjects belonging to GroupD are young (average of 24 years old) but
also present positive AIx values, out of the normal range for this age [144], varying from −3.33 %
to 19.05 %. The application of the previous model intends to discriminate the patterns and the
relationships in the pulse morphology and the identification of interesting risk labels. These values
were validated by AIx values. A positive correlation between risk (class A in this dataset) and AIx
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positive values was verified. The knowledge obtained through this study provides more information
than typical information provided by pulse wave analysis techniques.
5.8.4 Risk Scores
The first point concerning attention is related with the application of different risk scores in the same
population. From the analysis of all risk scores, it is visible the underestimation of risk levels by
the SCORE, comparatively to the other tools. Higher errors tend to occur for patients at higher risk,
but the errors seem to be systematic. The values from the correlation analysis are in agreement with
other authors, such as the values obtained by Haq et al. [202], that observed a significant strong
correlation (r = 0.82, p < 0.001) between FRS and PROCAM, similar to the value obtained in this
study (r = 0.782, p < 0.001). A significant correlation was also verified between ASSIGN and
FRS (r = 0.670, p = 0.001), but lower than the values obtained by Woodward et al. [205], that
for a population under gender discrimination obtained a correlation of 0.92 for men and 0.90 for
women. The verified differences within all scores are acceptable and justified by the dissimilarities
of the populations (age, the duration of the follow-up, number or participants and the definition of
end-point). Risk prediction, inevitably, has associated errors, but the use of multiple scores could
contribute to enhance its accuracy.
Parameters used by each risk scores are similar: age is included in all scores, lipidic
measurements have been used by several authors, being the Total-CH and the CH-HDL the most
used. Inclusion of other parameters, such as family history or smoking habits can improve the
results, and are effectively used by most of the scores. Additionally, diabetes information is required
by the ASSIGN and PROCAM scores, and can be particularly valuable in young people. Generally,
all of these parameters are positively correlated to the risk scores with the exception of CH-HDL
that correlates negatively to the scores. The CH-HDL values are strongly correlated with FRS
(r =−0.456, p < 0.05) and ASSIGN (r =−0.581, p < 0.01).
Significant correlations were verified for the PWA parameters. The SWTT and LVET parameters
presented higher values comparing to the reflected wave components (RWTT and RWA). The lower
significance verified for the reflected wave components can be interpreted as part of the more
complex reflection process. The reflection wave results from the sum of waves at the innumerous
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reflection sites and not from a single effective site. Analysing each one of the parameters, the
correlation between RWA and SWTT (r = −0.589, p < 0.01) and the correlation between RWA
and LVET (r =−0.486, p< 0.05) were preponderant comparatively to the values observed between
RWTT and SWTT (r =−0.283, p > 0.05) and between RWTT and LVET (r =−0.158, p > 0.05).
Additionally, strong correlations for the AIx and RWA (r =−0.965, p < 0.001) and for the AIx and
RWTT (r =−0.758, p < 0.001) were verified, as expected.
5.8.5 Clustering Analysis
The information that is extracted from the clustering analysis can be crucial to fully understand of the
data, mainly when there is no, or little, available information. It was verified, that Total-CH and TGL
values are intrinsically related to the APW variables, and than an increase of these levels is associated
to the RWTT decrease and SWTT increase. On the other hand, the higher CH-HDL values are
associated to the increase of RWTT and decrease of SWTT values. A significant correlation for the
cluster output with the ASSIGN (r = 0.582, p < 0.01) and with FRS (r = 0.458, p < 0.05) was also
verified.
This method is particularly interesting, if it was considered that this approach can avoid the
requirements of the classification procedures which often require costly labelling of a large set
of patterns, such as biochemical analysis used by traditional risk scores, as demonstrated on the
cluster analysis of subjects in GroupC. It was possible to identify the similarities with GroupH
clusters, using only morphological parameters. The possibility to emulate the performance of the
traditional risk scores by the use of only non-invasive parameters, which can be easily obtained
using a PWA technique, is an efficient alternative approach to study large datasets. In this sense,
clustering analysis is an easy method for large populations screening producing valuable knowledge
for posterior prioritising people for pharmacological measures. In summary, from the analysis of
the given results, it can be concluded that clustering risk assessment performed with multiple PWA
parameters is correlated to the risk score values.
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5.9 Conclusion
The healthcare public and private system faces the challenge of an increasingly ageing population
and the escalation of medical costs. Therefore, the development of techniques that allow for earlier
identification of subjects at risk, by including customised predictive and preventive methodologies,
are essential.
The developed methodology has proven its usage in screening studies due to its descriptive and
predictive power. The successful application of data mining techniques can help to predict under-
diagnosed patients, and identify and classify people at-risk in terms of cardiovascular health, as
well as reduce healthcare costs. In clustering methods, more than the usefulness when there is no,
or little, information available, the information that is extracted from them can be crucial in fully
understanding the data.
The high limitation of this work is its cross-sectional design that can explain why PWA measures
were low significantly associated with all cardiovascular risk outcomes. A prospective design would
more effectively elucidate the relationship between arterial stiffness indices and the outcomes from
the traditional scores. The sample size of the studied populations should also increase and include
the stratification by medication use, age, diabetes duration, and/or gender.
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Validation Tests
This chapter intends to assess the potential clinical use of the APW module. The validation tests
consisted in: comparison of the parameter values for different groups; comparison of non-invasive
APW measurements with intra-arterial measurements in patients, before and after an angioplasty
procedure; and, assessment of the system repeatability (intra-operator variation), reproducibility
(inter-operator variation) and pulse-by-pulse variability.
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6.1 Motivation
The motivation of this work consisted in the validation of the APW module measurements.
Generally, the validation of a new measurement device comprises the evaluation of its accuracy and
precision, with measurements close to, and tightly clustered around the known value. The accuracy
and precision of a measurement process is usually established by repeatedly measuring several
parameters. The accuracy of a measurement system is the degree of agreement of measurements
with a standard measurement methodology. The precision of a measurement system, also called
reproducibility or repeatability, is the degree to which repeated measurements, under unchanged
conditions, show the same results. In this sense, repeatability is the term used to describe the
intrinsic precision of an instrument. The most reliable way to evaluate this parameter is through the
repetitive analysis over a short period of time of the same measurand. This procedure implies the
same conditions of measurement, namely, the same measurement procedure, the same observer, the
same measuring instrument and, the same measurement location. On the other hand, reproducibility
is the variability associated to different operators during the measurement of the same parameters.
6.2 Methods
The groups of subjects, described in Section 4.1, were used in the validation tests:
• The GroupC, GroupD and GroupH were used in the characterization of the distribution of
values for the different parameters.
• The groupA was used for the comparison of the invasive and non-invasive waveforms.
• The groupR was used in the analysis of the significance of differences between consecutive
sessions, different operators and subjects, and left and right carotid arteries. This group was
also used in the analysis of the inter and intra-observer variability.
Statistical analysis was performed with SPSS v.17.0 (SPSS Inc, Chicago, IL, USA). The analysis
comprised several tests, that are described in the next sub-sections. The results were considered
statically different for p-values lower than 0.05. All data are expressed as mean±SD.
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6.2.1 Descriptive Statistics Analysis
Descriptive statistics gives information about the number of people or cases in the sample, the
number and percentage of males and females, the mean age of subjects, the smoking habits, as well
as the range of values, thus providing a useful description of the dataset. The main measurements
include mean and SD values, that are respectively, the effective methods for central trend and
dispersion evaluation.
6.2.2 Normality Assessment
Before choosing a proper statistic test, it is important to check, if the variables in the dataset have a
normal or a non-normal distribution. A normal distribution is used to describe a symmetric and bell-
shaped curve, which has the greatest frequency of scores in the middle, while the smaller frequencies
occur in the extremes [206]. The best quantitative way to assess the normality of the dataset is
through the application of the Kolmogorov-Smirnov one-sample test [207].
6.2.3 Parametric and Non-Parametric Tests Application
There are several families of statistical techniques that can be used for the exploration of differences
and relationships between groups. Generally, these techniques can be organized in parametric and
non-parametric tests that should be properly chosen [206]. Parametric methods can produce more
accurate and precise estimators and they have higher statistical power. However, before to the
application of a parametric tests, one should have to consider some general assumptions, and if one
or more are violated, the use of a non-parametric test must be considered. The general conditions
are:
• Normal distribution - It is important the assessment of the data normality, since some
parametric tests are not usually applicable for non-normal data. Fortunately, most of the
parametric techniques are reasonably robust, and with large sample sizes, the violation of this
assumption does not cause problems.
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• Continuous scale - Parametric approaches assume that the dependent variables are measured
in a continuous interval, and do not use discrete values.
• Independence of observations - Each observation or measurement must not be influenced
by any other observation or measurement.
• Random samples - Parametric techniques assume that the scores are obtained using a random
sample of the population. However, this is often not the case in real-life research.
• Homogeneity of variance - Parametric techniques also make the assumption that samples
are obtained from populations with similar variability.
6.2.4 Exploration of Relationships Among Variables
The strength of the relationships between variables is an important topic that can deliver important
information about the dataset. Correlation methods are used to describe the strength and direction
of the linear relationship between variables [206]. The main tests used in the correlation assessment
are the parametric test Pearson product-moment correlation, and the non parametric test Spearman
rank order correlation.
A positive correlation indicates that when one variable increases, so does the other, whereas
a negative correlation indicates that when one variable increases, the other decreases. Correlation
coefficients can range from −1 to +1, with the size of the absolute value providing an indication
of the strength of the relationship. A perfect correlation of −1 or +1 indicates that the value of
one variable can be exactly determined by knowing the other. On the other hand, a correlation of 0
indicates the absence of relationship between the two variables [206]. It is important to understand,
how to interpret the range of values, and to recognize small, medium and high correlations. The
guidelines suggested by Cohen [208] are presented in Table 6.1.
Table 6.1: Correlation coefficient ranges according to Cohen et al. [208].
Correlation coefficient range Correlation
r = 0.10 to 0.29 or r =−0.10 to −0.29 Small
r = 0.30 to 0.49 or r =−0.30 to −0.49 Medium
r = 0.50 to 1.00 or r =−0.50 to −1.00 Large
132
6.2. METHODS
6.2.4.1 Pearson Product-Moment Correlation
The Pearson’s correlation test is a parametric test which was designed for linear detection of
relationships among continuous variables. It can also be used in the presence of one continuous
and one nominal variable [206].
6.2.4.2 Spearman’s Rank Order Correlation
Spearman’s rank order correlation is also used to calculate the strength and direction of the
relationship between two variables, without making any assumptions about the frequency of the
distribution of the variables. It is the non-parametric alternative to the Pearson correlation, and
should be used in the case of highly skewed data or, when there are evidences of monotonic
relationships [206, 209].
6.2.5 Comparison of Groups
Comparison of groups is another family of statistics tests, that can be used to find out statistical
significant differences among groups. There are several tests that can be used depending of the
number of variables. The parametric and non-parametric tests adopted are summarized in Table 6.2.
Table 6.2: Summary of the techniques used in the exploration of the relationships among variables.
Number of variables Parametric Non-Parametric
2 Independent-samples t-test Mann-Whitney U Test
3 One-way ANOVA Kruskal-Wallis Test
6.2.5.1 Independent Samples T-Test
The independent samples t-test is used to compare the mean scores of the two different groups of
parametric data. The test reveals the statistical differences by the analysis of the mean score of the
groups [206].
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6.2.5.2 One-Way ANOVA
A one-way analysis of variance (ANOVA) is commonly used for the mean values comparison of
more than two groups, in the presence of parametric data. It compares the variability between two
different groups with the variability within the groups. An F ratio is calculated, which represents
the variance between the groups. A large F ratio indicates that there is more variability between
the groups (caused by the independent variable) than within each group (referred to as the error
term) [206].
6.2.5.3 Mann-Whitney U Test
This technique is the non-parametric equivalent to the independent samples t-test, and it is used to
evaluate the differences between two independent groups. This test compares the median values,
instead of mean values [206].
6.2.5.4 Kruskal-Wallis Test
The Kruskal-Wallis H test is also a non-parametric alternative to the one-way ANOVA test, where
the scores are converted to ranks, and the mean rank of each group is compared [206]. It is similar
to the Mann-Whitney U test, since it compares medians. However, it allows to compare more than
two groups.
6.2.6 Intra and Inter-observer Variability
The measurements by the same observer in different, but close occasions (intra-observer variability)
by two independent observers (inter-observer variability) can be evaluated calculating the limits of
agreement using Bland-Altman’s plots. In these plots the differences between the studied parameters
are plotted against the mean values. The coefficient of variation (CV) can also be used to assess the
pulse-by-pulse variability of a dataset.
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6.3 Results
6.3.1 Distribution of Values
The histograms in Figure 6.1 show the distribution of SWTT, LVET and RWTT for the GroupC
and GroupH. As, it can be seen in Figure 6.1(a), SWTT occurs later for the hypertensive group
(GroupH), where arrival times assume the mean value of 219.99±51.03 ms, while for GroupC, this
value is 144.12±50.46 ms. It is visible the SWTT dependency from RWTT values, by the overlap
of early reflected waves that coming before SWTT in GroupH. Concerning the LVET, its arrival
time is quite similar for both groups: 313.52±55.00 ms for the GroupH and 291.84±35.28 ms for
the GroupC (see Figure 6.1(b)). The RWTT occurs earlier for the GroupH (118.94±39.95 ms), in
opposition to the GroupC (200.46±34.19 ms), as it is shown in Figure 6.1(c).
Figure 6.1: Arrival time frequency distribution for SWTT, LVET and RWTT.
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When the algorithm is not able to identify the prominent points due to morphological artefacts, or
algorithm errors, a null timing is assumed and, consequently, the first histogram bin is incremented.
These events are more frequent for the RWTT analysis, in healthy subjects (GroupC), as it can be
seen in Figure 6.1(c).
The magnitude of AIx was also computed for each group, as it is shown in Figure 6.2. The
positive AIx values verified for GroupH are visible in black bars, and the negative values verified for
the GroupC are visible in grey bars. For the GroupD, the positive values are also predominant, as it
is visible in the white bar histogram distribution.
The RMSSD values intend to assess the variability associated to each one of the prominent
points, in time and amplitude. RMSSD values for GroupH (black) and for GroupC (grey) are
presented in Figure 6.3. For SWTT, it can be observed the presence of higher successive differences
(RMSSDSPt) for the GroupH. The similarities in both, RMSSDDWt and RMSSDDWa parameters
reveal the low predictive value of DW in this dataset. Concerning the inflection wave point time,
subjects from GroupH show a significant increase for the RMSSDPit distribution.
Figure 6.2: AIx values distribution for GroupC, GroupD and GroupH.
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Figure 6.3: RMSSD successive differences measured for the SW, DW and RW: (a) time information
(SWTT, LVET and RWTT); and (b) amplitude information (SWA, DWA, RWA).
6.3.2 Intra-arterial versus Non-invasive Waveforms
Data from GroupA were collected before and after a stent implementation, through invasive and
non-invasive methodologies. The comparison between methods was performed through visual
inspection.
The waveform comparison is shown in Figure 6.4 for a small segment (3− 4 s), for both
methods. The morphological changes that occur before and after the stent implementation are
clearly visible, mainly for the Pi parameterizations (blue and red circles). The waveform differences
were detected by the invasive device, but also by the non-invasive prototype under test. The
time parametrizations obtained using the non-invasive prototype are shown in Figure 6.5. Before
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Figure 6.4: Set of pulses detected invasively and non-invasively after and before the stent
implementation. The Pi arrival points for each method are represented by red and blue circles,
for pulses collected before and after angioplasty, respectively.
the cardiac catheterization, RWTT occurs earlier, while SWTT appears later, whereas after the
angioplasty, SWTT occurs prior to the RWTT. As expected, small changes in LVET values were
registered, since were not verified known cardiac valve complications in this group of subjects.
Figure 6.5: RWTT, SWTT and LVET comparison, before and after the angioplasty intervention.
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6.3.3 Normality Assessment
The Kolmogorov-Smirov test was applied to the GroupR, for each trial, to assess the normality of
the distribution. Each category in Trial 1 (month, carotid artery and sessions) and Trial 2 (operator,
carotid artery and sessions) was analysed. It was observed that most of the variables were non-
normally distributed. The non-normal distributions were expected, since they are quite common in
large datasets, such as those used in this study. These results suggest that non-parametric approaches
should be used. Few parameters presented normal-distributions in the Trial 2, namely the RWA
values for the subject 4; SWTT, DWA and RWTT values for the subject 9; DWA values for the
subject 10 and, RWA values for the subject 11. Other punctual situations were verified in the analysis
of Trial 1, such as described by Borba, J. [184].
6.3.4 Significance of Differences
6.3.4.1 Categorization by Month
The monthly categorization was performed for the GroupR (Trial 1). Results are presented in
Table 6.3. The Mann-Whitney U non-parametric test was used to compare the variables. It can
be verified the existence of differences in the SWTT analysis between month 1 and month 2. Month
1 presents the lower SWTT average value (155.63±58.76 ms versus 177.74±64.26 ms). Average
differences between months of about 7 ms and 2.5 ms were observed for the LVET and RWTT,
Table 6.3: Descriptive data categorization by month. The p-value indicates the Mann-Whitney test
significance value.
Parameter Total Month 1 Month 2 p-value
SWTT (ms) 166.27±62.44 155.63±58.76 177.74±64.26 < .05
RWTT (ms) 167.70±37.36 168.90±40.12 166.41±4.09 < .05
LVET (ms) 289.47±52.27 285.98±61.72 293.23±39.31 < .05
SWA (a.u)a 0.99±0.01 0.99±0.01 0.99±0.01 < .05
RWA (a.u)a 0.87±0.08 0.86±0.09 0.88±0.07 < .05
DWA (a.u)a 0.71±0.14 0.70±0.15 0.72±0.13 < .05
AIx (%) −1.16±15.05 −2.67±15.94 0.48±13.84 < .05
a Arbitrary Amplitude Units
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Figure 6.6: Boxplot of the AIx categorized by subject and sub-categorized by month.
respectively. AIx values are lower for month 1, comparing to month 2 (−2.67± 15.94 % versus
0.48±13.84 %). According to the Mann-Whitney test, the verified differences are significant for all
of the variables.
A categorization by subject and sub-categorized by month was performed and, the results
concerning the AIx analysis are presented in Figure 6.6. Mann-Whitney U test demonstrated that
only the subjects 1 and 4 do not present significant differences.
SWA was removed from subsequent statistical analysis, since the pulse amplitude was previously
normalized in reference to this parameter during the pre-processing.
6.3.4.2 Categorization by Operator
The categorization by operator allowed the consistency determination for all the measurements, with
the three operators. The subjects within the GroupR (Trial 2) were studied, and the descriptive data
categorized by operator are shown in Table 6.4. The Kruscal-Wallis test was used, since it allows
the comparison between more than 2 groups. The existence of significant differences for most of the
variables was verified. The only exception was the RWTT (p = 0.36).
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Table 6.4: Descriptive data categorized by operator. The p-value indicates the Kruscal-Wallis test
significance value.
Parameter Total Operator1 Operator 2 Operator 3 p-value
SWTT (ms) 180.51±62.77 175.11±60.81 180.45±65.93 186.09±61.16 < .01
RWTT (ms) 157.25±42.67 156.94±44.06 156.45±40.68 158.35±43.08 0.36
LVET (ms) 286.63±40.95 281.06±40.01 288.60±44.14 290.43±38.03 < .01
RWA (a.u) a 0.85±0.11 0.86±0.12 0.85±0.10 0.84±0.11 < .01
DWA (a.u)a 0.76±0.13 0.76±0.12 0.77±0.12 0.76±0.13 < .01
AIx (%) 2.63±18.45 2.34±18.23 2.41±18.05 3.15±9.04 < .01
a Arbitrary Amplitude Units
6.3.4.3 Categorization for the Left and Right Carotid Arteries
Table 6.5 shows the observed differences for the left and right carotid artery, considering all
operators. Data show for the RWTT parameter, that there was no significant differences between left
and right measurements. It is also visible that the left carotid artery presents lower differences, for
the SWTT, RWTT, and AIx analysis, comparatively to the right carotid artery. A detailed analysis,
sub-categorized by operator, concerning this topic, is presented in Appendix E.1. Several statistical
differences can be observed for the majority of parameters. However, there are exceptions, namely
in the analysis of the RWA differences, with p = 0.06, p < 0.05 and p = 0.51, for the operators 1, 2
and 3, respectively. Non-statistical differences were also verified in the analysis of LVET (operator
2), and DWA (operator 1).
Table 6.5: Kruskal test significance for the left and right measurements.
Parameter p-value (Left) p-value (Right)
SWTT 0.73 < .01
LVET < .01 < .01
DWA < .01 < .01
RWTT 0.22 0.16
RWA < .01 < .01
AIx 0.12 < .01
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6.3.4.4 Categorization by Subject
A statistical analysis for each subject, sub-categorized by operator and carotid artery was performed
to assess the differences among subjects. The Kruskal-Wallis test was conducted to assess these
dissimilarities, and the results presented in Tables 6.6 and 6.7.
Figures 6.7 and 6.8 show the AIx median values for each subject, sub-categorized by operator,
for the right and left carotid arteries, respectively. The analysis of the subjects 3, 4 and 19 evidences
a low number of pulses in the dataset for one of the operators (not the same for all). So, these subjects
were not included in the subsequent analysis due the lower number of pulses, comparatively to the
other subjects. Discrepancies in AIx values (i.e. positive and negative values) are visible for the
subjects 1 and 8 (right artery) and for the subjects 1, 6, 15 and 16 (left artery).
Other data were plotted, considering each subject and operators individually, being presented in
Appendix E.2. For all parameters, it can be observed that dicrotic features (DWA and LVET) have
lower significant differences, comparatively to the other parameters. However, for the majority of
the parameters, significant differences were found.
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Figure 6.7: AIx values (right carotid artery) obtained for each subject and operator.
Figure 6.8: AIx values (left carotid artery) obtained for each subject and operator.
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6.3.5 Intra-observer Variability
For the calculation of the intra-observer reproducibility, each of the three sets of data records,
performed by each operator, were analysed. So, for each operator 3 pairs of values (n = 51) were
considered (session1 versus session2, session1 versus session3, session2 versus session3), for both
arteries (left and right). Bland-Altman plots were analysed for all data and, the observed differences
are presented in Tables 6.8 and 6.9, for the left and right carotid arteries, respectively.
Generally, the verified differences were lower for the observer 3, comparatively to the others,
which is probably due to its larger experience in performing pulse wave measurements. These data
are consistent with the significant differences observed in Section 6.3.4.3. The results are similar (or
better) to the other data reported in literature (see Table 2.2). In the AIx analysis, it was observed a
Table 6.8: Intra-observer mean differences ± 2 SD derived from the Bland-Altman plots (n = 51,
obtained for the left carotid artery.
Parameter Operator1 Operator2 Operator3
SWTT(ms) 5.74±17.32 5.41±15.12 1.71±29.08
RWTT (ms) −2.4±18.54 −5.09±10.85 2.74±15.50
LVET (ms) 3.44±13.05 6.59±22.36 1.53±21.84
RWA (%) a 1.02±4.87 −0.90±3.13 −0.01±3.59
DWA (%) a 0.96±4.41 0.24±4.51 0.37±4.85
AIx (%) −0.36±5.16 0.96±3.26 0.52±3.58
a In reference to the normalized amplitude
Table 6.9: Intra-observer mean differences ± 2 SD derived from the Bland-Altman plots (n = 51,
obtained for the right carotid artery.
Parameter Operator1 Operator2 Operator3
SWTT(ms) 4.18±19.74 −4.18±30.41 0.61±25.46
RWTT (ms) −2.27±17.67 −8.97±23.80 2.70±17.24
LVET (ms) 0.19±15.73 −4.32±22.67 3.63±25.36
RWA (%) a −0.16±3.29 −1.18±8.06 −0.92±7.63
DWA (%) a 0.59±4.38 0.90±5.34 −0.31±4.31
AIx (%) 0.02±6.01 2.18±6.70 0.90±7.21
a In reference to the normalized amplitude
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difference in the intra-variability < 1 %, for the majority of cases (excluding the 2.18 % variability
value, observed by the operator 2, at right carotid artery). The significance of the differences was
also assessed using the Kruskal-Wallis test. The results are presented in Appendix E.3. These results
confirmed that the operator 3 presented a better performance, since the measurements have lower
significant differences among sessions.
Frimodt-Moller et al. [133] reported an RWTT variance of −6.9± 52.7 ms, −2.7± 32.8 ms,
−3.2± 33.9 ms, using three different sets of measurements, similar to the values verified in this
study, 2.27±17.67 ms, 8.97±23.80 ms, 2.70±17.24 ms, for the operator 1, 2 and 3, respectively.
The other timing variables (SWTT, RWTT) also evidence low differences, for the same order of
values. RWA and DWA mean differences were about of 1 % for all measurements.
6.3.6 Inter-observer Variability
The calculation of the inter-observer variation was based on the average of 153 double records
performed by all the operators (each pair of values comprises two of the three operator
measurements). Results are presented in Table 6.10. Higher differences were observed for the
right artery, comparatively to the left artery. In this case, an AIx value of −2.31± 7.29 % and a
SWTT value of −12.94± 31.46 ms was observed, which are higher than the left measurements,
0.94± 7.52 % and −2.96± 22.67 ms, respectively. Probably, these values are related with the
implemented acquisition protocol and operators positioning.
Siebenhofer et al. [134] reported an AIx mean difference of 0.4±6.4 %, while Crilly et al. [135]
reported 1.0±3.9 % mean value and, Frimodt-Moller et al. [133] state up 0.9±15.8 %, similar to
the values verified in this study (0.94± 7.52 %). It can be also observed that the lowest inter-
observer variability was recorded for the RWTT, 0.83± 27.10 ms, which represents an excellent
value comparing to the Frimodt-Moller et al. [133] observed value of 1.9± 30.8 ms. RWA and
DWA mean differences presented good variability range (< 3 %) for all measurements.
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Table 6.10: Inter-observer mean differences± 2 SD derived from the Bland-Altman plots (n = 153).
Parameter Left Right
SWTT(ms) −2.96±22.67 −12.94±31.46
RWTT (ms) −0.83±27.10 −1.08±23.49
LVET (ms) −5.83±26.06 −9.57±23.03
RWA (%) a −0.25±7.58 2.46±7.21
DWA (%) a 0.67±7.39 −1.07±6.86
AIx (%) 0.94±7.52 −2.31±7.29
a In reference to the normalized amplitude
6.3.7 Pulse-by-pulse Variability
There are no previous studies concerning the pulse-by-pulse variability for the APW features. In
this study, the CV was assessed for all pulses in the dataset (comprising session1, session2 and
session3) measured by each operator. Results are presented in Figure 6.9. Variability values were
very good for the LVET, DWA, RWA (CV< 10 %), but unsatisfactory for the AIx (28.07 %, 21.51 %
and 24.85 % for the operators 1, 2 and 3, respectively). And, the SWTT and RWTT presented
satisfactory results (10 %<CV>20 %). Only the AIx has unsatisfactory pulse-by-pulse variability
(in spite of borderline satisfactory) and, therefore careful standardization of this parameter is highly
required. Thus, AIx measurement should be reserved mainly to highly trained operators. The other
Figure 6.9: AIx values (right carotid artery) obtained for each subject and operator.
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parameters give good indicators concerning their potential use for cardiovascular risk assessment.
6.4 Conclusion
The validation tests demonstrated the feasibility of creating a database for research and clinical
practice. By indirect comparisons and internal consistency tests, it has been found that the database
created has enough quality for research purposes, presenting a wide range of parameter values.
In general, non-invasive measurements are less accurate, when compared with invasive trials,
mainly due to the dependency of the measurement conditions and operators. However, the non-
invasive APW module is capable of effectively detecting physiological modifications, before and
after a stent implementation. On an angioplasty procedure was demonstrated the usefulness of this
technology to ease the early identification of cardiac problems, when used in clinical practice.
The intra-observer ”limits of agreement” for the studied parameters, SWTT, RWTT, LVET,
RWA, DWA and AIx, are good markers comparatively to the values available on the literature.
Additionally, it was demonstrated that operators can be easily trained in the use of this prototype,
since different operators with only one week of training produced results quite reasonable. These
results have important implications concerning the use of this prototype for the clinical assessment of
patients and suggest that APW indices are reproducible and repeatable when measured by different
observers at repeated occasions.
A set of more well defined and demanding acquisition protocols could and should be
implemented, in order to minimize even further any possible external influences. Finally, it is
possible to suggest the application of this technique at a large scale, randomised clinical trials
to address important clinical questions, such as applications to anti-hypertensive therapies and
cardiovascular interventions.
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7.1 General Conclusions
The main motivation of this work was to provide a valid contribution for the assessment of the
cardiovascular condition. In order to accomplish this goal, the adopted methodology consisted
of: i) the development of a multichannel platform capable to add up several technologies and
methodologies in order to provide a refined cardiovascular assessment; ii) the development of data-
mining tools, incorporating personalized machine learning algorithms capable to deal with a wide
set of APW features; iii) the construction and population of a cardiac database essential to the system
validation.
The multichannel platform allows to integrate several technologies and methodologies used
in the traditional clinical path of cardiovascular patients (e.g., oximetry, ECG, PWV). The main
instrumental focus of this work remained on a module dedicated to APW monitoring, being the
PZ sensors the basis of the developed probe. The performance of the probe was assessed using a
dedicated purpose test bench, capable of generating arbitrary shaped pressure waves over a confined
artery-like flexible tube filled with an appropriate liquid. The performed tests in this environment
comprised an important role along the development of the instrumentation module and probe, since
they allowed the optimization of the signal conditioning circuit, and the choice of the optimal probe
design. The results demonstrated that the PZ probe performed very well in a number of fundamental
accuracy tests on elastic tubes. The maximum RMSE introduced by the electronic circuit itself is
0.33 % and the total average error (including the mechanical interface contribution) does not go
higher than to 1.80 %.
Concerning the algorithmic tool, the implemented processing tasks included algorithms for
baseline fluctuation elimination, pulse segmentation, establishment of the adequate bad pulse
flagging criteria and the development of a waveform delineator algorithm for the identification and
quantification of the most relevant APW features. Most of APW analysis frameworks individually
process each hemodynamic parameter and do not evaluate the inter-dependencies between features.
With this work, an extensive pool of parameters was established: time/amplitude intervals, some
ratios and indices concerning APW parametrizations and pulse variance measures. The extraction of
the appropriate features was essential for the development of the decision support system platform.
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The main advantage of the implementation of innovative decision support system algorithms
is the possibility to deal with a wide set of APW parameters in a broader variety of operating
situations, even in the case of missing values. It is possible to obtain important indices concerning
the arterial stiffness that can be used as estimates of the risk associated to the APW morphology.
Classification techniques have shown their usefulness in assessing CVD risk. The J48 or Random
Forest algorithms revealed to be appropriate options, that can be used by the clinicians. Neural
networks have also demonstrated good performance In general, for the tested classifiers, higher
accuracy values were obtained (above 95 %), as well as AUC values comparable to other models
described in the general cardiology literature. It was also demonstrated the potential use of multiple
classifier methodologies in producing more trustworthy diagnostic outputs in comparison with single
classifier analysis. Clustering procedures also revealed an important role, since they allowed the
premature determination of different CVD risk groups. These methods are particularly interesting
since can avoid the requirements of the classification procedures which often require costly labelling
of a large set of parameters, such as biochemical analysis used by traditional risk scores. One of
limitation of the proposed analysis methodology is its high dependence on the database subjects.
This means that for a successful modelling, data must be representative, i.e. they must cover all of
the possible physical situations.
The validation tests were essential in the assessment of the clinical use of the APW module. A
performed case study in subjects with carotid stenosis was accomplished, enabling the detection of
APW modifications before and after the angioplasty procedure. The inter and intra-observer limits
of agreement for SWTT, RWTT, LVET, RWA, DWA and AIx, are good markers comparatively to the
values available on literature, even when APW acquisition is undertaken by less trained operators.
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7.1.1 Future Research Lines
A long-term therapeutic trial for investigate the role of arterial stiffness, systolic blood pressure
and biochemical parameters, such as RAAS, should be planned in order to identify the most
important risk predictors associated with the development of CVD and correlate them with APW
modifications.
Additionally, it would be interesting to study the relationship between transthoracic
echocardiography and the APW parameters. The relationship between the increased load imposed
on the left ventricle by wave reflections and arterial stiffness parameters, such as AIx needs to be
widely explored [113, 210]. An interesting outcome at this stage could be the relationship between
the echocardiography parameters, such as, the increase in Left Ventricular Mass Index (LVMI) and
cardiac output, with the APW features.
Other interesting application could be the use of this platform (hardware and its algorithmic
tools) during the anaesthesia monitoring in surgery environment. Currently, the measurement of
the APW features, crucial for the patient condition monitoring, is accomplished through invasive
methods. This procedure is important for the cross-correlation with other routine parameters in order
to assess the volemic state of the patient and the nociception balance. The availability of non-invasive
sensors will enable the full arterial pulse profile measurement, avoiding invasive probes. Moreover,
this approach is particularly suitable to use in intensive care patients with hemodynamic instability
also for volemic characterization and analgesia dose adequacy. The outcome of this approach
could be a set of APW parameters chosen to fully characterize the patient anesthesia/analgesia
demand over time. A training period with both, invasive and non-invasive probes would be the
basic requirement for the establishment of the most suitable classifiers (through data mining) to deal
with the set of parameters.
The developed prototype must be validated against SphygmoCor and Complior devices. The
evaluation is mandatory along with the demonstration of the PZ sensor, in large clinical and research
units. The database established along this study comprises 246 subjects, but there is lack of data from
unhealthy subjects and, data from healthy subjects in the 30−50 age range.
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In the field of machine learning algorithms some improvements can also be performed. The
application of clustering techniques in a sample composed by patients with different CVD, can be
relevant to assess the power of the clustering methodologies in partitioning the groups by different
cardiovascular pathologies. Future improvements can also focus on the study of other machine
learning algorithms, such as Support Vector Machines (SVMs) algorithms that can improve the
accuracy, due to the known ability to deal with non-categorical features. SVMs are frequently
referred to as the classification technique with higher overall accuracy [211].
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A Database Structure
Main menu includes several icons useful to perform common operations and a top menu bar that
allows for the selection of the operations. Table A.1 presents a description of main menu shortcuts.
Table A.1: Cardiocheck main menu icons.
Icon Description
Opens Acquisition window where are available several settings: the operator and
its institution, the place of acquisition, the patient, the hardware modules and the
time settings.
Opens Search window that allows the search of patients, institutions, operators
and hardware modules. There are some filtering options, that allows to adapt the
search results to the desired conditions.
Opens a side menu that allow for the creation of a new patient, institution or
operator.
Opens Processing window where the acquired data can be viewed and
processed.
Opens a side menu, where a patient, institution or operator can be excluded or
restored from the database. It is also possible the creation of a new database
or, the choice of another database available in the computer. The access to this
menu is limited to an administrator, since it requires a password.
Closes all windows that might be opened and exits the Cardiochek interface.
The Acquisition menu is dedicated to the operator, patients, acquisition place. An overview of
this window is presented in Figure A.1.
Search menu is intended to perform searches on patients, institutions and operators inserted into
the Cardiocheck database. This menu is presented in Figure A.2. This process is essential to perform
the data analysis for different subsets.
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A B C
D
F E
Figure A.1: Cardiocheck Acquisition window: institution and patient settings. This window has the
following fields: (A) institution select pop-up; (B) operator select pop-up and a field for notes; (C)
place of acquisition select pop-up; (D) patient select pop-up and the corresponding information and
notes; (E) proceed to signals and hardware window; (F) main menu button.
Figure A.2: Cardiocheck Search menu: simulation of a patient search with ”M” gender filtering
condition. Fields in search window include: (A) entity selection; (B) filtering conditions; (C) search
result list; (D) operations buttons; (E) main menu button.
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Patient window has four tabs with diverse information: personal info, clinical history, family
history and biochemical analysis. When inserting a new patient, it is possible to fill these fields,
but the edition a posteriori is also allowed. Additionally, for each acquisition are also required
information and institution and operator informations. This interface communicates with other
window capable to deal with signals from the modules of the multichannel platform, namely with
the algorithms described in Section 4.4.
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B Simulink Configurations
The Master Block configurations (Table B.1) set important dsPIC options like PLL, oscillator mode
or clock frequency.
Table B.1: dsPIC MASTER
Number of Instructions Per Second 50000000
Oscillator Mode Quartz (XT - HS)
Clock frequency 8e6
PLL Activate
Timer step 0.001
Error 0 %
PR1 49999
The UART Configuration block (Table B.2) set the parameters for the UART. Each UART has
one Receive (Rx) pin and one Transmit pin (Tx). The following parameters are fixed: 1 stop bit,
8 bits data, no parity and no flow control. Information about the real baud rate obtained and the
corresponding % error, comparatively to the selected baud rate is obtained from simulink. The %
error must be near or lower than 3 % for the RS-232 serial transmission work properly [180].
Table B.2: UART 2 Configuration
Baud Rate (kb/s) 4608800
UxBRG 6
Real Baud 446429
Error −3.12 %
44.6429 Bytes/step
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C WEKA Toolkit
Weka is a collection of machine learning algorithms for data mining tasks. The algorithms can
either be applied directly to a dataset or called from Java code. Weka contains tools for data pre-
processing, classification, regression, clustering, association rules, and visualization. Weka’s main
graphical user interface, the Explorer menu, gives access to all its facilities using menu selection
and form filling. It is illustrated in Figure C.1. There are six different panels that can be selected by
the tabs at the top, corresponding to the various data mining tasks that Weka supports.
Figure C.1: The Weka Explorer: (a) choosing the Explorer interface and (b) visualization of the data
(Preprocess panel).
In summary, the main functions of each one of tabs presented at the top of the Explorer menu
are described below. The Clustering and Classification panels are shown in Figure C.2.
1. Preprocess - Choose the dataset and modify it in various ways.
2. Classify - Train learning schemes that perform classification or regression and evaluate them.
3. Cluster - Learn clusters for the dataset.
4. Associate - Learn association rules for the data and evaluate them.
5. Select attributes - Select the most relevant aspects in the dataset.
6. Visualize - View different two-dimensional plots of the data and interact with them.
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Figure C.2: Visualizing the result (a) of J48 classifier algorithm and, (b) its tree; (c) k-means
clustering results, and (d) the cluster distributions.
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The Visualize panel helps to visualize a dataset, not only the result of a classification or a
clustering model, but the dataset itself. It displays a matrix of two-dimensional scatter plots for
each pair of attributes. Figure C.3 shows the distributions for a studied dataset.
Figure C.3: Visualize menu.
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D Scores
D.1 Framingham Risk Score (FRS)
Since 1948, the Framingham Heart Study, under the direction of the National Heart, Lung and Blood
Institute (NHLBI), formerly known as the National Heart Institute (USA), has been committed to
identifying the common factors or characteristics that contribute to cardiovascular disease (CVD).
This study followed CVD development over a long period of time in several generations of
participants. It was used the score for General Cardiovascular Risk (10-year risk), such as presented
in Figure D.1.
Figure D.1: FRS interface.
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D.2 PROspective Cardiovascular Mu¨nster (PROCAM)
The PROCAM Quick Check estimates the 10-year risk of developing a coronary event. This version
allows rapid initial assessment of coronary risk and includes only variables that do not require
laboratory testing. The other version is a more detailed score that includes laboratory values (LDL-
cholesterol, HDL-cholesterol, triglycerides and blood glucose). This platform is suitable for subjects
aged 20-75 years. The interactive PROCAM Quick Check version is presented in Figure D.2.
Figure D.2: PROCAM interactive tool.
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D.3 ASsessing cardiovascular risk using Scottish Intercollegiate Guidelines Network
(ASSIGN)
ASSIGN includes social deprivation for the first time, and family history of cardiovascular disease,
with the classic risk factors. It identifies people free of cardiovascular disease most likely to develop
it over 10-years. ”High risk” (score 20 or more) implies risk-lowering medication and/or other
medical help. The ASSIGN interactive tool is presented in Figure D.3.
Figure D.3: ASSIGN interactive tool.
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D.4 Systematic Coronary Risk Evaluation Project (SCORE)
SCORE is based on a large dataset tested thoroughly on European data. The SCORE risk function
can be calibrated to each country’s national mortality statistics. Two versions are available. The
low risk charts can be used in Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, The Netherlands,
Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.
The high risk charts may be used other European countries. These include Armenia, Azerbaijan,
Belarus, Bulgaria, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Macedonia FYR, Moldova,
Russia, Ukraine and Uzbekistan. CVD risk assessment tool is presented in Figure D.4.
Figure D.4: SCORE interactive tool.
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E Additional Statistical Data
E.1 Operators Significance
To complete the operator analysis, the categorization for operators and sub-categorization for carotid
site was also performed and, it is presented in Table E.1.
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E.2 Sub-categorization by Subject
In this section are presented the GroupR (Trial2) results, considering each subject and operator
individually, for the SWTT, RWTT, LVET, RWA, DWA, measured at the left and right carotid
arteries.
Figure E.1: Bar plot for the SWTT measured at right carotid site.
Figure E.2: Bar plot for the SWTT measured at left carotid site.
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Figure E.3: Bar plot for the RWTT measured at right carotid site.
Figure E.4: Bar plot for the RWTT measured at left carotid site.
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Figure E.5: Bar plot for the LVET measured at right carotid site.
Figure E.6: Bar plot for the LVET measured at left carotid site.
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Figure E.7: Bar plot for the DWA measured at right carotid site.
Figure E.8: Bar plot for the DWA measured at left carotid site.
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Figure E.9: Bar plot for the RWA measured at right carotid site.
Figure E.10: Bar plot for the RWA measured at left carotid site.
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E.3 Trials Significance
Table E.2: Comparison of variability values obtained from commercial devices.
Subject Operator Carotid SWTT RWTT RWA LVET DWA AIx
1
1
Left 0.16 p < 0.01 p < 0.05 0.66 0.06 p < 0.01
Right 0.95 p < 0.01 p < 0.05 0.07 p < 0.01 p < 0.01
2
Left p < 0.01 p < 0.05 p < 0.01 p < 0.01 p < 0.01 p < 0.05
Right p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
3
Left p < 0.05 p < 0.05 p < 0.05 0.19 0.62 p < 0.05
Right 0.21 0.34 0.71 0.10 0.41 0.34
2
1
Left p < 0.01 p < 0.01 0.48 0.20 0.84 0.64
Right p < 0.01 p < 0.01 0.83 0.08 0.34 0.89
2
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.05 0.07
Right 0.18 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
3
Left p < 0.05 p < 0.01 p < 0.01 p < 0.05 p < 0.01 p < 0.01
Right 0.18 0.46 0.30 0.09 0.36 0.23
5
1
Left p < 0.05 0.88 p < 0.05 p < 0.01 p < 0.01 0.08
Right p < 0.01 p < 0.01 0.52 p < 0.01 p < 0.01 0.68
2
Left 0.10 0.37 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right 0.87 p < 0.05 p < 0.05 0.20 p < 0.01 p < 0.05
3
Left 0.08 0.72 0.68 0.28 0.20 0.77
Right p < 0.05 0.86 p < 0.01 p < 0.05 p < 0.01 p < 0.01
6
1
Left 0.15 p < 0.01 p < 0.01 p < 0.05 p < 0.05 p < 0.01
Right p < 0.05 0.24 0.96 p < 0.01 p < 0.05 0.60
2
Left p < 0.01 p < 0.01 p < 0.05 0.30 p < 0.01 p < 0.01
Right 0.21 p < 0.01 p < 0.05 p < 0.05 p < 0.05 p < 0.01
3
Left p < 0.05 p < 0.01 p < 0.01 p < 0.05 0.86 p < 0.01
Right p < 0.01 0.06 p < 0.01 p < 0.01 0.06 p < 0.01
7
1
Left 0.40 p < 0.01 p < 0.01 0.42 p < 0.05 p < 0.01
Right p < 0.01 0.36 0.87 p < 0.01 p < 0.05 0.82
2
Left 0.32 0.06 0.07 p < 0.01 p < 0.01 0.85
Right p < 0.05 0.08 0.06 0.20 p < 0.05 0.06
3
Left p < 0.01 p < 0.05 0.13 p < 0.01 p < 0.01 p < 0.05
Right p < 0.01 0.75 p < 0.01 p < 0.01 p < 0.01 p < 0.01
8
1
Left 0.14 p < 0.05 0.93 p < 0.01 p < 0.05 0.13
Right p < 0.01 0.44 0.19 p < 0.01 0.06 0.55
2
Left 0.16 0.60 0.06 0.22 p < 0.05 0.66
Right 0.65 0.62 0.72 0.64 0.47 0.42
3
Left 0.47 p < 0.05 p < 0.05 p < 0.05 p < 0.01 0.06
Right 0.14 0.58 0.58 0.46 0.77 0.91
9
1
Left p < 0.05 p < 0.05 0.95 0.42 0.30 0.95
Right 0.51 p < 0.05 0.05 0.40 0.45 p < 0.05
2
Left 0.17 0.09 0.09 p < 0.05 0.07 0.09
Right p < 0.05 p < 0.01 p < 0.01 p < 0.05 p < 0.01 p < 0.01
3
Left 0.12 0.27 0.33 0.24 0.69 0.33
Right p < 0.01 p < 0.01 p < 0.01 0.30 p < 0.01 p < 0.01
10
1
Left p < 0.05 p < 0.01 p < 0.05 p < 0.01 0.35 p < 0.05
Right p < 0.01 0.07 p < 0.01 p < 0.01 p < 0.01 p < 0.01
2
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right p < 0.01 p < 0.05 0.55 p < 0.01 p < 0.01 0.54
Continued on next page
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Table E.2 – Continued from previous page
Subject Operator Carotid SWTT RWTT RWA LVET DWA AIx
3
Left 0.20 p < 0.01 p < 0.01 0.36 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 0.21 0.25 p < 0.01 0.21
11
1
Left 0.47 0.36 0.81 0.14 0.70 0.81
Right 0.51 p < 0.01 0.40 p < 0.01 0.56 0.35
2
Left 0.32 p < 0.01 p < 0.01 0.09 p < 0.01 p < 0.01
Right 0.47 p < 0.05 0.63 0.53 p < 0.05 0.63
3
Left 0.42 0.95 0.14 0.67 0.39 0.14
Right 0.41 p < 0.01 p < 0.01 0.44 0.95 p < 0.01
12
1
Left p < 0.01 p < 0.05 0.28 0.30 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 0.71 p < 0.01 p < 0.05 p < 0.01
2
Left 0.52 0.73 0.35 0.37 0.29 0.35
Right p < 0.01 p < 0.01 p < 0.01 0.72 p < 0.01 p < 0.01
3
Left 0.80 p < 0.01 0.51 p < 0.01 p < 0.05 p < 0.01
Right 0.07 0.12 p < 0.05 0.83 p < 0.05 p < 0.01
13
1
Left p < 0.05 p < 0.05 0.18 p < 0.01 p < 0.01 p < 0.01
Right 0.89 0.40 0.30 0.40 p < 0.01 0.30
2
Left 0.79 p < 0.05 p < 0.01 0.81 0.29 p < 0.01
Right p < 0.01 0.30 p < 0.01 p < 0.05 0.08 p < 0.01
3
Left 0.15 p < 0.01 0.54 p < 0.01 p < 0.01 p < 0.05
Right p < 0.01 0.33 p < 0.01 p < 0.01 0.34 p < 0.01
14
1
Left p < 0.05 p < 0.01 p < 0.01 0.21 p < 0.01 p < 0.01
Right 0.73 0.35 0.75 0.53 0.06 0.51
2
Left p < 0.01 p < 0.01 p < 0.01 p < 0.05 0.10 p < 0.01
Right p < 0.01 p < 0.01 0.08 p < 0.01 p < 0.01 p < 0.01
3
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 0.41 p < 0.01
Right 0.81 0.23 0.36 0.85 p < 0.05 0.43
15
1
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 0.43 p < 0.01
Right p < 0.01 0.20 p < 0.05 p < 0.01 p < 0.05 p < 0.05
2
Left 0.16 p < 0.05 0.19 0.59 0.88 0.28
Right 0.31 0.49 0.70 p < 0.05 0.17 0.70
3
Left 0.08 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right 0.74 p < 0.01 p < 0.01 p < 0.01 0.40 p < 0.01
16
1
Left 0.12 0.22 p < 0.05 p < 0.05 0.24 0.85
Right p < 0.05 0.20 p < 0.05 0.45 0.41 0.29
2
Left 0.55 0.07 0.78 0.09 0.06 p < 0.05
Right 0.12 p < 0.01 p < 0.05 0.06 p < 0.01 p < 0.05
3
Left p < 0.05 p < 0.01 p < 0.01 p < 0.01 0.77 p < 0.05
Right
17
1
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right 0.08 0.20 0.61 0.30 0.14 0.38
2
Left 0.49 p < 0.05 p < 0.01 0.77 p < 0.01 0.07
Right 0.13 p < 0.05 0.12 p < 0.05 p < 0.05 p < 0.01
3
Left 0.08 0.11 0.11 0.84 0.19 0.94
Right 0.97 0.52 0.28 0.13 0.62 0.52
18
1
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 p < 0.05 p < 0.01 p < 0.01 p < 0.01
2
Left p < 0.01 0.79 0.07 p < 0.05 p < 0.05 p < 0.05
Right p < 0.01 p < 0.01 0.71 p < 0.01 p < 0.01 0.71
3
Left p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 p < 0.05 p < 0.01 p < 0.01 p < 0.01
Continued on next page
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Table E.2 – Continued from previous page
Subject Operator Carotid SWTT RWTT RWA LVET DWA AIx
20
1
Left 0.16 p < 0.01 p < 0.01 0.38 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 0.50 p < 0.05 p < 0.01 0.25
2
Left 0.15 p < 0.01 p < 0.01 p < 0.05 p < 0.05 p < 0.01
Right 0.44 0.36 0.13 0.27 0.22 0.13
3
Left 0.30 p < 0.01 p < 0.01 p < 0.01 p < 0.01 p < 0.01
Right p < 0.01 p < 0.01 p < 0.01 0.43 p < 0.01 p < 0.01
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